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ABSTRACT
The development of synthetic vectors enabling efficient intracellular delivery
of macromolecular therapeutics such as nucleic acids and proteins could potentially
catalyze the clinical translation of many gene and protein-based therapies. However,
progress has been hindered by a lack of safe and effective materials and by
insufficient insight into the relationship between key delivery properties and
efficacy.
Accordingly, working with a promising class of cationic, degradable gene
delivery vectors, poly(-amino ester)s (PBAEs), we develop novel, hydrophobic
PBAE terpolymers that display dramatically increased gene delivery potency and
nanoparticle stability. We then develop a technique based on size-exclusion
chromatography that enables the isolation of well-defined, monodisperse PBAE
polymer fractions with greater transfection activities than the starting polymer. This
technique also allows us to elucidate the dependence of gene delivery properties on
polymer molecular weight (MW). Subsequently, we examine the cellular uptake and
trafficking mechanisms of PBAE/DNA polyplexes, and demonstrate that polyplex
internalization and transfection depend on a key endo/lysosomal cholesterol
transport protein, Niemann-Pick C1 (Npcl).
Finally, working with cationic lipids termed lipidoids, which have shown
exceptional potency for the delivery of RNAi therapeutics, we develop these
materials for intracellular delivery of proteins using a simple and novel approach in
which nucleic acids serve as a handle for protein encapsulation and delivery.
Preliminary in vivo experiments suggest the potential application of this approach
toward lipidoid-mediated delivery of protein-based vaccines.
Taken together, the work presented here advances the development of
polymer and lipid materials for the safe and effective intracellular delivery of DNA
and protein therapeutics.
Thesis Supervisors: Robert Langer and Daniel G. Anderson
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1 INTRODUCTION
The development of synthetic vectors enabling efficient intracellular delivery
of macromolecular therapeutics such as nucleic acids and proteins could potentially
catalyze the clinical translation of many gene and protein-based therapies. However,
progress has been hindered by a lack of safe and effective materials and by
insufficient insight into the relationship between key delivery properties and
efficacy. For instance, the biodegradable, cationic polymers known as poly(p-
aminoester)s (PBAEs) have shown tremendous potential as non-viral gene delivery
carriers in numerous studies, yet several key challenges and questions remain
unaddressed, such as poor stability of polymer/DNA nanoparticles under
physiological conditions, batch-to-batch variability in transfection performance, and
the lack of mechanistic knowledge of cellular uptake and trafficking pathways.
Similarly, lipid-based nanoparticles (LNPs) incorporating cationic lipid materials
termed lipidoids have demonstrated excellent in vitro and in vivo efficacy for
delivery of oligonucleotides such as short interfering RNA (siRNA), but their
application toward intracellular delivery of protein-based therapeutics is impeded
by the wide range of physicochemical properties characterizing these diverse
macromolecules.
Accordingly, the overall objective of this thesis is to develop polymer and
lipid-based materials for safe, effective intracellular delivery of gene and protein
therapeutics, primarily through the following specific aims:
12
(1) Development of novel, degradable PBAE polymers with enhanced gene
delivery potency and nanoparticle aggregation resistance
(2) Systematic investigation into the gene delivery properties of PBAE polymers,
particular with respect to the effects of polymer hydrophobicity and
molecular weight, and with respect to the mechanisms employed for cellular
internalization and trafficking
(3) Development of lipid-based nanoparticles for efficient intracellular delivery
of proteins by way of oligonucleotide conjugation
In light of these aims, Chapter 2 of this thesis offers a broad survey outlining
the current clinical prospects for gene therapy, the limitations of viral vectors, the
barriers to non-viral delivery, and the most commonly studied synthetic gene
carriers. It also details the development of poly(P-amino ester)s as gene delivery
materials and presents some of the remaining unresolved challenges and questions
for these polymers. Chapter 3 describes the development of novel, degradable PBAE
terpolymers demonstrating significantly improved gene delivery potency and
nanoparticle stability, and Chapter 4 explores the potential of these polymers for
gene transfection of clinically relevant cell types as well as for in vivo gene delivery.
Chapter 5 details a systematic study of the effect of PBAE molecular weight on gene
delivery properties, the results of which elucidate a potential cause of PBAE batch-
to-batch variability. Chapter 6 then reveals new mechanistic insights into the
dependence of PBAE/DNA polyplex internalization and transfection on a key
cholesterol transport protein, Niemann-Pick C1 (Npc1). Subsequently, Chapter 7
describes a simple and novel approach for achieving efficient intracellular protein
13
delivery with lipid-based nanoparticles via oligonucleotide conjugation. Finally,
Chapter 8 provides a conclusion that summarizes the major findings and
contributions of this thesis and discusses the future outlook for continued
development of these materials.
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2 BACKGROUND
2.1 MOTIVATION FOR GENE THERAPY
In a broad sense, gene therapy can be defined as the intentional modulation
of gene expression within cells to prevent or treat a pathological process[l'. More
narrowly, this modulation of gene expression is accomplished through the
introduction of exogenous nucleic acids, such as DNA, messenger RNA (mRNA),
small interfering RNA (siRNA), microRNA, or antisense oligonucleotides. In contrast
to many small molecule or protein-based drugs, a singular aspect of DNA
therapeutics is that for many diseases, especially monogenic disorders defined by
inheritance of one mutated gene, the cure - a nucleic acid representing a functional
copy of the gene - is plainly manifest. However, because most cells are impermeable
to these large, negatively charged macromolecules, a carrier or vector is typically
required to mediate effective intracellular delivery.
This fundamental engineering challenge, which is in equal measures both
exciting and exasperating, largely explains why within the U.S., gene therapy
remains a strictly experimental approach, with no FDA-approved gene therapeutics
yet on the market despite nearly 2,000 clinical trials of gene therapy worldwide
since 1989 (Figure 2.1). Nevertheless, recent clinical progress, including the
approval of the first gene therapeutic for use in Europe, has marked a resurgence of
optimism for a field burdened by a tumultuous history[21.
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Figure 2.1 Clinical trials of gene therapy approved by year
1,903 clinical trials of gene therapy have been approved worldwide since 1989.
Adapted from Ginn et al.[31
Over the past two decades, gene therapy has been investigated clinically for
the treatment or prevention of a wide range of diseasesl31 (Figure 2.2). Cancer-
related diseases comprise nearly two-thirds of the indications addressed by clinical
trials thus far. Gene therapies for cancer treatment generally adhere to one of the
following broad strategies: mutation compensation, immunopotentiation, suicide
gene therapy, oncolytic virotherapy, and radio- or chemo-sensitization[ 4-51.
Controversially, two cancer gene therapeutics have already been approved for use
in China, even though similar versions have failed to pass clinical development in
the U.S.: Gendicine, a modified adenovirus encoding the human p53 gene, and
H101/Oncorine, a recombinant oncolytic adenovirus targeting p53-deficient cancer
cells[2,61.
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Figure 2.2 Indications addressed by gene therapy clinical trials worldwide
since 1989
Adapted from Ginn et al.[31
Within the U.S., Allovectin-7, a locally administered formulation consisting of
a DNA plasmid encoding two immunotherapeutic genes and a cationic lipid delivery
reagent, is currently undergoing a Phase III clinical study for treatment of advanced
metastatic melanoma[71 (ClinicalTrials.gov ID: NCT00395070). Also undergoing a
Phase III clinical trial is ProstAtak, which consists of an adenoviral vector encoding
the herpes thymidine kinase gene, for suicide gene therapy of prostate cancer in
conjunction with a prodrug and radiation therapy (ClinicalTrials.gov ID:
NCT01436968).
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Despite the enormous potential of gene therapy to address monogenic
diseases, this class of disorders represents only -9% of gene therapy clinical trials
to date (Figure 2.2), which include some major successes along with some tragic
failures. One of the earliest human trials of gene therapy in the early 1990s involved
the retroviral transfer of adenosine deaminase (ADA) into the T cells of two children
with ADA-associated severe combined immunodeficiency disorder (ADA-SCID)[8]. In
2000, the first gene therapy cure was reported in children with X-linked SCID who
experienced dramatic clinical improvement following delivery of interleukin-2
receptor gamma chain with a murine retroviral vector[91. Unfortunately, the trial's
success was marred two years later when several of these young patients developed
leukemia resulting in one death[10' 111. Just a few years earlier, the gene therapy field
had suffered its first major setback with the death of a Jesse Gelsinger, an 18-year-
old clinical trial patient who experienced a severe immune response after receiving
adenoviral gene therapy for a mild form of ornithine transcarbamylase (OTC)
deficiency[ 21. On the basis of preclinical studies, cystic fibrosis, a severe and fatal
lung disease caused by mutations in the CFTR gene, appeared to be a promising
early candidate for gene therapy, but clinical trials in humans have so far shown a
disappointing lack of efficacy[12 1.
Nevertheless, one recent triumph has been the approval of Glybera in Europe
for the treatment of lipoprotein lipase (LPL) deficiency[131. This orphan metabolic
disease results from mutation of the LPL gene and is characterized by elevated
levels of blood plasma triglycerides and debilitating bouts of pancreatitis[141. When
administered as a series of intramuscular injections, Glybera, an adeno-associated
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viral (AAV) vector encoding an LPL gene construct, has shown efficacy in reducing
plasma triglycerides and rates of pancreatitis [111.
Cardiovascular diseases are the targets of approximately 8% of clinical gene
therapy studies to date, but clinical trial results have so far been marked by low
gene transfer efficacy[161. A promising exception may be Mydicar, an AAV vector
encoding SERCA2a (sarcoplasmic reticulum Ca+2-ATPase), currently under Phase IlIb
study for congestive heart failure (ClinicalTrials.gov ID: NCT01643330). In a Phase
Ila trial, patients treated with the highest dose of Mydicar experienced significant
reduction of major cardiovascular events over a 12-month period compared with
those receiving placebo[' 71.
Infectious diseases comprise another 8% of indications that have been
addressed for clinical gene therapy trials. One interesting example under Phase I/II
study is a cell-based therapy for HIV/AIDS termed SB-728-T, which consists of
autologous CD4+ T cells genetically modified with a zinc finger nuclease to resist
HIV infection (ClinicalTrials.gov ID: NCT00842634).
Neurological diseases comprise a relatively small proportion of targets of
active gene therapy trials. In a Phase II study, patients with Parkinson's disease
showed some improvement in motor function following subthalmic infusion of
AAV2-GAD, an adeno-associated viral vector encoding glutamic acid decarboxylase
(GAD)[ 181, yet its clinical development is in doubt following the bankruptcy of the
trial's corporate sponsor. However, another gene therapeutic for Parkinson's
disease, an AAV vector encoding neurturin, is currently undergoing Phase I/II
studies[191.
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With respect to ocular diseases, recent early-phase clinical trials have raised
the prospects for treatment of some forms of inherited blindness, such as Leber's
congenital amaurosis (LCA)[ 201. In a pair of landmark studies, some patients with
LCA caused by mutations in the gene encoding an essential retinal pigment
epithelial protein (RPE65) experienced marked improvements in vision following
local injection of AAV vectors delivering the RPE65 gene[21t 221. A follow-up study in
three patients showed efficacy after a second administration to the contralateral
eye[2 3I.
2.2 LIMITATIONS OF VIRAL VECTORS
As suggested above, the key challenge limiting clinical translation of gene
therapeutics is the lack of delivery vectors considered safe and effective. Many of the
aforementioned clinical trials have employed modified viruses such as retroviruses,
lentiviruses, adenoviruses, and adeno-associated viruses (AAVs) to deliver genes; in
fact, nearly 70% of gene therapy clinical trials to date have involved viral vectors[ 31
(Figure 2.3). Although they can be quite efficient and have advanced the field of gene
therapy in significant ways, several limitations have been associated with viral
vectors, as described below.
(1) Carcinogenesis: Retroviruses and lentiviruses in particular have been
associated with a risk of carcinogenesis[ 24 . The development of leukemia in
children receiving retroviral gene therapy for X-linked SCID has been
attributed to a combination of insertional mutagenesis caused by viral
genome integration, acquired somatic mutations[251, and transgene-specific
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effects[261. Although AAV vectors are generally considered safer due to a very
low probability of integration, and have become more widely used in recent
years, tumorigenesis has been observed in mice treated with this class of
vectors 271, and the long-term cancer risk is still unclear[13.
(2) Immune responses: Pre-existing immunity comprises a serious safety concern
for certain classes of viral vectors, especially adenoviruses[ 28 . The death of
Jesse Gelsinger within days of receiving adenoviral gene therapy was blamed
on a severe innate immune response characterized by dramatically elevated
levels of inflammatory cytokines[281. In contrast, AAVs have not been
associated with such severe immune responses, but pre-existing immunity to
many AAV serotypes in significant fractions of the human population can
greatly diminish their efficacy[2 9I. Furthermore, adaptive immune responses,
both humoral and cell-mediated, can prevent the possibility of repeat dosing
and result in the elimination of transduced cells[2 9 1.
(3) Broad tropism: Some viral serotypes show relatively narrow transduction
specificity, or tropism, for particular cells or tissues, but many others have
broad tropism[30 l. This feature may be undesirable if the transgene is
expressed in non-target tissues following systemic delivery.
(4) Limited DNA packaging capacity: AAVs have a DNA cargo capacity of <5 kb;
retroviruses, lentiviruses, and some adenoviruses have packaging capacities
of -8 kb, which may limit the potential for transduction of long
transgenes[311.
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(5) Difficulty of production: Depending on the viral vector, raising the necessary
numbers of vector particles can be challenging, requiring purification
procedures that may be difficult and costly to scale up[3 21.
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Figure 2.3 Vectors used in gene therapy clinical trials worldwide since 1989
Adapted from Ginn et al.[3]
Non-viral gene therapy has the potential to address many of these
limitations, particularly with respect to safety. For DNA-based therapeutics,
transgenes are often encoded on plasmids that are episomal and non-integrating,
reducing the risk of cancer due to insertional mutagenesis. Moreover, due to the
general lack of pre-existing immunity, synthetic vehicles tend to have comparably
lower immunogenicity and toxicity. These carriers also have the potential to deliver
larger genetic payloads and are typically easier to synthesize.
A number of non-viral gene delivery strategies have been developed so far.
These strategies include the injection of naked DNA alone or in combination with
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physical methods[33-391, such as gene gun, electroporation, hydrodynamic delivery,
sonoporation, magnetofection, and laser irradiation. Because these techniques are
generally less applicable to systemic gene delivery in humans, a panoply of synthetic
delivery vectors have also been developed including lipids and liposomes 40 411,
polymers (linear and branched polymers, dendrimers, and polysaccharides)[42-50 ,
polymersomes[51I, cell-penetrating peptides 5 2-s4 , and inorganic nanoparticles[551.
Traditionally, synthetic vectors have been plagued by low delivery efficiency
relative to viral vectors[451.Whereas viruses have been naturally selected to deliver
their genomes efficiently to mammalian cells, most synthetic vectors have not been
designed to mediate gene delivery past the multiple barriers that confront them,
which are detailed in the next section.
2.3 BARRIERS TO SYSTEMIC NON-VIRAL GENE DELIVERY
2.3.1 Extracellular barriers
For systemic delivery of DNA therapeutics, an initial barrier is the poor
chemical stability of nucleic acids due to the presence of endonucleases in
physiological fluids and the extracellular space. The half-life of plasmid DNA has
been estimated to be 10 min. following intravenous injection in mice[56 and 60 min.
following intratracheal instillation in mouse lungs[571. For this reason, entrapment of
the DNA within a nanoparticulate carrier is desirable in order to provide protection
from nuclease degradation, as well as to improve circulation time.
Polyplexes, for instance, are spherical or toroidal nanoparticulate complexes
formed from the condensation of plasmid DNA by cationic polymers 461. The collapse
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of DNA's expanded wormlike chain, representing a loss of entropy, is driven
primarily by entropic gain due to the release of counterions upon polymer-DNA
binding, which is favored by electrostatic interaction between the cationic polymer
and the anionic phosphate backbone[581. Similarly, mixtures of cationic lipids,
neutral lipids, and DNA are able to spontaneously assemble into lipoplexes or
liposomes characterized by DNA entrapped within lamellar or inverted hexagonal
arrangements of lipid bilayers[91. An excess of cationic polymer or lipid promotes
enhanced DNA binding and the formation of stable complexes with positively
charged surfaces; however, at high salt concentrations, electrostatic repulsion
between the positively charged complexes is reduced, making them prone to
colloidal instability and aggregation within physiological fluids[60l. In particular,
aggregation of nanoparticles within the blood, either via colloidal instability or via
interaction with blood components such as serum proteins and erythrocytes, can
inhibit localization within the desired tissues, induce rapid clearance by circulating
macrophages, and even cause embolism within lung capillaries[ 421.
Selective accumulation of the gene therapeutic at the cell or tissue of interest
is another major challenge[611. Passive targeting can be achieved through
modulation of nanoparticle size, charge, shape, or surface chemistry. For instance,
systemic gene delivery to liver hepatocytes generally requires particles smaller than
-100-200 nm to traverse the fenestrated endothelium 6 2 , whereas uptake in
macrophages can be achieved with positively charged, spherical particles on the
order of 500 nm and above[631. Stabilization of nanoparticles with non-fouling
polymers such as polyethylene glycol (PEG) can increase circulation time within the
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blood and promote accumulation in tumors with leaky vasculatures, a phenomenon
known as the enhanced permeation and retention (EPR) effect[641. Active targeting
of synthetic gene vectors has been attempted using numerous ligands including
small molecules, vitamins, carbohydrates, peptides, growth factors, antibodies, and
aptamers 6 2 ,s651, but unfortunately there have been relatively few clear
demonstrations of efficacy.
2.3.2 Cellular internalization
Once the nanoparticulate gene carrier is within the vicinity of the target cell,
it may adsorb to the cell surface non-specifically through electrostatic interaction
with negatively charged proteoglycans[66 . Internalization and endocytosis of the
nanoparticle may then proceed through a variety of mechanisms[671 . Besides
phagocytosis for some types of immune cells, these endocytic mechanisms include
macropinocytosis, clathrin-dependent endocytosis, caveolae-mediated endocytosis,
and a growing number of clathrin- and caveolae-independent pathways such as
RhoA-dependent, Arf6-dependent, Cdc42-dependent, and flotillin-dependent
endocytosis[681. For most of the nanoparticles commonly used for non-viral gene
delivery, including poly-L-lysine (PLL) and polyethylenimine (PEI)-based
polyplexes, as well as various lipoplexes and liposomes, evidence exists for the use
of multiple endocytic mechanisms[69-771, not all of which may contribute to
successful gene expression[71' 781. In some cases, an active targeting ligand may allow
uptake and endocytosis of the nanoparticle to proceed selectively through one
pathway after binding to a specific cell surface receptorl 79 1.
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2.3.3 Endosomal escape
Once internalized, the nanoparticle will generally be located within a
vesicular structure known as an endosome formed from pinching off an
invagination of the membrane[681. Depending on the endocytic mechanism, cargo
within the endosomes may then follow a pathway leading through increasingly
acidified compartments toward enzymatic degradation within lysosomes (pH -4.5),
or may get recycled back to the extracellular space[671. Dissection of these routes has
been accomplished primarily via co-localization of the nanoparticles with certain
protein markers of endocytic trafficking pathways, such as caveolin-1 (caveolae),
Rab5 and EEA1 (early endosomes), Rab7 and ESCRTs (late endosomes), LAMP-1
(lysosomes), and Rab11 (recycling compartments)[ 801.
Efficient cytosolic localization and gene expression have generally been
assumed to depend on an active mechanism for endosomal escape mediated by the
gene carrier[461. For lipoplexes, two mechanisms have been proposed, one involving
interaction and fusion of the lipid carrier with endosomal membranes, and the other
involving detergent-like destabilization of these membranes[771. In contrast,
polyplexes have been hypothesized to escape via a "proton-sponge" mechanism
hinging on the ability of amines in the polymer with suitable pKa values to buffer
acidic endosomes or lysosomes 8 1 821. The polymer's ability to absorb protons
presumably results in increased activity of pH-dependent proton pumps, which in
turn promotes facilitated diffusion and internalization of chloride ions to maintain
electroneutralityle31. This increase in osmolarity is then thought to cause osmotic
swelling of the endosomes or lysosomes leading to rupture. Despite the relative lack
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of alternative hypotheses, this mechanism has been controversial, with some
reports providing evidence to bolster it[84 -861 and others challenging itl87 -8 91.
2.3.4 Cytosolic trafficking and nuclear localization
Microinjection experiments suggest that a key cellular barrier limiting the
efficiency of polymeric gene delivery is the transport of DNA from the cytoplasm to
the nucleus. Working with a mouse cell line deficient in thymidine kinase (TK),
Mario Capecchi reported nearly 30 years ago that if he microinjected plasmid DNA
encoding TK directly into the nuclei, 50-100% expressed TK activity, as detected by
the incorporation of 3H-thymidine into DNA following autoradiographic analysis[901.
However, in over 1,000 cells receiving cytoplasmic injections of the same plasmid
DNA, no TK activity was detected. The inefficiency of transgene expression following
cytoplasmic microinjection of DNA relative to nuclear microinjection has since been
confirmed by several other groupsl91 .
The importance of the nuclear barrier is further highlighted in the
observation that quiescent or slowly dividing cells with intact nuclei are generally
more difficult to transfect than cells that divide rapidly and undergo frequent
breakdown of their nuclear envelopes 921. In one study, transfection efficiency with
lipoplexes and polyplexes was found to be cell-cycle dependent: luciferase
expression was 30- to 500-fold higher in K-562 and HeLa cells transfected during S
or G2 phase compared with cells transfected during G1 phase[931. This effect was
much less pronounced (only a fourfold difference) when the cells were transduced
with recombinant adenoviruses.
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Both deterministic and stochastic kinetic models of synthetic gene delivery
have identified nuclear uptake as a potential rate-limiting step. In a direct
comparison of the kinetics of intracellular gene transfer by PEI and by an adenoviral
vector in the C3A human hepatocellular carcinoma cell line, one of the main
advantages of the adenovirus in its superior gene delivery was its faster rate of
nuclear import[941. Similarly, after running stochastic simulations of synthetic gene
delivery using PEI as an example, another group suggested that slow nuclear
transport greatly reduced overall delivery because plasmids in the cytoplasm are
quickly digested by nucleases[951, with an apparent half-life of 50-90 min[961. Due to
their relatively large size (25-80 nm in diameter), the diffusion coefficient of DNA
plasmids in the cytoplasm is estimated to be small, on the order of 10- or 104
[tm 2/s, and it has been observed for HeLa cells that DNA longer than 2,000 bp
undergoes little or no diffusion in the cell cytoplasm[971. Even so, polyplexes have
been seen to accumulate quickly in the perinuclear region apparently via motor-
protein driven transport on microtubules[981.
The nuclear envelope features a double membrane studded with -3,000-
5,000 nuclear pore complexes (NPCs) that serve as conduits between the nuclear
and cytoplasmic compartments. Transport through the NPCs is selective, not only
due to the small diameter of the pore (-25 nm), but also the presence of
hydrophobic Phe-Gly (FG) sequence motifs in nucleoporin proteins lining the
channel[991. Molecules with a molecular weight less than -40 kDa can enter the
nucleus passively, but larger molecules require active transport[1001.
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Several groups have tried co-opting endogenous mechanisms for nuclear
trafficking of proteins by directly attaching a nuclear localization signal (NLS)
peptide to plasmid DNA or to the vector; however, these efforts have yielded mixed
results likely attributable to confounding variables such as the conjugation method,
the site of attachment, and the number of NLS peptides attached, as well as masking
of the positively-charged NLS through its association with the negatively-charged
DNA backbone[101 -1031. An alternative strategy relies on the presence of a so-called
DNA nuclear targeting sequence (DTS) within the plasmid to enhance nuclear
localization, presumably by binding to newly synthesized transcription factors in
the cytoplasm that facilitate shuttling to the nucleus [92, 1041. The evidence in support
of such a strategy has also been mixed[1051.
2.3.5 Vector unpacking
Vector unpacking is generally assumed to be necessary for DNA release and
gene expression, but the extent to which suboptimal dissociation affects gene
delivery is not fully clear. For lipoplexes, it has been proposed that fusion of the
cationic lipid with endosomal membrane lipids facilitates not only endosomal
escape but also DNA release[106,1071. Polyplexes, meanwhile, have been observed to
localize to the nucleus intact where they presumably undergo dissociation[108 1091.
For certain polyplexes, mechanistic studies have implicated slow vector unpacking
as an explanation for decreased transfection efficiency["0-1121.A recent report
suggests that lipoplex-delivered plasmids are nearly 10-fold more efficiently
expressed, on the basis of protein expression per plasmid number in the nucleus,
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than polyplex-delivered plasmids, a potential consequence of incomplete polyplex
dissociation within the nucleus[113 .
2.3.6 Gene expression
For DNA therapeutics, expression of the transgene and production of the
protein of interest constitute the final barrier, which has sometimes been neglected
despite its significant contribution to the overall transfection efficacy of a gene
carrier. Plasmids are routinely used as expression vectors in non-viral gene therapy
studies due to the relative ease of construction and amplification. The choice of
enhancer/promoter combination has a tremendous impact on both the level and
duration of transgene expression. Viral enhancers and promoters derived from
cytomegalovirus (CMV), respiratory syncytial virus (RSV), and simian virus 40
(SV40) are frequently used to achieve high-level expression in a wide variety of
mammalian cell types and tissues, but this expression is typically short-lived[1 41.
Constitutive mammalian promoters such as the human polyubiquitin C (UbC) and
the elongation factor 1-a (EF1-a) promoters have been observed to result in more
persistent expression1" 51. Tissue-specific promoters such as the a-fetoprotein
enhancer/albumin promoter for expression within the liver[1161 offer the possibility
of enhanced safety by minimizing off-target transgene expression. Numerous cis-
acting sequences including various polyadenylation signals[1171, introns[117-1181, and
scaffold/matrix attachment regions (S/MAR) [1191 have been reported to increase the
level and persistence of transgene expression. DNA size and topology have been
shown to affect gene expression efficiency, with small, covalently closed circular
(ccc) plasmids mediating greater transgene expression than large or linearized
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constructs[12 01. Highly supercoiled plasmid DNA is often stated to be preferable for
transfection over relaxed forms, although there is evidence to contradict this
assumption[1211.
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Figure 2.4 Schematic representation of plasmid and minicircle vectors
Recently, compact DNA vectors known as minicircles have been developed
that demonstrate superior levels and duration of gene expression relative to full-
length DNA plasmids[12 2 -12 6 1. The major distinction between the two constructs is
that minicircles lack a bacterial backbone, consisting of an origin of replication and
an antibiotic resistance gene, necessary for propagation in bacteria, while retaining
only the mammalian expression cassette (Figure 2.4). Like plasmids, minicircles are
non-integrating and characterized by transient expression. However, minicircles
present at least four key advantages over plasmids: (1) increased potency due to the
elimination of features that are unnecessary for therapeutic gene expression; (2)
lower risk of TLR9-mediated immunogenicity owing to the reduction of
unmethylated CpG motifs[ 1 2 7 ,1 2 8 1; (3) increased gene delivery efficiency due to more
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compact DNA cargo; and (4) significantly greater level and potential for duration of
gene expression[ 1291. This last advantage has been hypothesized to result from the
absence of the bacterial backbone, which may induce gene silencing through the
formation of repressive heterochromatin[1301.
In an effort to promote longer-term expression, a number of systems for
transgene integration have been developed, including transposition systems based
on the recombinases phiC31[1311, piggyBac[1321, and Sleeping Beauty[1 33 1. However,
the safety of these integrating systems with respect to unwanted side effects as a
result of transgene insertion has not yet been established[1 .
2.4 OVERVIEW OF CURRENT NON-VIRAL VECTORS
To address these formidable barriers, myriad natural and synthetic materials
have been explored as non-viral vectors for safe and effective gene delivery. A brief
survey of the most commonly studied materials has been provided below.
2.4.1 Lipid-based vectors
Lipid-based vectors are among the most widely used and most clinically
advanced non-viral gene carriers. Fraley et al. first showed in 1980 that liposomes
composed of the phospholipid phosphatidylserine could entrap and deliver SV40
DNA to CV-1 monkey kidney cells[13 41. More efficient transfection was obtained in
1987 by Felgner et al., who demonstrated that the synthetic cationic lipid DOTMA
spontaneously formed small, uniform liposomes capable of efficient encapsulation
and delivery of DNA to various mammalian cell lines [1351. Cationic lipids such as
DOTMA are characterized structurally by three components: a cationic headgroup, a
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hydrophobic tail, and a linking group between these domains[411. DOSPA, DOTAP,
DMRIE, and DC-Cholesterol feature particular modifications of these three domains
and are examples of cationic lipids that have been applied for liposomal gene
delivery[1071 (Figure 2.5). Neutral lipids, such as the fusogenic phospholipid DOPE or
the membrane component cholesterol, have been included in liposomal
formulations as "helper lipids" to enhance transfection activity and nanoparticle
stabilityl401. Pairs of cationic lipids and helper lipids are widely available as
commercial reagents for in vitro transfection, with one example being
Lipofectamine, a combination of DOSPA and DOPE[4 1 1.
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Figure 2.5 Chemical structures of cationic and neutral lipids commonly used in
gene delivery studies
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Although some traditional liposomes including DC-Chol/DOPE and
DMRIE/DOPE have been applied clinically for gene therapy[411, their delivery
efficacy has generally been low due to poor stability and rapid clearance, and more
recently, lipid formulations have been developed that show greater clinical
potential[1361. So-called stable nucleic acid-lipid particles (SNALPs), or lipid-based
nanoparticles (LNPs), typically comprise at least four components including a
synthetic cationic amino lipid, a phospholipid such as DSPC, a PEG-lipid conjugate,
and cholesterol; these components are combined in an organic solvent such as
ethanol and then mixed with nucleic acids in an acidic aqueous buffer to form stable
nanoparticles[ 401. The most promising amino lipid materials, such as DLinDMA-
based ionizable lipids[1371 and cationic lipid-like molecules termed lipidoids[138,1391
(Figure 2.6), have been developed primarily for LNP-mediated delivery of RNAi
therapeutics and are currently under clinical investigation[ 14 0,1411. Interestingly, the
pKa of the ionizable DLinDMA-based lipids has been found to correlate tightly with
their hepatic gene silencing activity in mice, with an optimal pKa range of 6.2-6.5[1421.
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Figure 2.6 Synthesis of epoxide-derived lipidoids
Adapted from Love et al.[1391
In general, although they have been used to achieve systemic DNA delivery to
subcutaneous mouse tumor xenografts[1431, such LNPs appear to have less potency
for delivery of plasmid DNA as compared with siRNA, perhaps a consequence of
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poorer relative entrapment of the larger DNA cargo. An additional limitation is that
cationic lipids have been observed to stimulate immune or anti-inflammatory
responses[144 .
2.4.2 Polymeric vectors
The extraordinary chemical diversity of polymers has enabled a plethora of
biomaterials applications, most notably within the fields of tissue engineering and
the controlled release and delivery of drugs. Selected examples of polymers that
have been frequently studied as gene delivery vectors are highlighted below.
2.4.2.1. Poly(L-lysine)
Poly(L-lysine) (PLL) is a homopolypeptide of the basic amino acid lysine, the
side chain of which terminates in a primary E-amine with a pKa of ~9.3-9.5[145].
Polylysine's capacity to condense DNA has been known since at least the 1960s[146,
1471. Pioneering studies in the late 1980s indicated that PLL conjugated to the
asialoorosomucoid glycoprotein could potentially be applied toward non-viral liver-
targeted gene deliveryl1 4 8-1 4 9]. In general, in the absence of a lysosomal disruption
agent such as chloroquine, PLL has relatively poor transfection activity, presumably
because its amine groups tend to be positively charged at physiological pH and
therefore have low capacity for endosomal buffering and lysis[ 41]. Moreover,
unmodified PLL demonstrates fairly significant in vitro cytotoxicity[150l. Numerous
modified variants of PLL with enhanced gene delivery properties have been
reported[14s. One prominent example includes the grafting of histidine's imidazole
functionalities (pKa ~ 6.5) to the side chains of PLL in an effort to increase its
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endosomal buffering capacity[151l. Another example is the synthesis of a degradable
polyester analog of PLL, poly[a-(4-aminobutyl)-L-glycolic acid] (PAGA), which is
characterized by improved transfection activity and reduced cytotoxicity[15 21.
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Figure 2.7 Chemical structures of selected polymeric gene vectors
2.4.2.2. Polyethylenimine
Polyethylenimine (PEI) and its variants have become the most widely used
polymeric materials for gene delivery. With a nitrogen atom at every third position
along the polymer, PEI is capable of an extremely high charge density at reduced pH
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values, a characteristic which is postulated to aid in condensation of DNA and
endosomal escape[15 31. PEI's gene transfection activity in vitro was first
demonstrated in 1995 by Behr and colleagues[811. Soon after, it was shown that the
transfection efficiency and cytotoxicity of PEI strongly depend on its structural
properties, especially with respect to molecular weight[154 (MW) and the linear
versus branched forms[155-1561. In mice, intravenous injection of PEI/DNA polyplexes
has been observed to afford gene transfection in the lungs[157-1591, perhaps as a
result of nanoparticle aggregates accumulating within pulmonary capillaries[ 6 01.
Several groups have also reported tumor gene delivery in mice using PEI/DNA
polyplexes[161,1621. In humans, PEI is under clinical study for local gene therapy of
bladder cancer (ClinicalTrials.gov ID: NCT00595088) and pancreatic cancer
(ClinicalTrials.gov ID: NCT01413087). Nonetheless, because PEI is well known to
induce significant cytotoxicity[163,1641, modifications to PEI have been extensively
investigated, with prominent examples including block copolymers of PEG and PEI
to improve stability and biocompatibility[165 ,1661, degradable disulfide-crosslinked
PEls to reduce toxicity[1671, and alkylated PEI to increase potency[168 ,1691.
2.4.2.3. Poly[(2-dimethylamino) ethyl methacrylate]
Poly [(2 -dimethylamino) ethyl methacrylate] (pDMAE MA) is a water-soluble
cationic polymer first investigated for gene delivery by Hennink and coworkers[170,
1711. Effective DNA condensation and gene transfer require relatively high MW (>300
kDa) pDMAEMA[1 721. Although these polymers have been evaluated in rodents for
systemic in vivo gene delivery[1 73,1741, additional studies are needed to ameliorate
aggregation and toxicity issues that have been observed[1751.
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2.4.2.4. Carbohydrate-based polymers
A number of promising natural and synthetic carbohydrate-based polymers
are currently under study for gene delivery applications. One of the oldest chemical
methods of transfection, developed in the late 1960s, involves the use of cationic
diethylaminoethyl (DEAE)-modified dextran[1761; however, this material is mainly
limited to in vitro gene transfer for biological studies. A carbohydrate-based
material more actively being researched is chitosan, a polysaccharide derivative of
chitin composed of cationic glucosamine and N-acetyl glucosamine units joined by
P(1,4) glycosidic linkages. A relatively biocompatible, biodegradable, and
inexpensive material, unmodified chitosan has relatively low transfection activity,
but modified versions of chitosan have been synthesized with greater gene delivery
potential[1 7 7 -1781. Chitosan's mucoadhesive and permeability-enhancing properties
have enabled its use for certain oral gene delivery applications[1791, such as
immunization of mice against peanut antigen-induced anaphylactic responses[1801.
Produced from the enzymatic degradation of starch, cyclodextrins (CDs) are
cyclic oligosaccharides of glucose linked by a(1-4) glycosidic bonds, with six-, seven-
, or eight-membered glucose rings respectively defining the a-, P-, or y-variants.
Cyclodextrin's membrane-permeabilizing properties have been exploited for gene
transfection through the synthesis of CD-based polymers and through the grafting of
CDs to existing gene delivery materials[1811. Davis and colleagues synthesized novel,
linear P-CD-containing polycations and described the effects of a variety of
structural modifications on gene transfection activity[182 1 8 41. Although they are
typically extremely water soluble, CDs are characterized by a cup-shaped topology
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with a hydrophobic internal cavity that can facilitate the inclusion of non-polar
guest molecules such as poorly soluble drugs18 51. This unique feature was used to
enable direct non-covalent PEGylation of polyplexes formed from p-CD-containing
polymers and DNA through the addition of adamantane-PEG conjugates; stable
ternary complexes are efficiently formed due to the interaction of adamantane with
CD[1 86 1. Targeted versions of these CD-containing polymer systems are currently
under clinical investigation for delivery of RNAi therapeutics to solid tumors [187,188].
2.4.2.5. Dendrimers
Dendrimers are polymers featuring perfectly defined, tree-like molecular
architectures in which monomers with branching points radiate symmetrically from
a central core[501. They are synthesized in a stepwise fashion, with each reaction step
yielding a new layer and defining an additional "generation" of dendrimer. A
chemically diverse set of cationic dendrimers has been studied for gene deliveryl491,
with the most common based on polyamidoamine (PAMAM). The potential of
PAMAM dendrimers for in vitro gene delivery was first explored through a series of
studies in the mid-1990s[189-1911. Like PEI-based polymers, PAMAM dendrimers have
a high density of secondary and tertiary amines and appear to be capable of
endosomal buffering and osmotic swelling[8 51. PAMAM/DNA complexes have also
been observed to accumulate and mediate transgene expression within the mouse
lungs following systemic administration[1921 . Moreover, they have been used for
suicide gene therapy of subcutaneous mouse tumor xenografts via intratumoral
injection1 93,194]. As with many cationic vectors, one issue has been toxicity
associated with PAMAM's positive charge[501, but a variety of modified PAMAM
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dendrimers have recently been developed to improve the efficacy and safety profile
of these materials[1951.
2.4.3 Cell-penetrating peptides
Within the last two decades, hundreds of natural and synthetic cell-
penetrating peptides (CPPs) have been identified and developed, with most falling
into two classes, cationic arginine-rich peptides and amphipathic peptides[1961. The
former class includes the HIV TAT protein transduction domain (PTD), the
Drosophila Antennapedia homeodomain-derived penetratin peptide, and the
synthetic octoarginine (Arg8) peptide, whereas the latter class includes the chimeric
peptides KALA, MPG, Pep-1, and Transportan (Table 2.1).
TAT HIV-1 TAT YGRKKRRQRRR [9
(47-57)
transcriptional
activator
Penetratin Drosophilia RQIKIWFQNRRMKWKK [198]
Cationic Antennapedia
homeodomain
Ar8Chimeric RRRRRRRR [19-,
2001
CHs-TAT-HsC Chimeric CHHHHHRKKRRQRRRRHHHHHC [201]
KALA Chimeric WEAKLAKALAKALAKHLAKALAKALKACEA [202]
MPG Chimeric GALFLGFLGAAGSTMGAWSQPKKKRKV [2031
Amphipathic Pep-1 Chimeric KETWWETWWTEWSQPKKKRKV [204]
Transportan Chimeric GWTLNSAGYLLGKINLKALAALAKKIL [205]
PPTG1 Chimeric GLFKALLKLLKSLWKLLLKA [206]
Table 2.1 Selected examples of cell-penetrating peptides
Although these peptides have been fused to or non-covalently complexed
with nucleic acids to promote cellular internalization, the major limitation for many
CPPs is the inability to mediate efficient endosomal escape[2071. For this reason, CPPs
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are often either conjugated to traditional non-viral gene vectors such as polyplexes
or liposomes[208I, or they are otherwise designed with specific functionalities to
enhance endosomal escape or overall gene transfection[5 3, 2071. Examples of peptides
intentionally designed to mediate more efficient gene transfer include an
endoosmolytic TAT peptide incorporating cysteine and histidine residues[2011 (CHs-
TAT-HsC), an N-terminal stearylated oligoarginine peptide[2091, and the chimeric
amphipathic peptide PPTG1[ 206I.
2.4.4 Inorganic nanoparticles
Several kinds of inorganic nanoparticles (NPs) have been applied for non-
viral gene delivery, most prominently silica, gold, iron oxide, quantum dots, and
carbon nanotubes[551. Technically, inorganic NPs have been used since the 1970s to
achieve low levels of in vitro gene transfer using the method of calcium phosphate
transfection 2101. While calcium phosphate NPs continue to receive some study, more
recently attention has shifted to NPs with better prospects for in vivo translation.
Each class of inorganic NP presents particular advantages and disadvantages.
For instance, silica NPs are considered biodegradable and relatively biocompatible,
with surfaces that are easily functionalized, but they present some issues with
respect to toxicity[2 1 1 -2 1 31. Similarly, gold NPs are easily functionalized using thiol
moieties, and can enable a number of interesting imaging and treatment modalities
such as photothermal cancer therapy, but they lack degradability[2141. Useful as MRI
contrast agents and effectors for magnetic hypertherapy, iron oxide NPs are
biodegradable and biocompatible, but achieving uniform surface functionalization
and NP stabilization is challenging[215l. Quantum dots are extremely small particles
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(< 10 nm) that can enable unique fluorescent imaging applications[ 2161, but elements
commonly present within their cores, especially cadmium and selenium, are known
to induce considerable cytotoxicity[2 171. Finally, the unique physical and chemical
properties of carbon nanotubes (CNTs), which allow them to be easily
functionalized and applied as photoluminescence, Raman, and photoacoustic
contrast agents[21 l, are quite exciting, yet concerns remain regarding their lack of
degradability and potential toxicity[2191.
In order to bind nucleic acids and mediate transfection, the surfaces of most
inorganic NPs need to be suitably functionalized. Silica nanoparticles, for example,
have been shown to yield efficient gene delivery when functionalized with various
amine groups[220' 2211 or with PAMAM dendrimers[221 . Preliminary studies have
established that amine-functionalized CNTs are capable of binding and condensing
plasmid DNA[ 2 2 , 2231. Recently, magnetically-enhanced delivery of DNA and RNA was
accomplished using novel lipidoid-coated iron oxide NPs[ 224I. Gold nanoparticles,
meanwhile, have been shown to mediate effective gene transfection in vitro when
conjugated to PEI[225 2261. In another example, efficient siRNA transfection of stem
cells was achieved using gold nanoparticles functionalized with poly(p-amino
ester)s, a promising group of cationic polymers which are described at length in the
next section.
2.5 DEVELOPMENT OF POLY(BETA-AMINO ESTER)S FOR GENE THERAPY
Poly(p-amino esters) (PBAEs) are a class of polymeric gene vectors
characterized by their relative ease of synthesis and their biodegradability. With
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their ability to condense plasmid DNA into nanoparticles on the order of 50-200 nm
in diameter, PBAEs have demonstrated high gene delivery efficiency to a variety of
cell types with low cytotoxicity[2 271. In addition to gene transfer, these polymers
have been employed for a number of other applications, including hydrophobic drug
delivery[2 2 8-2 3 41, biomaterials for cell encapsulation and tissue engineering[23 -238],
drug release from polyelectrolyte films[ 239-2421, and the modification of other
delivery materials[2 4 3 , 2441. PBAEs have also been incorporated into poly(lactic-co-
glycolic acid) (PLGA) microparticles for the generation of improved non-viral
genetic vaccines for cancer[245, 246]. The rapid development of poly(p-amino ester)s,
from their initial synthesis and characterization to their extensive preclinical
evaluation ten years later, owes at least in part to the powerful approach of
combinatorial polymer library synthesis coupled with high-throughput screening
and characterization.
2.5.1 Initial synthesis and characterization
Although in the 1980s the synthesis of poly(ester amines) formed from the
Michael-type addition of bisfunctional amines to diacrylate esters had been
previously reported[247, 2481, the suitability of these polymers as gene carriers was
first explored in 2000 by Lynn and Langer[249I. The polymer reaction scheme is
displayed in Figure 2.8. These polymers were selected for investigation for three
reasons. First, it was hypothesized that the incorporation of tertiary amines into the
polymer backbone could facilitate electrostatic interactions with DNA as well as
buffer the endosomal compartment, allowing for escape of DNA to the cytoplasm[811.
Second, the presence of hydrolysable ester bonds in the backbone offered the
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possibility of a less toxic polymer than non-degrading alternatives, assuming that
the small-molecule acid degradation products could be cleared rapidly. Third, and
perhaps most significantly, the polymers could be synthesized in a one-step reaction
from commercially available monomers with a range of structural diversity, thereby
allowing the investigation of structure-property relationships and the engineering
of polymers with desired functionalities. In this initial study, three such polymers
were synthesized from the addition of the bis(secondary amines) N,N'-
dimethylethylenediamine, piperazine, or 4,4'-trimethylenedipiperidine to 1,4-
butanediol diacrylate, and critical features of the resulting polymers, including the
degradation kinetics, cytotoxicity, and DNA binding abilities, were explored.
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Figure 2.8 Synthesis of poly(p -amino ester)s
Poly(p-amino ester)s are synthesized from either the conjugate addition of a
primary amine to a diacrylate monomer (top), or from the addition of a
bis(secondary amine) to a diacrylate monomer (bottom).
Clearly, the degradation kinetics of an ideal gene delivery carrier should
reflect a careful balance between a slow rate that inhibits unpacking and clearance
and a rapid rate that precludes its functional utility. The degradation profiles of the
polymers were assessed in water at 37*C in the presence of salt at two
physiologically relevant pH values: (1) pH 5.1, roughly the pH encountered in the
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lysosome, and (2) pH 7.4, as is encountered in the cytoplasm. In general, the
polymers, which ranged in molecular weight from 5.8 to 31.2 kDa, degraded more
rapidly at pH 7.4, with two of the polymers undergoing complete degradation within
5 hours. At the reduced pH, the half-life was approximately 7-8 hours. Though at
odds with the well-known phenomenon of acid- (or base-) catalyzed ester
hydrolysis, these degradation profiles match those of similar polyesters containing
pendant amines; these amines are thought to act as intramolecular nucleophilic
catalysts for which reactivity increases with pH[25 0 , 251]. Given that the polymers
contained only tertiary amines, which make for poor nucleophiles, Lynn and Langer
considered this mechanism unlikely, but a more in-depth mechanistic investigation
of the degradation kinetics of such polymers has not yet been performed.
To assess cytotoxicity, the authors used the commonly employed MTT assay.
Strikingly, at concentrations as high as 100 pg/mL, the polymers had no effect on
the viability of NIH 3T3 cells. In contrast, linear 25 kDa polyethylenimine (PEI) was
highly toxic at this concentration, lending support to the hypothesis that the
incorporation of degradable functionalities helps to reduce the toxicity of cationic
polymers. The polymers also appeared promising in their capacity to bind and
condense DNA. An agarose gel retardation assay showed that these polymers could
inhibit the migration of plasmid DNA at weight ratios above 10:1 polymer:DNA.
More importantly, quasi-electric light scattering revealed that in HEPES buffer at pH
7, complexes formed from the polymers and DNA above a 2:1 weight ratio were in
the range of 50-150 nm. The measured C-potentials for these complexes were
slightly positive at +10-15 mV, and the relative consistency of both particle size and
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charge over time at 25'C suggested good particle stability with only a minor degree
of particle aggregation. In general, as the polymer:DNA weight ratio increased, the
polymer was better able to condense DNA into nanoparticles of smaller size with a
more positive C-potential. For in vitro gene delivery, the slight positive charge on the
particles may be desirable with respect to facilitation of cellular uptake via
electrostatic interaction with the negatively charged cell surface.
One year later, Lynn and colleagues published a follow-up report in which
they synthesized an initial library of 140 structurally diverse poly(p-amino esters)
and screened them for DNA binding ability and in vitro transfection efficiency[151].
This paper provided a significant proof-of-concept for the combinatorial library
approach to the identification of superior gene delivery materials. The library was
formed by reacting 7 different diacrylates with each of 20 different amines. The
resulting polymers ranged in molecular weight from 2 to 50 kDa, and half of them
were sufficiently water-soluble to be included in a high-throughput DNA binding
assay. Using an agarose gel slab with 500 lanes, they found that 56 of 70 water-
soluble PBAEs could retard plasmid DNA when complexed at a polymer:DNA weight
ratio of 20:1.
They then tested whether these PBAEs could mediate delivery and
expression of a luciferase-encoding plasmid DNA in COS-7 cells, an immortalized
line of African green monkey kidney fibroblasts frequently used in transfection
assays. Two of the polymers yielded transfection levels 4 to 8 times that of PEI, with
their performance rivaling that of a leading commercially available lipid reagent,
Lipofectamine 2000. The short time required for these experiments, two weeks
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from library synthesis to identification of "hits," further bolstered the value of this
approach.
A more thorough characterization of this initial library revealed additional
features of the structure-activity relationship for these polymers[25 21. In general,
smaller particle sizes below 250 nm and positive C-potentials were correlated with
higher rates of DNA uptake, as assessed by the degree of internalization of a
fluorescently labeled plasmid. Additionally, the authors used a FACS-based assay
they developed[25 31 to measure the local pH environment of the delivered DNA. In
this assay, pH values of 5 or less indicate that the polyplexes are unable to avoid
eventual trafficking to lysosomes, whereas values closer to neutral pH suggest that
the polymeric vector has mediated endosomal escape. The polymer-DNA complexes
with the highest transfection efficiency in this library yielded average pH
measurements above 6.5, implying that they had been able to buffer the endosome
and successfully escape the lysosomal pathway. With regard to cytotoxicity, the
majority of the DNA nanoparticles formed from PBAEs in this library appeared to
have no impact on cell viability as measured by the MTT assay. Optimization of the
synthesis, formulation, and transfection conditions for two members of the library
resulted in polyplexes that could yield higher gene transfection efficiency in COS-7
cells than Lipofectamine 2000 and PEI[2 5 41.
2.5.2 High-throughput screening and selection
To accelerate the development of these polymeric gene carriers, Daniel
Anderson and colleagues in the same group synthesized a large combinatorial
library of 2,350 structurally distinct PBAEs from the reaction of 25 diacrylates,
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designated by letters, with 94 primary or bis(secondary amine)s, designated by
numbers.[25 l Because the polymer products were generally viscous and therefore
not amenable to automated fluid handling, all polymerization reactions were carried
out in DMSO in a 96-well plate format, and the resulting polymer-DMSO solutions
were directly processed for downstream characterization and screening. The
authors determined that the residual levels of DMSO had no effect on gene delivery
efficiency or cytotoxicity. After optimization of transfection conditions, 46 of the
polymers, or roughly 2%, were found to transfect COS-7 cells at efficiencies better or
equal to that of PEI.
Analysis of the structure-activity relationship for the lead polymers from this
first-generation library suggested that the acrylate monomers were almost always
hydrophobic, whereas the amine monomers tended to contain an alcohol, imidazole,
or secondary diamine. It was also observed that the molecular weight and end-
group termination, as governed by the ratio of monomers used during
polymerization, dramatically affected transfection efficiency. Consequently, the
authors decided to synthesize a more focused, second-generation library of PBAEs
with 6 to 12 different molecular weights and chain end-groups - 486 variants in all -
to probe the structural space represented by the best performing polymers[ 256I.
In this focused library, the top performing PBAEs converged in chemical
structure, lending support to the identification of important structure-function
trends. The top nine polymers were synthesized from amino alcohols, which may
suggest a key role for pendant hydroxyl functionalities in the side chains. The top
three polymers, C32, JJ28, and C28, differed in structure by only one carbon. Formed
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from the addition of 5-amino-1-pentanol ("32") to 1,4-butanediol diacrylate ("C") at
a molar ratio of 1.2:1, C32, the most effective polymer overall, outperformed PEI and
Lipofectamine 2000 in transfection of COS-7 cells. This polymer also formed the
tightest complexation with DNA, resulting in 71 nm particles with a -potential of
+15 mV in HEPES buffer at pH 7.2. C32 synthesized with a 1.2:1 amine:acrylate ratio
was nearly 50-fold more effective than C32 synthesized with a ratio of 1.025:1. This
difference in transfection efficiency is likely due to differences in both molecular
weight and terminal chain groups.
In another study, the C32 PBAE was used to deliver a suicide gene to prostate
tumor xenografts in mice[25 71. The prostate tumor xenografts were generated by
mixing PC3 or LNCaP human prostate cancer cells with Matrigel and injecting the
cells subcutaneously into the flanks of nude (athymic) mice. As a proof-of-concept,
two days after intratumoral (i.t.) injection of a luciferase-encoding plasmid
complexed with C32 nanoparticles, the local level of luminescence was 26-fold
higher than with naked DNA alone and 4-fold higher than could be achieved with in
vivo-jetPEI, a commercially available linear PEI intended for in vivo application.
Interestingly, intramuscular injections yielded the opposite results; naked DNA gave
the highest expression in healthy muscle, followed by jet-PEI and then C32,
suggesting that the PBAE/DNA nanoparticles may be useful for targeting tumors
while avoiding the surrounding healthy tissue. Histological analyses of the muscle
tissue injected with the PBAE nanoparticles showed no evidence of pathology, and
there was no significant difference relative to saline-injected mice with respect to a
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number of commonly used toxicity markers for renal function, liver function, and
muscle damage.
The researchers then used C32 to deliver a DNA construct encoding the A-
chain of the diphtheria toxin (DT-A) to the prostate tumor xenografts. DT-A inhibits
protein synthesis and causes apoptosis by catalyzing the transfer of ADP-ribose
from NAD to elongation factor 2 (EF-2), which is essential for protein production.
Because tight control of DT-A expression is crucial, two levels of gene regulation
were used. The construct, which also encodes the Flp site-specific recombinase,
must undergo a recombination event by Flp in order to express DT-A. Because Flp
transcription is driven by a modified promoter/enhancer of the human prostate
specific antigen (PSA) gene, DT-A expression is localized to prostate cells. When a
series of i.t. injections of nanoparticles containing C32 and the DT-A construct was
performed, the average growth rate of these tumors was suppressed twofold
compared with tumors injected with a mock treatment. 40% of the experimentally
treated tumors regressed in size. Combined with the data showing that C32
transfected healthy muscle poorly without noticeable toxicity, these experiments
provided evidence that PBAEs may be promising carriers for suicide gene delivery
for prostate cancer.
2.5.3 End-modification and ligand coating for cell-specific gene delivery
Because the high-throughput screening results highlighted the importance of
the terminal functional group, researchers in the Langer lab synthesized and
characterized a third-generation library of amine end-capped PBAEs[258 -2 60 . The
researchers were motivated by the desire to further expand the limits of the
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chemical space imposed by the conjugate addition reaction[2 611. To this end, in one
version of the library, they developed a synthesis scheme (Figure 2.9) that involved
the production of an intermediate acrylate-terminated C32 polymer, which was then
end-capped by reaction with each of 37 different amine molecules, including
primary monoamines and primary or secondary diamines [2591.
HO-" NH2
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Figure 2.9 Synthesis of amine end-modified PBAEs
5-amino-1-pentanol (32) is added to an excess of 1,4-butanediol diacrylate (C) to
yield acrylate-terminated C32, which is then reacted with excess diamine to produce
amine end-modified PBAE.
The modification of the end groups had a significant impact on in vitro
transfection efficiency. Following optimization of the polymer:DNA weight ratio, five
of the 37 provided gene delivery performance better or equal to that of the
unmodified C32 polymer in COS-7 cells. The most effective polymers were those
conjugated with primary diamines, but even among these polymers, single carbon
differences in the end-capping group dramatically modulated DNA binding ability
and cellular uptake. Characterization of C32-117, a lead end-modified PBAE, relative
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to unmodified C32, showed that this polymer was able to complex DNA roughly
twice as efficiently, form nanoparticles that were 30% smaller, and mediate a
twofold improvement in plasmid cellular uptake[258 . Because the unmodified
polymer contained no primary amines, with its chains terminating in alcohol
groups, the authors reasoned that the addition of primary amine end-groups
increased the polymers' cationic charge, which improved DNA binding and
condensation[2611. For the first time, cationic polymers, including C32-117 and two
other end-capped PBAEs, were shown to be nearly as effective as adenovirus at
transfecting primary human endothelial cells.
The polymer group was also found to alter the specificity of in vitro gene
transfection in various cell lines[2 62 1. In a report that screened 60 additional end-
capped C32 variants for transfection efficiency in five different cell lines, it was
observed that in some cases, variants that yielded the maximum transfection
efficiency for delivery to one cell line mediated little or no transfection in others. For
example, C32-117 was found to yield high levels of transfection in the HeLa human
cervical cancer cell line and the HepG2 human hepatocellular carcinoma cell line,
but not in the DC2.4 immortalized murine dendritic cell line; in contrast, a different
end-modified variant, C32-254, had excellent performance in DC2.4 cells and poor
activity in HeLa and HepG2 cells. End-capped PBAEs have demonstrated particularly
efficient DNA transfection of cultured stem cells; for this reason, they have been
used to genetically modify mesenchymal stem cells and embryonic stem cell-derived
cells for the promotion of angiogenesis in a mouse ischemic hindlimb modell263, 2641.
Recently, end-modified PBAEs have been used for non-viral gene transfection of
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mouse mammary epithelial cells[2651, human endothelial cells[2 6 6 1, and human
glioblastoma cells[267, 2681.
End-modified C32 polymers were also found to have promising in vivo gene
delivery performance. In transgenic mice bearing ovarian tumors, C32-117 was able
to deliver and mediate strong expression of a luciferase gene in the tumors at a level
significantly higher than that of unmodified C32 following intraperitoneal
administrationl 25 8 .A follow-up study demonstrated preclinical safety and efficacy of
C32-117 complexed with a DT-A gene construct for suicide gene therapy of three
different mouse models of ovarian cancer[2691. Biodistribution data in mice
suggested that intraperitoneal administration of PBAE/DNA polyplexes yielded high
gene expression in the fat and stomach, whereas intravenous administration
resulted in expression concentrated in the lungs, liver, and spleen[2 91. Perhaps in an
analogous manner to the cell line preferences observed in vitro, the polymer end
group may play a role in dictating organ-to-organ differences in gene expression.
One of the long-term objectives in the drug delivery field has been the
incorporation of targeting functionalities to reduce possible adverse effects of
nonspecific delivery and to minimize the total drug dose required. As mentioned
earlier, these targeting functionalities include small molecules, peptides, proteins,
antibodies, or aptamers that recognize and bind to cell surface markers expressed
specifically in the tissue of interest. The integrin-binding arginine-glycine-aspartic
acid (RGD) peptide has been well-studied for its ability to enhance tumor-targeted
drug delivery due to the overexpression of xvp3 and avp5 integrins on the surface
of endothelial cells in many malignant tumors[2701.
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The use of RGD peptides to achieve targeted gene delivery with poly(p-amino
ester)s has been explored. In one study, the RGD peptide was chemically conjugated
to the side chains of poly(P-amino ester)s via disulfide linkages, which enabled the
targeting ligand to be cleaved upon encountering the reducing environment within
the cell[2 7 11. In another study, an RGD peptide was linked to a stretch of negatively
charged glutamate residues, and the anionic peptide was electrostatically coated to
the surface of positively charged PBAE/DNA nanoparticles by mixing at a slightly
acidic pH[27 21. RGD-coated C32/DNA nanoparticles were found to deliver DNA in a
ligand-specific manner to primary human umbilical vein endothelial cells (HUVEC).
It has been further reported that PBAE/DNA nanoparticles coated with various
peptides can mediate tissue-specific gene expression in mice even in the absence of
a particular targeting motif like RGD, although the mechanism at play is
unknown[2731. Electrostatically coated targeting ligands may be advantageous to
those that are chemically coupled because they may be less likely to alter the
chemical and biophysical properties of the polymer that enable efficient
delivery[2741.
2.5.4 Unsolved challenges
As illustrated above, PBAEs have shown tremendous potential as non-viral
vectors for gene therapy. Nonetheless, for this class of polymers, several challenges
and questions remain, among them the following three:
(1) Poor stability under physiological conditions: Aggregation in the blood poses a
serious challenge to the development of many cationic gene delivery
polymers for systemic administration. For PBAE/DNA polyplexes, one
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indication of poor stability is the rapid growth in particle diameter within
minutes of dilution in a high ionic strength buffer. As seen from dynamic light
scattering (DLS) measurements in Figure 2.10, at low salt concentration,
polyplexes remain relatively stable at either pH 5.2 or pH 7.55; however, at
physiological salt concentration (150 mM NaCI), nanoparticles demonstrate a
rapid increase in diameter, implicating salt as a major contributor to polyplex
aggregation. Another sign of instability has been breathing difficulty and
acute toxicity observed in some mice upon intravenous injection of
polyplexes, suggesting the possibility of embolism with lung capillaries.
1400
1200 25 mM NaOAC (pH 5.2)
1000
800 25 mM HEPES (pH 7.55)
6 800 25 mM HEPES + 150 mM
400 NaCl (pH 7.55)
200 PBS (pH 7.4)
0
0 5 10 15 20 25 30
Time after addition of indicated solution (min)
Figure 2.10 Aggregation of PBAE polyplexes under physiological conditions
Polyplexes consisting of the PBAE C32-122 and plasmid DNA were prepared at a
30:1 w/w ratio in 25 mM sodium acetate buffer (NaOAc) at pH 5.2. After a 5 min
incubation at RT, the polyplexes were diluted in the indicated buffers and the
diameters were measured by dynamic light scattering (DLS).
(2) Batch-to-batch variability: Inconsistency in the transfection performance of
various batches of PBAE polymers has sometimes been observed, as shown
in Figure 2.11. This variation was hypothesized to result at least in part from
subtle differences in the molecular weight distributions (MWD) of the
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batches. As a result, we were motivated to examine in detail the effect of MW
and MWD on the gene delivery properties of amine end-modified PBAEs, a
subject which had not yet received systematic investigation.
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Figure 2.11 PBAE batch-to-batch variability
Different batches of the PBAE C32-117 were complexed with GFP-encoding plasmid
DNA and incubated with HepG2 cells. Transfection efficiency was assessed after 24
h by FACS analysis.
(3) Limited understanding of cellular uptake and trafficking: The mechanisms by
which PBAE polyplexes are internalized and trafficked within cells have not
yet been studied. This lack of knowledge represents a hindrance to the
rational design of more effective gene carriers.
As suggested in the introduction, the thesis research detailed here aims to
make contributions within these areas that deepen our understanding of the gene
delivery properties of these polymers and facilitate their continued development as
non-viral gene vectors.
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3 DEVELOPMENT OF DEGRADABLE HYDROPHOBIC
POLY(BETA-AMINO ESTER) TERPOLYMERS FOR
ENHANCED GENE DELIVERY POTENCY AND
NANOPARTICLE STABILITY*
3.1 INTRODUCTION
Gene therapy is a promising treatment strategy for a variety of inherited and
acquired diseases, but safe and efficient delivery remains a challenge. Though gene
therapy mediated by viral vectors has recently made great clinical progress,
limitations associated with their use persist, such as the possibility of adverse
immune reactions, the difficulty of repeat dosing, and small DNA loading
capacities.[" 21 Non-viral vectors, meanwhile, continue to suffer from generally low
DNA delivery efficiency.[3 1 Nonetheless, the diversity of synthetic materials offers
potential for the identification and incorporation of functional motifs that confer not
only efficient gene transfection, but also formulation stability and
biocompatibility.[4
Poly(P-amino ester)s (PBAEs) are a class of cationic gene delivery polymers
that have been studied pre-clinically for applications including local cancer therapy
and the genetic modification of stem cells for treatment of ischemia[5 ,61. Synthesis is
relatively simple and versatile, and is based on the Michael-type conjugate addition
* This chapter has been published as Eltoukhy, A. A., Chen, D., Alabi, C. A., Langer, R.,
Anderson, D. G. Degradable terpolymers with alkyl side chains demonstrate
enhanced gene delivery and nanoparticle stability. Adv. Mater. 25, 1487 (2013).
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of a primary or secondary amine to a diacrylate. Using this approach, combinatorial
library synthesis and high-throughput screening methods have been developed to
identify polymers that deliver DNA with high efficiency and low cytotoxicity[7-91.
Through these experiments, structural features associated with highly active gene
delivery polymers have emerged, such as the presence of hydroxyl groups in the
side chains and the conjugation of certain primary amines to the chain ends[1013 1. In
addition to high transfection efficiency, the degradability of the polyester backbone
offers the possibility of reduced toxicity and rapid clearance, a feature that
distinguishes PBAEs from polyethylenimine (PEI), the most widely used gene
delivery polymer[141.
Cationic polymers can form polymer-DNA polyplexes that may aggregate
under physiological conditions[15-161. This potential aggregation in the blood
represents a serious barrier to the systemic delivery of nucleic acids, since large
aggregates can in some cases lead to embolism or otherwise may be quickly cleared
by the reticuloendothelial system[16,171. Colloidal stability is a complex phenomenon
influenced by many factors including concentration, surface charge, pH, ionic
strength, and the presence of serum proteins, but a common approach to improve
formulation stability is to introduce a polymer shield comprising polyethyleneglycol
(PEG), poloxamers, or other non-fouling polymers[181.Although attachment of PEG
can be covalent or non-covalent, the latter may be preferable to avoid potential
issues resulting from direct PEGylation of gene delivery polymers, such as impaired
DNA condensation and decreased uptake[19, 20. For nanoparticles with sufficiently
hydrophobic surfaces, one simple non-covalent approach entails coating the
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particles with PEGylated phospholipid conjugates[211. Therefore, we hypothesized
that the inclusion of long, linear alkanes in PBAE side chains might facilitate non-
covalent, hydrophobic interaction with PEG-lipid conjugates, resulting in stable
particle formulations upon nanoprecipitation with DNA at high concentration.
Because the modification of cationic polymers with hydrophobic groups has been
reported to increase the physical encapsulation of nucleic acids, promote cellular
adsorption, and reduce the positive surface charge associated with cytotoxicity and
aggregation, we further hypothesized that hydrophobic PBAE terpolymers might
deliver DNA more efficiently than PBAEs lacking alkyl side chains and might
condense DNA into polyplexes with greater aggregation resistance[22 -241.
3.2 MATERIALS AND METHODS
3.2.1 Materials
Diacrylate and amine monomers, as well as end-capping reagents, were
purchased from Sigma-Aldrich (St. Louis, MO, USA), Alfa Aesar (Ward Hill, MA, USA),
TCI America (Portland, OR, USA), and Monomer-Polymer & Dajac Labs (Trevose, PA,
USA). (PEO)4-bis-amine ("122") was acquired from Molecular Biosciences (Boulder,
CO, USA). All reagents were used without further purification. Plasmid DNA
encoding green fluorescent protein (gWiz-GFP) was purchased from Aldevron
(Fargo, ND, USA). PEG-lipid conjugate (1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000], or 18:0 PEG5000
PE) was obtained from Avanti Polar Lipids (Alabaster, AL, USA). Slide-A-Lyzer MINI
dialysis devices (20 kDa MWCO, 0.1ml) were purchased from Pierce Biotechnology
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(Rockford, IL, USA). HeLa cells (ATCC, Manassas, VA, USA) were cultured in DMEM
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum
(Invitrogen).
3.2.2 Polymer synthesis
The monomers were dissolved in DMSO (Sigma-Aldrich) to a concentration
of 200 mg ml 1 .Alkylamines generally required heating to 60'C to enable complete
dissolution. Library scale reactions were performed in glass shell vials (1 mL) with
polyethylene snap caps (Waters, Milford, MA, USA) in a 96-well reaction block
(Symyx, Santa Clara, CA, USA). To each vial equipped with stir bar, diacrylate
monomer, hydrophobic amine monomer, and hydrophilic amine monomer were
added such that their molar ratio was 1.2:0.3:0.7 and the total mass of monomers
was 100 mg. After heating and stirring at 90'C for 48 h, the reactions were allowed
to cool to RT, and to each vial, end-capping amine (0.2 mmol in 0.5 mL DMSO) was
added. The reactions were stirred at 40'C for 24 h, divided into aliquots, and then
stored frozen at -20'C. Top-performing polymers were resynthesized by scaling up
the reactions tenfold.
3.2.3 Analytical Gel Permeation Chromatography (GPC)
GPC was performed using a Waters system equipped with a 2400 differential
refractometer, 515 pump, and 717-plus autosampler. The flow rate was 1 ml min-'
and the mobile phase was tetrahydrofuran (THF). The Styragel columns (Waters)
and detector were thermostated at 352C. Linear polystyrene standards were used
for calibration.
78
3.2.4 Preparative GPC/HPLC
DD24-C12-122 was subjected to GPC using a Phenogel 5pm MXL gel filtration
column (300 mm x 7.8 mm, Phenomenex, P/No. OOH-3087-KO) with THF as the
mobile phase at a flow rate of 1 ml min-'. The separation was performed on a 1200
Series Agilent HPLC system equipped with a UV diode array detector and a 1260
Infinity analytical scale fraction collector. The column compartment was kept at
40'C during fractionation. Based on the absorption of the polymer at 260 nm (Fig.
S2), polymer was collected between 5.2 and 7.7 min. The fractionated polymer was
transferred to a tared vial and dried until further analysis.
3.2.5 NMR
The HPLC-purified DD24-C12-122 polymer, along with the monomers and
end-capping reagent, was characterized on a Varian mercury spectrometer by 1H-
NMR spectroscopy (500 MHz, DMSO-d 6).
3.2.6 Transfection experiments
One day before transfection, 12,500 HeLa cells (100 Rl) were seeded into
each well of a 96-well polystyrene tissue culture plate. In a typical example, for a
150 ng/well DNA dose, gWiz-GFP plasmid DNA (5 mg ml-1) was diluted to 15 [tg ml-'
in 25 mm sodium acetate (NaOAc) buffer at pH 5.2. Polymers (100 mg ml-1) were
thawed immediately prior to transfection and diluted in NaOAc buffer to a
concentration of 300 Rg ml-1 (20:1 w/w polymer:DNA). To form DNA-polymer
nanoparticles, polymer solution (25 lI) was added to DNA (25 [l) in a half-area 96-
well plate, mixed by repeated pipetting using a multichannel pipette, and allowed to
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incubate for 10 min at room temperature. Polymer-DNA complexes (30 [d) were
then gently mixed with fresh medium (195 [d) pre-warmed to 37*C. Conditioned
medium was removed using a 12-channel aspirating wand and replaced with the
complexes diluted in medium (150 d). Following a 4-h incubation, complexes were
removed with the aid of a multi-channel aspiration wand and replaced with fresh
medium (100 [d). Lipofectamine 2000 (Invitrogen) was used according to the
protocol provided by the vendor.
3.2.7 Fluorescence-activated cell sorting (FACS)
GFP expression was assessed 48 h after transfection. After aspirating
conditioned medium, cells were washed with PBS and detached with 0.25% trypsin-
EDTA (25 [d, Invitrogen). FACS running buffer (50 pil), consisting of 98% PBS and
2% FBS, was added to each well. Cells were mixed thoroughly and then transferred
to a 96-well round-bottom plate. GFP expression was measured using FACS on a BD
LSR II (Becton Dickinson, San Jose, CA, USA). To determine the viabilities of treated
cells relative to non-treated control cells, propidium iodide stain (Invitrogen) was
added to the FACS buffer (1:200 v/v). The relative viability was calculated as the
ratio of live treated cells per well to the mean number of live non-treated cells per
well. 2D gating was used to separate increased auto-fluorescence signals from
increased GFP signals to more accurately count positively expressing cells. Gating
and analysis were performed using FlowJo v8.8 software (TreeStar, Ashland, OR,
USA).
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3.2.8 Dye exclusion assay
A working solution of PicoGreen was prepared by diluting 80 [l of stock
solution in 15.92 ml NaOAc buffer. In each well of a 96-well plate, 50 [d of polymer
at 0.6, 1.2, or 2.4 mg ml-1 in NaOAc buffer was added to 50 RL of DNA at 0.06 mg ml-1
in NaOAc buffer. After 5 min, 100 R.l of PicoGreen working solution was added to the
complexes. After an additional 5 min incubation, 30 [l was transferred to 200 [l of
10% serum-containing medium in a black 96-well assay plate. The fluorescence was
then measured on a Tecan Infinite M1000 plate reader using the FITC filter set
(excitation 485 nm, emission 535 nm). The reduction in relative fluorescence (RF),
or the relative encapsulation efficiency, was calculated using the relationship (FDNA-
Fsample)/(FDNA - Fblank), where Fsample is the fluorescence of the polymer-DNA-
PicoGreen sample, FDNA is the fluorescence of DNA-PicoGreen (no polymer), and
FbIank is the fluorescence of a sample with no polymer or DNA (only PicoGreen).
3.2.9 Gel electrophoresis
Polyplexes were formed by repeatedly mixing 25 RI of polymer (0.04, 0.2, or
0.8 mg ml-1 in NaoAc buffer) with 25 [tl of plasmid DNA (0.04 mg ml-1 gWiz-GFP in
NaOAc buffer). After 10 min incubation at RT, 10 Rl of each sample (-200 ng total
DNA) was loaded into each lane of a pre-cast 0.8% agarose E-gel (Invitrogen)
stained with ethidium bromide. Control lanes were loaded with 200 ng of free
control pDNA and -5 tl of TrackIt 1 Kb Plus DNA ladder (Invitrogen). The gel was
run using the E-gel electrophoresis system (Invitrogen) for 30 min at RT, and the
bands were visualized with a gel imager.
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3.2.10 Particle formulation with PEG-lipid at high DNA concentration
Polymer in DMSO (100 mg ml-1) and 18:0 PEG5000 PE in ethanol (10 mg ml-
1) were co-dissolved in acetonitrile to yield final concentrations of 8 mg ml-1 and 10
mol%, respectively. gWiz-GFP pDNA (5 mg ml-1) was diluted to 0.4 mg ml-1 in 25 mm
NaOAc buffer. The polymer and PEG-lipid in acetonitrile (25 pl) was then added to
DNA (25 pil) and mixed by repeated pipetting. After incubation for 10 min, the
formulations were diluted in PBS (50 pl) and dialyzed against PBS (3 1) for 3 h at RT.
3.2.11 Dynamic light scattering (DLS) measurements
Particle sizes and ( potentials were measured using a ZetaPALS DLS detector
(Brookhaven Instruments Corp., Holtsville, NY, USA, 15-mW laser, incident beam
676 nm). Correlation functions were collected at a scattering angle of 90*, and
particle sizes were obtained from the MAS option of BIC's particle sizing software (v.
2.30) using the viscosity and refractive index of water at 25*C. Particle sizes are
expressed as effective diameters (z-average or hydrodynamic diameters) calculated
using the Stokes-Einstein relationship from the diffusion coefficient obtained by
cumulant analysis. Average electrophoretic mobilities were measured at 25"C using
BIC PALS (-potential analysis software, and (-potentials were calculated using the
Smoluchowski model for aqueous suspensions. For polyplex sizing, particles were
prepared in NaOAc buffer as for DNA transfection, except volumes were scaled up
by a factor of five. Once formed in NaOAc buffer, complexes were diluted fourfold in
either additional NaOAc buffer or PBS and then sized at the indicated times. For DLS
measurements of particles prepared by nanoprecipitation, particles (either freshly
prepared or dialyzed) were diluted 100-fold in NaOAc buffer or PBS as indicated.
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3.3 RESULTS AND DISCUSSION
3.3.1 PBAE terpolymer library synthesis and screening
In this study, we synthesized random PBAE terpolymers by step-growth
polymerization of three starting monomers: a diacrylate, a hydrophobic alkylamine,
and a comparatively hydrophilic amine. Previous work has shown the importance of
terminal amine groups[1" 121. Therefore, we used a two-step reaction scheme
involving co-polymerization of the amine monomers with excess diacrylate to yield
acrylate-terminated base polymer, followed by reaction with excess diamine to
produce amine end-modified PBAE terpolymer (Figure 3.1a). Because it is not easily
predicted which PBAEs would benefit from the inclusion of alkyl side chains, we
used combinatorial library synthesis and screening as a tool to accelerate their
development. Our initial library (Figure 3.1b) consisted of 80 amine-end modified
PBAE terpolymers synthesized using 8 diacrylates, 10 hydrophilic amines, one
hydrophobic amine (dodecylamine), and one end-capping diamine ("122"). Based
on pilot studies, we chose a monomer molar feed ratio of 1.2:0.7:0.3
diacrylate:hydrophilic amine:hydrophobic amine for the polymerization, and the
reactions were carried out in DMSO. Under these conditions, eight of the 80
polymers precipitated out of reaction, while the remaining library members were
soluble.
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Figure 3.1 Synthetic scheme and monomers for a library of hydrophobic,
amine end-modfied PBAE terpolymers
a) Two-step synthesis of hydrophobic, amine end-modified poly(P-amino ester)
(PBAE) terpolymers. b) Structures of diacrylates (A-LL), hydrophilic amines (20-
94), hydrophobic amine (C12), and end-capping diamine (122) used for the
synthesis of the initial screening library. c) Additional monomers used to synthesize
the second screening library. ("EO" = ethylene oxide.)
Using these 72 polymers, we formed complexes with GFP-encoding plasmid
DNA and incubated them with cultured HeLa cells in serum-containing growth
medium for 4 h. As a screen for transfection efficiency, we performed fluorescence-
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activated cell sorting (FACS) 48 h later to quantify the proportion of cells expressing
GFP.
As shown in the heat map (Figure 3.2a), the top five PBAE terpolymers
transfected over 70% of HeLa cells, and four of these five, D90-C12-122, D60-C12-
122, D21-C12-122, and D24-C12-122, shared a common diacrylate structure based
on bisphenol A ethoxylate ("D"). The top two polymers from this screen
outperformed one of the best previously identified PBAEs lacking alkyl side chains,
C32-122, and rivaled the commercially available lipid reagent Lipofectamine 2000
in transfection efficiency (Figure 3.2b).
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Figure 3.2 Development of hydrophobic PBAE terpolymers with high DNA
transfection potency
a) Heat map of DNA transfection efficiencies of HeLa cells with the initial terpolymer
library (300 ng DNA/well; 20:1 polymer:DNA w/w), as determined by FACS
analysis. b) Transfection of HeLa cells with lead polymers from the initial library. c)
Heat map of HeLa transfection efficiencies with the second, focused library (150 ng
DNA/well).
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To investigate the structural space surrounding these polymers, we
synthesized a second library of hydrophobic PBAE terpolymers focused on
bisphenol diacrylate monomers (Figure 3.1c). When we screened this set of
polymers for transfection efficiency at half the DNA dose used in the first library,
five polymers emerged in addition to D60-C12-122 and D90-C12-122 that
transfected HeLa cells with greater than 85% efficiency (Figure 3.2c). After re-
synthesizing these polymers on a larger scale, and transfecting cells at reduced DNA
doses, we observed that these five polymers, based on DD24, DD90, DD60, DF90,
and DF60, exhibited transfection potencies in HeLa cells superior to Lipofectamine
2000 (Figure 3.3a-b). These polymers were generally short, ranging in weight-
average molecular weight (Mw) from 2.40 to 2.94 kDa with polydispersity indices
(PDI) from 1.7 to 2.3 (Table 3.1). DD24-C12-122, in particular, appeared to be the
most potent terpolymer to emerge from these screens, yielding -80% transfection
efficiency at the 50 ng dose without producing significant toxicity (Figure 3.3c). This
polymer was purified by preparative gel permeation chromatography (GPC) using
an HPLC system (Figure 3.4). The resulting polymer (Mw = 4.37 kDa, PDI = 1.43) was
characterized by 'H-NMR spectroscopy, which confirmed the incorporation of the
hydrophobic amine as well as the end-capping amine (Figure 3.5).
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Figure 3.3 Transfection performance of lead PBAE terpolymers at reduced
DNA doses in HeLa cells
a) DNA transfection efficiencies, b) geometric mean fluorescent intensities, and c)
relative viabilities of HeLa cells after treatment with the top PBAE terpolymers at
reduced DNA doses.
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Polymer Mw (Da) Mn (Da) PDI
D60-C12-122 2400 1167 2.057
D90-C12-122 2689 1356 1.983
DD24-C12-122 2891 1622 1.782
DD60-C12-122 2375 1381 1.712
DD90-C12-122 2811 1553 1.810
DF60-C12-122 2713 1176 2.307
DF90-C12-122 2939 1315 2.235
Table 3.1 MW of top-performing PBAE terpolymers
GPC analysis of top-performing PBAE terpolymers. Mw = weight-average molecular
weight, Mn = number-average molecular weight, PDI = polydispersity index =
Mw/Mn.
5' 10 15
Elution time (min)
Figure 3.4 HPLC/SEC purification of DD24-C12-122
An example chromatogram showing the elution of DD24-C 12-122 polymer from the
GPC column. Using a preparative HPLC system, eluted polymer was collected
between 5.2 and 7.7 min.
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Figure 3.5 'H NMR spectra of DD24-12-122 and monomers
1H NMR spectrum (500 MHz, DMSO-d 6) of HPLC-purified DD24-C12-122 polymer
(top), compared with the spectra for the monomers (DD, 24, C12) and the end-
capping reagent (122). The structure of a representative DD24-C12-122 oligomer is
shown. The disappearance of the acrylate peaks (a-c for monomer DD) in the
polymer spectrum suggests that amine end-capped polymer was successfully
formed from acrylate-terminated base polymer.
3.3.2 Effect of alkyl side chain content on PBA Epolyplex stability and transfection
When we used dynamic light scattering (DLS) measurements to compare the
stabilities of D60-C12-122, D90-C12-122, and C32-122 polyplexes formed at low
DNA concentration, we observed that all three polymers formed stable, sub-100 nm
complexes with plasmid DNA under conditions of reduced pH and low ionic strength
(Figure 3.6a). However, when the polyplexes were diluted in phosphate-buffered
saline (PBS) at physiological pH and ionic strength, only the complexes formed from
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the PBAE terpolymers remained stable, with effective diameters below 100 nm
(Figure 3.6b).
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Figure 3.6 Effect of alkyl side chain content on PBAE polyplex stability and
transfection
a-b) Stabilities of polyplexes formed from C32-122, D60-C12-122, and D90-C12-122
after self-assembly in sodium acetate (NaOAc) buffer at pH 5.2 or after dilution in
phosphate-buffered saline (PBS) at pH 7.4. Polyplexes were formed at low DNA
concentration (0.03 mg ml-) with a polymer:DNA w/w ratio of 20:1. c) HeLa
transfection efficiencies and d) polyplex stabilities of D60-122 polymers
synthesized with varying dodecylamine molar feed ratios.
To examine the effect of alkyl side chain content on PBAE terpolymer
transfection efficiency and complex stability in greater depth, we synthesized D60-
C12-122 using a range of molar feed ratios for which the dodecylamine (C12) feed
varied from 0 to 50 mol% of the total amine feed, while the diacrylate:amine ratio
was kept constant at 1.2:1.0. An increase in the alkylamine feed ratio up to 30 mol%
C12 generally corresponded to an increase in transfection potency in HeLa cells,
with a rough plateau in efficiency between 30 and 50 mol% C12 (Figure 3.6c).
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Interestingly, the alkylamine feed ratio also appeared to correlate positively with
polyplex stability in PBS (Figure 3.6d). One hour after dilution in PBS, polyplexes
formed from D60-122 polymer lacking alkyl side chains grew 50% in diameter, in
contrast to <10% growth for those formed from D60-122 terpolymers synthesized
with C12 feed ratios at or above 20 mol%.
(a) C32-122 (b) DD24-122
-100- 100
60--- 0 mo1%
-- 10 mol%
- 40 - 40- -e 0ml20 mol%
JOB 30 mol%
20 20' -e- 40 mol%
8 10 12 14 16 8 10 12 14 16
Alkyl Side Chain Length Alkyl Side Chain Length
Figure 3.7 Effect of alkyl side chain length and content on PBAE transfection
efficiency
HeLa transfection efficiencies of C32-122 (a) and DD24-122 (b) polymers (100 ng
DNA/well) synthesized with varying chain lengths and molar feed ratios of
alkylamine. At these doses, C32-122 and DD24-122 synthesized with 0 mol%
alkylamine yielded transfection efficiencies of 0.2% and 4.2%, respectively.
To determine how the alkyl side chain length affects the gene delivery
efficiency of PBAE terpolymers, we synthesized C32-122 and DD24-122 using
alkylamines ranging from 8 to 16 carbons in length. We also varied the alkylamine
molar feed from 0 to 40 mol% of the total amine feed, with the diacrylate:amine
molar ratio fixed at 1.2:1.0. We observed a positive association between the alkyl
side chain length of C32-122 terpolymers and transfection efficiency of HeLa cells
(Figure 3.7a). As was true for D60-122, there was also a positive correlation
between alkylamine feed ratio and transfection activity of the C32-122 terpolymers.
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At this DNA dose, though, varying the alkyl side chain length and content of DD24-
122 terpolymers did not yield much variation in observed transfection efficiencies
of HeLa cells (Figure 3.7b). Nonetheless, for both C32-122 and DD24-122, the best-
performing hydrophobic terpolymers produced a marked enhancement in
transfection activity relative to the polymers synthesized without alkylamine (C32-
122: 0.22% vs. 78.1%; DD24-122: 4.2% vs. 87.5%).
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Figure 3.8 Effect of amine end-modification of PBAE terpolymer transfection
efficiency
a) Structures of diamine end-capping molecules. b) Effect of amine end-modification
on DNA transfection efficiency of HeLa cells with C32 and DD24 terpolymers.
Terpolymers were synthesized using a monomer molar feed ratio of 1.2:0.3:0.7
diacrylate:hydrophobic amine:hydrophilic amine. "None" refers to terpolymers
synthesized using an excess of amine monomers (1.0:0.36:0.84
diacrylate:hydrophobic amine:hydrophilic amine) and no end-modification.
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Because polymer terminal group modification has been previously shown to
affect transfection efficiency[1 111, we also synthesized C32-C12 and DD24-C12
polymers with end-capping diamines other than 122 (Figure 3.8a). For the C32
terpolymers, amine end-modification dramatically influenced transfection
efficiency, but for the DD24 terpolymers, there was less variation at this dose
(Figure 3.8b). We expect that at lower DNA doses, we would observe greater
variation in transfection activity as a result of changes to the alkylamine feed ratio
and terminal groups of DD24 terpolymers.
Due to their low molecular weights and high polydispersities, the polymers
resulting from the step-growth polymerization of the three starting monomers
likely represent a mixture of three species: copolymers of the diacrylate and the
hydrophilic amine, copolymers of the diacrylate and the hydrophobic amine, and
finally terpolymers incorporating all three monomers. To elucidate which species is
responsible for the observed enhancements in transfection potency and
nanoparticle stability, and whether there might be a synergistic interaction between
the relatively hydrophilic and hydrophobic copolymer species, we prepared four
PBAE variants containing the DD diacrylate: one synthesized with only the
hydrophilic 24 amine (DD24-122, DD:24 = 1.2:1.0 mol/mol, Mw = 2.48 kDa); another
synthesized with only the hydrophobic C12 amine (DDC12-122, DD:C12 = 1.2:1.0,
Mw = 5.38 kDa); a third synthesized with 70 mol% of the hydrophilic amine and 30%
of the hydrophobic amine (DD24-C12-122, DD:24:C12 = 1.2:0.7:0.3, Mw = 3.03 kDa);
and a fourth comprising a 70%:30% v/v mixture of DD24-122 to DDC12-122 (Mw =
3.44 kDa). To avoid polymer crosslinking that was observed at high molar ratios of
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the C12 amine, these end-capping reactions were performed at room temperature
rather than at 40"C.
PBS (pH 7A)
-0- DD24-122
-E- DDC12-122
-0- DD24-C12-122
-* DD24-122 / DDC1 2-122 mix
30
Time (min)
60
0 lOng
25 ng
fly
Cp,
Figure 3.9 Identification of polymer species responsible for polyplex stability
and transfection potency
Comparison of (a) polyplex stabilities in PBS and (b) DNA transfection efficiencies
of HeLa cells for a DD diacrylate-based PBAE synthesized with only the hydrophilic
24 amine (DD24-122, DD:24 = 1.2:1.0 mol/mol); a PBAE synthesized with only the
hydrophobic C12 amine (DDC12-122, DD:C12 = 1.2:1.0); a PBAE synthesized with
70 mol% of the hydrophilic amine and 30% of the hydrophobic amine (DD24-C12-
122, DD:24:C12 = 1.2:0.7:0.3); and a 70%:30% v/v mix of DD24-122 and DDC12-
122.
When we examined polyplex stabilities in PBS, only the relatively hydrophilic
DD24-122 was unstable, whereas DDC12-122, DD24-C12-122, and the polymer
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mixture all resisted aggregation (Figure 3.9a). When we compared their transfection
efficiencies, the polymer synthesized using all three monomers (DD24-C12-122)
was significantly more potent than the mixture of the DD24-122 and DDC12-122
polymers, as well as the hydrophobic DDC12-122 polymer alone (Figure 3.9b).
These data suggest that although a synergistic effect between the hydrophilic and
hydrophobic polymers may contribute to polyplex stability, the presence of
terpolymer species incorporating both the hydrophilic and hydrophobic amines is
most likely responsible for the enhanced potency of the alkane-containing PBAEs.
3.3.3 Effect of alkyl side chain content on DNA binding and encapsulation efficiency
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Figure 3.10 Relative encapsulation efficiencies of C32-C12-122 terpolymers of
varying hydrophobicity
PicoGreen assay on polymer-DNA polyplexes formed from C32-C12-122
terpolymers of varying dodecylamine feed ratio. The complexes were formed in
NaOAc buffer (pH 5.2), and then diluted in 10% serum-containing medium
containing the fluorescent DNA-binding dye PicoGreen.
While some studies suggest that hydrophobic modification of polymers
decreases binding and encapsulation of nucleic acids (cite ZZZ), several others
report the opposite trend (cite ZZZ). We observed that C32-C12-122 terpolymer
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hydrophobicity was associated with increasing encapsulation of plasmid DNA upon
complexation, as reflected in the results of a PicoGreen dye exclusion assay
performed in 10% serum-containing media (Figure 3.10). Strictly speaking, it
should be noted that the dye exclusion assay measures the degree of protection
afforded to DNA by the polymer from intercalation of the fluorescent stain (i.e.
encapsulation), and not necessarily the polymer-DNA binding/complexation
efficiency, because PicoGreen could label both free DNA in solution as well as any
accessible polymer-bound DNA (e.g., on the nanoparticle surface).
%C12 010203 0j 0123040F
L F 0 1020 3040 010 20 3040 0 10 203040 F L
F: Free DNA
L: Ladder
1 w/w 5 w/w 20 w/w
Figure 3.11 Relative DNA binding efficiencies of C32-C12-122 terpolymers of
varying hydrophobicity
Polymer-DNA polyplexes were formed in NaOAc buffer (pH 5.2) from C32-C12-122
terpolymers of varying dodecylamine feed ratio and then electrophoresed on a 0.8%
agarose gel.
To assess the relative DNA binding efficiencies of these C32-C12-122
hydrophobic terpolymers, we used a gel retardation assay by forming polyplexes
with DNA at various weight ratios and then visualizing the relative quantity of free
DNA remaining by agarose gel electrophoresis. At polymer:DNA weight ratios of 5:1
or higher, which are most commonly used for transfection, we could not detect free
96
DNA from any of complexes formed from the C32-C12-122 variants (Figure 3.11).
However, at a lower weight ratio of 1:1, it was observed that as the terpolymer alkyl
side chain content increased, the relative amount of retarded, polymer-bound
plasmid DNA at the top of the gel generally increased, and that of free DNA
decreased (Figure 3.11). Therefore, taking the results from the PicoGreen and the
gel retardation assays together, increasing hydrophobicity of C32 terpolymers was
correlated with increasing efficiency of DNA binding and encapsulation.
3.3.4 Formulation of terpolymer/DNA nanoparticles with PEG-lipid conjugates
Finally, to test our hypothesis that the incorporation of hydrophobic side
chains in PBAEs can facilitate their interaction with PEG-lipid conjugates, we used a
nanoprecipitation approach to formulate particles comprised of polymer and DNA
in the presence or absence of PEG-lipid. Working with C32-122 and D60-122-based
polymers, we dissolved either the copolymers lacking alkyl side chains (C:32 =
1.2:1.0 mol/mol; D:60 = 1.2:1.0) or the terpolymer variants (C:32:C12 = 1.2:0.7:0.3;
D:60:C12 = 1.2:0.7:0.3) in acetonitrile with or without PEG-lipid and mixed them
with DNA at high concentration in sodium acetate buffer at pH 5.2. To remove the
organic solvent, we then dialyzed the formulations against PBS for 3 h. Comparing
particle sizes before and after dialysis, we found that only the formulations
employing both the terpolymers and the PEG-lipid conjugate gave rise to well-
defined and stable nanoparticles (Figure 3.12a). At this high DNA concentration,
D60-122, for instance, produced large particles -1 pm in size whether or not PEG-
lipid was present. In contrast, when PEG-lipid was present, the terpolymer version,
D60-C12-122, produced particles that remained stable after dialysis at -250 nm in
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size; in the absence of PEG-lipid, the particles grew to >700 nm in diameter after
dialysis, a size which seemed poorly defined given the large variation between
replicate measurements.
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Figure 3.12 Effects of PBAE alkyl side chains (C12) and the presence of PEG-
lipid conjugate on nanoparticle formulation stability and transfection
efficiency at high DNA concentration
a) Particle sizes before and after dialysis against PBS. b) Transfection efficiencies of
HeLa cells using equal doses of each formulation (approximately 75 ng and 150 ng
of DNA/well).
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C32-122
When we then transfected HeLa cells using identical volumes of formulation
per well, corresponding to approximately 75 ng and 150 ng of DNA, we found that
only the terpolymer formulations including PEG-lipid yielded significant
transfection (Figure 3.12b). Further support for non-covalent interaction of the
PEG-lipid conjugate was provided by (-potential measurements, which showed a
reduction in (-potential upon inclusion of PEG-lipid for particles formed from
hydrophobic C32-122 terpolymers, but not for particles formed from regular C32-
122 (Table 3.2). Taken together, these data suggest that at high DNA concentration,
PBAE terpolymers incorporating alkyl side chains, but not polymers lacking them,
are capable of interacting with PEG-lipid conjugates and DNA to form stable
nanoparticles, and that these particles retain the ability to mediate gene delivery.
No PEG-lipid(mV) PEG-lipid (mV)
C32-122 (0 mol% C12) 27.0 ± 4.1 27.2 ± 3.3
C32-C12-122 (20 mol% C12) 37.2 ± 5.1 11.1 ± 1.9
C32-C12-1 (40moI% ± 2.1 12.9 ± 2.5
Table 3.2 (-potential measurements of nanoparticles formed from C32-122
terpolymers of varying hydrophobicity
Formulations were prepared by nanoprecipitation of DNA with the polymers (20:1
w/w polymer:DNA) in the presence or absence of PEG-lipid conjugate (10 mol%).
Freshly prepared nanoparticles were diluted 100-fold in NaOAc buffer (pH 5.2)
prior to measurement (mean ± SD, n = 3).
Due to the commercial availability of functionalized PEG-lipid conjugates, the
capacity of the hydrophobic PBAE terpolymers to support formulation with PEG-
lipid represents a straightforward non-covalent method for attaching targeting
ligands such as peptides to the polymer/DNA nanoparticles. Although the particles
produced using a combination of PBAE terpolymers and PEG-lipid were rather large
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here, with effective diameters of -250-350 nm, there is likely significant potential
for optimization of particle size through variation of the PBAE alkyl side chain
length and content, the ratio of PBAE:DNA:PEG-lipid, the lengths of the lipid tails
and PEG polymer in the PEG-lipid conjugate, and the use of additional excipients
such as cholesterol or poloxamers. Furthermore, increasing the mixing rate with the
aid of a microfluidic mixing device should enable the formulation of smaller
nanopartices[25I.
3.4 CONCLUSIONS
In summary, we employed parallel synthesis and screening as a tool to
accelerate the development of degradable alkane-containing PBAE terpolymers for
gene delivery, guided by our hypothesis that they might provide superior
transfection potency and particle stability over polymers lacking hydrophobic side
chains. The top-performing PBAE terpolymers exhibited transfection potencies in
HeLa cells significantly higher than that of Lipofectamine 2000. Transfection
efficiency was generally positively correlated with increasing hydrophobicity, as
defined by either increasing the feed ratio of alkylamine monomer or increasing its
chain length. Increasing the hydrophobic content of the polymers also appeared to
be associated with greater polyplex stability at low DNA concentration. At high DNA
concentrations under conditions of physiological pH and ionic strength, these
hydrophobic PBAE terpolymers were better able to facilitate interaction with PEG-
lipid and DNA to yield stable, well-defined nanoparticles capable of transfecting
cultured cells in vitro. This simple yet powerful approach to improving the
100
transfection potency and formulation stability of degradable cationic polymers may
facilitate the development of multifunctional, nanoparticulate gene delivery systems
suitable for in vivo application.
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4 DEVELOPMENT OF DEGRADABLE HYDROPHOBIC
PBAE TERPOLYMERS FOR CELL-SPECIFIC GENE
DELIVERY
4.1 INTRODUCTION
As presented in Chapter 3, the initial development of the hydrophobic PBAE
terploymers proceeded through library synthesis and screening in HeLa cells, a
cervical cancer cell line. Although this cell line has been commonly used in in vitro
assays due to its potential relevance to cancer biology and its ease of culture,
efficient gene transfection of HeLa cells is readily achieved through a variety of
means. In this chapter, we focus on the development of these degradable
hydrophobic PBAE terpolymers for gene transfection of difficult-to-transfect
primary cells with greater clinical relevance.
We identify terpolymers such as DD24-C12-122 and LL24-C12-122 that
mediate gene transfection of primary human umbilical vein endothelial cells
(HUVECs), mesenchymal stem cells, and primary neonatal rat cardiomyocytes with
greater efficacy than that of a widely used commercial reagent. We explore the
chemical space surrounding these polymers by synthesizing a small library of
structurally related terpolymers, characterizing their biophysical properties, and
screening them for gene delivery to HeLa cells, HUVECs, and rat cortical neurons.
Finally, we present preliminary experiments exploring the potential of these
polymers for systemic gene delivery in vivo.
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4.2 MATERIALS AND METHODS
4.2.1 Materials
Diacrylate and amine monomers, as well as end-capping reagents, were
purchased from Sigma-Aldrich (St. Louis, MO, USA), Alfa Aesar (Ward Hill, MA, USA),
TCI America (Portland, OR, USA), and Monomer-Polymer & Dajac Labs (Trevose, PA,
USA). (PEO)4-bis-amine ("122") was acquired from Molecular Biosciences (Boulder,
CO, USA). All reagents were used without further purification. Plasmids encoding
green fluorescent protein (gWiz-GFP) and firefly luciferase (gWiz-Luc) were
purchased from Aldevron (Fargo, ND, USA). PEG-lipid conjugates were obtained
from Avanti Polar Lipids (Alabaster, AL, USA). HeLa cells (ATCC, Manassas, VA, USA)
were cultured in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10%
fetal bovine serum (Invitrogen). Primary human umbilical vein endothelial cells
(HUVECs) were obtained from Lonza (Walkersville, MD, USA) and cultured
according to the vendor's protocols. Primary porcine mesenchymal stem cells
(pMSCs), primary neonatal rat cardiomyocytes (NRCMs), and primary rat cortical
neurons were isolated and cultured according to standard protocols.
4.2.2 Polymer synthesis
The monomers were dissolved in DMSO (Sigma-Aldrich) to a concentration
of 200 mg ml 1 . Dodecylamine required heating to -60'C to enable complete
dissolution. Library scale reactions were performed in glass shell vials (1 mL) with
polyethylene snap caps (Waters, Milford, MA, USA) in a 96-well reaction block
(Symyx, Santa Clara, CA, USA). To each vial equipped with stir bar, diacrylate
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monomer, hydrophobic amine monomer, and hydrophilic amine monomer were
added such that their molar ratio was 1.2:0.3:0.7 and the total mass of monomers
was 100 mg. After heating and stirring at 90C for 48 h, the reactions were allowed
to cool to RT, and to each vial, end-capping amine (0.2 mmol in 0.5 mL DMSO) was
added. The reactions were stirred at 40C for 24 h, divided into aliquots, and then
stored frozen at -20"C. Top-performing polymers were resynthesized by scaling up
the reactions tenfold.
4.2.3 Analytical Gel Permeation Chromatography (GPC)
GPC was performed using a Waters system equipped with a 2400 differential
refractometer, 515 pump, and 717-plus autosampler. The flow rate was 1 ml min-'
and the mobile phase was tetrahydrofuran (THF). The Styragel columns (Waters)
and detector were thermostated at 352C. Linear polystyrene standards were used
for calibration.
4.2.4 Transfection experiments
One to three days before transfection, cells (100 tl) were seeded into each
well of a 96-well polystyrene tissue culture plate, clear bottom for GFP transfections
and white bottom for luciferase transfections (HeLa: 12,500 per well 1 d prior;
HUVEC: 9,000 per well 1 d prior; pMSCs: 4,500 2-3 d prior). In a typical example, for
a 150 ng/well DNA dose, plasmid DNA (5 mg ml-1) was diluted to 15 [tg ml-1 in 25
mm sodium acetate (NaOAc) buffer at pH 5.2. Polymers (100 mg ml-1) were thawed
immediately prior to transfection and diluted in NaOAc buffer to a concentration of
300 [tg ml-1 (20:1 w/w polymer:DNA). To avoid precipitation within the pipet tip,
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hydrophobic PBAE terpolymers were diluted by first adding polymer and then
adding aqueous buffer; maximum solubility for these poylmers was typically on the
order of 5 mg ml- in NaOAc buffer.
To form DNA-polymer nanoparticles, polymer solution (25 [d) was added to
DNA (25 Rl) in a half-area 96-well plate, mixed by repeated pipetting using a
multichannel pipette, and allowed to incubate for 10 min at room temperature.
Polymer-DNA complexes (30 [d) were then gently mixed with fresh medium (195
[tl) pre-warmed to 37C. Conditioned medium was removed using a 12-channel
aspirating wand and replaced with the complexes diluted in medium (150 Rl).
Following a 4-h incubation, complexes were removed with the aid of a multi-
channel aspiration wand and replaced with fresh medium (100 [d). Lipofectamine
2000 (Invitrogen) was used according to the protocol provided by the vendor.
4.2.5 GFP expression analysis
After aspirating conditioned medium, cells were washed with PBS and
detached using 25 [l per well of 0.25% trypsin-EDTA (Invitrogen). 50 pl of FACS
running buffer, consisting of 98% PBS, 2% FBS, and 1:200 v/v propidium iodide
solution (Invitrogen), was added to each well. Cells were mixed thoroughly and then
transferred to a 96-well round-bottom plate. GFP expression was measured using
FACS on a BD LSR II (Becton Dickinson, San Jose, CA, USA). Propidium iodide (PI)
staining was used to exclude dead cells from the analysis. PI staining was also used
to determine the viabilities of treated cells relative to non-treated control cells,
where the relative viability was calculated as the ratio of live (unstained) treated
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cells per well to the mean number of live non-treated cells per well. 2D gating was
used to separate increased auto-fluorescence signals from increased GFP signals to
more accurately count positively expressing cells. Gating and analysis were
performed using FlowJo v8.8 software (TreeStar, Ashland, OR, USA).
4.2.6 Luciferase expression analysis
Luciferase expression was analyzed using a Bright-Glo assay kit (Promega,
Madison, WI, USA). Briefly, Bright-Glo solution (100 [d) was added to each well of
the 96-well plate containing medium and cells. Luminescence was measured using a
Tecan Infinite M1000 plate reader.
4.2.7 Dynamic light scattering (DLS) measurements
Particle sizes were measured using a ZetaPALS DLS detector (Brookhaven
Instruments Corp., Holtsville, NY, USA, 15-mW laser, incident beam 676 nm).
Correlation functions were collected at a scattering angle of 90*, and particle sizes
were obtained from the MAS option of BIC's particle sizing software (v. 2.30) using
the viscosity and refractive index of water at 25*C. Particle sizes are expressed as
effective diameters (z-average or hydrodynamic diameters) calculated using the
Stokes-Einstein relationship from the diffusion coefficient obtained by cumulant
analysis. Particles were prepared in NaOAc buffer as for DNA transfection, except
volumes were scaled up by a factor of five. Once formed in NaOAc buffer, complexes
were diluted fourfold in additional NaOAc buffer, 1X PBS, or 10% serum-containing
media as indicated.
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4.2.8 Dye exclusion assay
A working solution of PicoGreen was prepared by diluting 80 RI of stock
solution in 15.92 ml NaOAc buffer. In each well of a 96-well plate, 50 [l of polymer
at 1.2 mg m-1 in NaOAc buffer was added to 50 [tL of DNA at 0.06 mg ml-l in NaOAc
buffer. After 5 min, 100 il of PicoGreen working solution was added to the
complexes. After an additional 5 min incubation, 30 [d was transferred to 200 d of
10% serum-containing medium in a black 96-well assay plate. The fluorescence was
then measured on a Tecan Infinite M1000 plate reader using the FITC filter set
(excitation 485 nm, emission 535 nm). The reduction in relative fluorescence (RF),
or the relative encapsulation efficiency, was calculated using the relationship (FDNA-
Fsample)/(FDNA - Fblank), where Fsampie is the fluorescence of the polymer-DNA-
PicoGreen sample, FDNA is the fluorescence of DNA-PicoGreen (no polymer), and
FbIank is the fluorescence of a sample with no polymer or DNA (only PicoGreen).
4.2.9 Nanoparticle formulation at high DNA concentration
Hydrophobic PBAE terpolymer in DMSO (100 mg ml-1) and various PEG-
lipids in ethanol as indicated (10 mg ml-1) were co-dissolved in acetonitrile to yield
final concentrations of 8 mg ml-1 and either 3 mol% or 10 mol%, respectively. gWiz-
GFP pDNA (5 mg ml-1) was diluted to 0.4 mg ml-1 in 25 mm NaOAc buffer. The
polymer and PEG-lipid in acetonitrile was then added to DNA and mixed by
repeated pipetting. After incubation for 10 min, the formulations were diluted in
PBS (1:1 v/v) and dialyzed against PBS (3 1) for 3 h at RT using a Pierce Slide-A-
Lyzer MINI dialysis devices (20 kDa MWCO, 0.1ml; Pierce, Rockford, IL, USA) for
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small volume formulations and a Pierce Slide-A-Lyzer G2 cassette (20K MWCO, 3
ml) for large volume formulations.
4.2.10 In vivo transfection experiments
In vivo transfection experiments were performed using 6-8 wk old, male
BALB/c mice (Charles River, Wilmington, MA). All mouse experiments were done in
accordance with protocols approved by MIT's Committee on Animal Care (CAC). As
described above, D60-C12-122 and D90-C12-122 were formulated with 16:0 PEG
5000 PE and gWiz-Luc using a 20:1 w/w ratio of polymer:DNA and a PEG-lipid
concentration of 10 mol%. After overnight dialysis at 40C, the nanoparticle
formulation was removed from G2 dialysis cassette. Due to wide variability in
measurements of total DNA concentration using the PicoGreen assay in combination
with a particle disruption agent such as heparin, the DNA concentration was
calculated based on volume change as a result of dialysis, and the formulations were
accordingly diluted to 0.1 mg ml-1 in sterile PBS and stored at 40 C until
administration. Using a 28-gauge 0.5-inch insulin syringe, 200 pl (-1 mg/kg dose)
was injected into the peritoneal cavity of a mouse (IP) or into the tail-vein (IV).
For C32-122/DNA complexes, polymer diluted in 25 mM NaOAc buffer (60 pl,
12 mg ml-1) was added to gWiz-Luc DNA (60 ul, 0.4 mg ml-1) diluted in 25 mM
NaOAc buffer to yield a 30:1 w/w polymer:DNA ratio. After a 5-minute incubation at
RT, 120 [d of a 20% w/v solution of glucose in PBS was added to the polymer-DNA
mixture. Of the resulting 240 [d volume, 200 p1 was injected immediately into the
peritoneal cavity of a mouse.
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4.2.11 Whole-animal bioluminescence imaging
Bioluminescence imaging was performed using an IVIS imaging system
(Xenogen, Alameda, CA) on whole mice at 6 h, 24 h, and 72 h after injection of
luciferase-encoding DNA nanoparticles. To capture the peak of luminescence
emission, a series of images were taken five min. apart for 30 min. on each
treatment group of isoflurane-anesthetized mice following IP injection of Xenolight
Rediject D-luciferin (150 mg/kg; Caliper Life Sciences, Waltham, MA). Xenogen
Living Image v. 4.2 acquisition and analysis software was used to quantify luciferase
expression from the optical images.
4.3 RESULTS AND DISCUSSION
4.3.1 PBAE terpolymer transfection of HUVECs, pMSCs, and NRCMs
To assess the potential of the hydrophobic PBAE terpolymers for transfection
of endothelial cells, we re-screened our initial library of -72 terpolymers (Figure
3.1a-b) for DNA transfection of primary human umbilical vein endothelial cells
(HUVECs). The polymers were complexed with GFP-encoding DNA at a 20:1 w/w
ratio and the resulting particles were incubated with HUVECs at a DNA dose of 100
ng per well for 4 hours. GFP expression and transfection efficiency were analyzed by
FACS measurements after two days.
The results of this screen in HUVECs (Figure 4.1) differed strikingly from
those of our initial one in HeLa cells (Figure 3.2). As with the results in HeLa cells,
the structure of the diacrylate monomer appeared to influence transfection efficacy
to a greater extent than that of the amine monomer; in the HeLa screen, the top-
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performing terpolymers were those formed from the bisphenol-containing
diacrylate monomer "D", but in HUVECs, there was a preference for the terpolymers
formed from long straight-chain alkyl diacrylates such as "JJ" and "LL." Four
terpolymers, including LL24-C12-122, LL28-C12-122, LL32-C12-122, and LL36-
C12-122 mediated gene transfection efficiencies of -30% or more in HUVECs, which
at this dose represented significantly higher potency than that of Lipofectamine
2000 (-10% efficiency). These terpolymers also significantly outperformed C32-
122, one of the top PBAE copolymers lacking alkyl side chains.
20 21 24 28 32 36 60 80 90 94
A #.1 071 0#4 .53 0.57 0.6 53 0.69 0.43 insoluble
C 126 3.77 0,2 088 8.16 14.88 0.63 0AQ 1.35 insoluble
D .72 089 1.06 .69 0.84 076 6.88 16.53 4.32 1.78
E 3.87 4.40 3.13 10.50 9.26 14.95 1,56 insoluble 3.01 5.32
J 0u$7 0A8 0.62 0.54 0.43 0.37 0.A3 045 0.M O0
T o.62 O.M 0.58 0.46 0,47 0.74 1.97 1.24 1.10 0.67
JJ 6.48 23.45 15.18 18.98 21.73 23.05 1.12 13.15 insoluble
LL 0.83 0.72 29.58 30.75 34.33 insoluble insoluble insoluble insoluble
Non-treated Naked DNA C32-122 LF2000
Controls 010 an .99 9.58
Figure 4.1 Screening the initial PBAE terpolymer library for gene transfection
of HUVECs.
Heat map of DNA transfection efficiencies in HUVECs with the initial PBAE
terpolymer library (100 ng DNA/well; 20:1 polymer:DNA w/w), as determined by
FACS analysis.
When the results of the two screens were plotted side-by-side or in a scatter
plot, no significant overlap was observed between the polymers that performed best
in HeLa cells and those that performed best in HUVECS (Figure 4.2). Besides the
difference in the DNA doses that were used for the screens, we hypothesized that
one factor contributing to the apparent lack of correlation could be the difference in
the transfection media between the two cell types. While the HeLa growth medium
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consisted of 10% fetal bovine serum (FBS), the HUVEC growth medium contained
only 2% FBS.
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Figure 4.2 Comparison of PBAE terpolymer library screen results in HeLa cells
and HUVECs
The results of the PBAE terpolymer library screens in the two cell types plotted
side-by-side. Inset: correlation between gene transfection efficiencies of HUVEC and
HeLa cells by hydrophobic PBAE terpolymers represented in the initial library.
To examine the effect of serum content on PBAE-mediated gene transfection
of HUVECs, we performed a side-by-side transfection of these cells in 2% FBS-
containing growth medium or 10% FBS/DMEM, i.e. regular HeLa medium (Figure
4.3). As a control, HeLa cells were transfected in parallel with the same polyplexes in
10% FBS/DMEM medium. The transfections were performed using the top nine
PBAE terpolymers identified in the HeLa cell screen as well as the top nine
terpolymers identified in the HUVEC screen. Interestingly, no significant difference
was observed with regard to the effect of growth medium on PBAE-mediated
HUVEC gene transfection. As expected, in this side-by-side transfection, HeLa cells
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proved more amenable to DNA transfection than HUVECs, and in general the same
trends were observed with regard to the influence of diacrylate structure on PBAE-
mediated cell-type specificity.
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Figure 4.3 Influence of growth medium on PBAE-mediated transfection of
HUVECs and HeLa cells
Side-by-side GFP transfection of HUVECs with top-performing PBAE terpolymers in
2% FBS-containing growth medium or 10% FBS/DMEM, and of HeLa in 10%
FBS/DMEM. A90-D90 (left to right) and C36 to LL36 represent the top nine PBAE
terpolymers identified in the HeLa cell screen and the top nine terpolymers
identified in the HUVEC screen, respectively.
Contrary to our expectations based on the initial screening results, some of
the LL-containing terpolymers, in particular LL24-C12-122, mediated highly potent
gene transfection in HeLa cells. This result was previously missed due to the higher
dose used in the initial screens (300 ng/well vs. 100 ng/well); at this high dose,
significant cytotoxicity was observed with the LL-containing polymers, but at
reduced doses, both viability and transfection were dramatically improved.
Moreover, a few of the polymers that had performed well in HeLa in the initial
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screen, such as A60 and D24, performed quite poorly in this particular experiment, a
difference that may likely be attributed not only to the reduced DNA dose but also to
potential degradation of the polymers since their synthesis (-3 months).
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Figure 4.4 Transfection of porcine mesenchymal stem cells by hydrophobic
PBAE terpolymers
Porcine mesenchymal stem cells (pMSCs) were transfected with a GFP-encoding
plasmid using various PBAEs and Lipofectamine 2000 (LF 2000). FACS analysis was
used two days later to quantify GFP expression efficiency (left), geometric mean GFP
fluorescent intensity (middle), and relative viability (right).
We next assessed the potential for the top-performing terpolymers to
emerge from these screens to deliver genes to primary mesenchymal stem cells
(pMSCs). Working with porcine MSCs, we transfected cells with a GFP plasmid using
C32-122, LL24-C12-122, DD-24-C12-122, or Lipofectamine 2000, and compared the
resulting transfection efficacies by microscopy and FACS analysis. At the low doses
applied, LL24-C12-122 and DD24-C12-122 mediated significantly greater GFP
transfection in the pMSCS than was achieved with C32-122 or Lipofectamine 2000
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(Figure 4.4). For instance, at the 75 ng dose, FACS analysis showed that LL24-C12-
122 yielded a pMSC gene transfection efficiency of -35%, in comparison with -3%
efficiency for Lipofectamine 2000. GFP expression in the LL24-C 12-122-treated cells
was -4-fold that of the Lipofectamine-treated cells. At this dose, there was a small
but non-significant reduction in relative viability for the LL24-C12-122-treated cells.
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Figure 4.5 Transfection of neonatal rat cardiomyocytes by hydrophobic PBAE
terpolymers
Neonatal rat cardiomyocytes (NRCMs) were transfected with a GFP-encoding
plasmid using DD24-C12-122, C32-C12-122, and Lipofectamine 2000 (LF 2000).
FACS analysis was used two days later to quantify GFP expression efficiency (left)
and relative cell viability (right).
We also evaluated the potential of hydrophobic PBAE terpolymers for
efficient DNA transfection of cardiac tissue. We performed a screen of a subset of
these polymers for transfection of primary neonatal rat cardiomyocytes (NRCMs).
NRCMs are notoriously difficult to transfect, and as expected, many of the PBAEs
that were screened, including the top performing polymers lacking alkyl side chains
such as C32-103, C32-117, and C32-122, showed minimal transfection (<2%
efficiency; data not shown). Nonetheless, a handful of hydrophobic PBAE
terpolymers, including DD24-C12-122 and C32-C12-122, showed modest but
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significant improvements in transfection potency over Lipofectamine 2000; for
example, C32-C12-122 achieved a transfection efficiency of nearly 12% compared
with -7% for Lipofectamine 2000 (Figure 4.5).
4.3.2 Combinatorial library of PBAE terpolymers centered on DD24-C12-122 and
LL24-C12-122
OH OH
DD O O O 
O
O 0O C12 NH2
LL O
O 0
HO -, NH2 NH2
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Figure 4.6 Combinatorial library of 24 PBAE terpolymers centered on DD24-
C12-122 and LL24-122
Structure of diacrylate monomers (DD, LL), hydrophobic amine (C12), hydrophilic
amines (24-405), and end-capping diamine (122) used for the synthesis of the small
combinatorial library of PBAE terpolymers surrounding the chemical space of
DD24-C12-122 and LL24-C12-122. The diacrylate:hydrophobic amine:hydrophilic
amine molar ratio was 1.2:0.3:0.7.
Given the high potencies observed using DD24-C12-122 and LL24-C12-122
in multiple cell types, and the fact that they share a common hydrophilic amine
monomer ("24"), we explored the chemical space surrounding these terpolymers by
synthesizing and characterizing a small library of polymers built using the same
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diacrylate, hydrophobic amine, and end-capping amine reagents, but varying in
their hydrophilic amine monomers. Based on the structure of the "24" amine, 3-
amino- 1,2-propanediol, which notably features two hydroxyl groups, for the
combinatorial library we selected nine other hydrophilic amine monomers also
possessing multiple hydroxyl groups (Figure 4.6). Because the 24 monomer is a
racemic mixture, we also included the purified enantiomers, 24R and 24S, within the
library to determine whether polymer tacticity might influence its gene delivery
properties.
After synthesizing this small library of 24 terpolymers, we then applied GPC,
DLS, and a PicoGreen dye exclusion assay to rigorously characterize the biophysical
properties of these polymers and the nanoparticles resulting from their
complexation with DNA. As expected, GPC analysis showed that most of these
polymers were quite short, with M, ranging from 1.33 kDa for LL26 to 3.5 kDa for
DD24 (Figure 4.7a). (For brevity, the PBAE terpolymers in this library will be
referred to by only their diacrylate and hydrophilic amine monomers, since they
share the same hydrophobic amine monomer and end-capping reagent.) With
respect to the DD24 and LL24 terpolymers varying in tacticity, DD24R and DD24S
showed no significant difference in MWD, although these polymers were slightly
shorter than the polymer constructed from the racemic 24 monomer. The LL24
stereochemical variants showed minimal variation in MWD.
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Figure 4.7 Biophysical properties of the DD24- and LL24-focused
combinatorial library
(a) Mw and M of the terpolymers as determined by GPC analysis. (b) Particle
diameters of the terpolymer/pDNA complexes formed in NaOAc buffer (pH 5.2) and
then further diluted and measured by DLS as indicated. (c) Relative pDNA
encapsulation efficiencies of the terpolymers as determined by a PicoGreen dye
exclusion assay. Polyplexes were formed at a 20:1 w/w polymer:DNA ratio.
With respect to nanoparticle size, DLS measurements showed that most of
these polymers were capable of forming sub-100 nm complexes with DNA in NaOAc
at pH 5.2, with some swelling immediately after dilution in PBS at pH 7.4 (Figure
4.7b). However, the measured particle sizes in 10% FBS/DMEM media tended to be
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more variable and generally quite large, reflecting some degree of aggregation. Most
of the DD-containing polymers, with the exception of DD401, formed particles that
remained sub-300 nm in serum-containing medium, whereas only LL26, LL34, and
LL403 formed similarly tight particles in medium. The remainder of the LL-
containing polymers grew in size to 600 nm or larger upon dilution in serum-
containing medium. There was little variation in the nanoparticle sizes under these
three conditions for the DD24 and LL24 polymers varying in tacticity.
Finally, we measured the relative DNA encapsulation efficiency at 20:1
polymer:DNA w/w ratio using a PicoGreen DNA-binding dye exclusion assay. In
general, most of the DD-containing polymers were able to encapsulate ~-35% of the
DNA. However, DD86 was characterized by a lower encapsulation efficiency of only
-20%. Several of the LL-containing polymers, including LL24, LL25, LL86, and LL87,
were characterized by relatively high DNA encapsulation efficiencies approaching
50%. The stereochemical variants of DD24 and LL24 did not show significant
variation in DNA encapsulation efficiency.
When we transfected HeLa cells with these polymers, 21 of the 24 polymers
in the library outperformed Lipofectamine 2000 (LF 2000) at a DNA dose of 50 ng
per well (Figure 4.8). LL86, LL401, LL25, DD403, and DD87 in particular, showed
excellent transfection activities along with the original library members DD24 and
LL24. Polymer tacticity did not appear to affect transfection activity to a significant
extent. One of the polymers that had the lowest DNA encapsulation efficiencies,
DD86, also had the poorest DNA transfection activity in HeLa cells.
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Figure 4.8 HeLa transfection efficiencies of the DD24- and LL24-focused
combinatorial library
Transfection efficiencies in HeLa cells using the 24 members of the terpolymer
library at a polymer:DNA w/w ratio of 20:1. Efficiencies were determined by FACS
analysis of GFP expression two days after transfection of GFP-encoding p DNA.
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Figure 4.9 HUVEC transfection efficiencies of the DD24- and LL24-focused
combinatorial library
Transfection efficiencies in HUVECs using the 24 members of the terpolymer library
at a polymer:DNA w/w ratio of 20: 1. Efficiencies were determined by FACS analysis
of GFP expression two days after transfection of GFP-encoding pDNA.
In analogous fashion, we screened the polymers for DNA transfection
efficiency in HUVECs, and we found that LL86, DD403, DD401, and DD87 displayed
potent transfection activity along with the variants of DD24 and L L24. Notably,
LL86, DD403, and DD87 were also among those polymers that performed best in
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HeLa cells. At the other end of the performance spectrum, DD86, LL26, and LL34
again showed the three poorest transfection potencies, as they had in HeLa cells. As
with HeLa cells, 21 of the 24 polymers displayed transfection efficiencies rivaling or
outperforming LF 2000. These common trends suggest possible structural
convergence with respect to optimal transfection activity.
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Figure 4.10 Rat cortical neuron transfection activities of the DD24- and LL24-
focused combinatorial library
Transfection activities in rat cortical neurons using the 24 members of the
terpolymer library at a polymer:DNA w/w ratio of 20:1. Relative luciferase
expression was measured using a plate reader two days after transfection of
luciferase-encoding pDNA.
Nonetheless, when we then screened the polymers for transfection of
primary rat cortical neurons, we obtained very different results (Figure 4.10). In
contrast to the previous experiments using GFP DNA and FACS analysis, this
experiment was performed by complexing the polymers with luciferase-encoding
DNA, incubating the nanoparticles with the cells for 4 hours, and then assaying for
luminescence after two days. In this experiment, we observed that the structure of
the diacrylate significantly influenced the measured transfection efficacy. All DD-
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containing polymers, including DD86, demonstrated significantly enhanced
transfection activity relative to LF 2000, whereas the LL-containing polymers
displayed activity that was equivalent or worse. Surprisingly, only LL24 failed to
mediate significant luciferase expression.
Taken together, these screening results suggest weak correlations between
the measured polymer and nanoparticle properties and DNA transfection activity.
Although there was some correlation between polymer DNA encapsulation
efficiency and transfection activity, structural differences appear to account for most
of the variation in polymer transfection activity. In this study, polymer tacticity
showed no discernible influence on gene delivery properties. With respect to cell-
type specificity, HeLa and HUVECs generally appeared to share common preferences
with regard to gene delivery polymer structure. The intriguing preliminary
experiment that suggests very different structural preferences in rat cortical
neurons warrants further study to corroborate the observations and elucidate a
mechanism.
4.3.3 PBAE terpolymer/DNA formulation development and in vivo transfection
The in vitro results described so far in this chapter have been performed
using simple polyplexes, which tend to be relatively unstable at high concentrations
under physiological conditions (as covered in detail in the Chapter 3). Ultimately,
clinical application will require the development of stable formulations displaying
excellent in vivo biocompatibility without compromising gene delivery efficacy.
Toward this end, we explored the development of PBAE terpolymer nanoparticle
formulations suitable for in vivo use. Using the nanoprecipitation approach
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described previously, we co-dissolved D60-C12-122 (1.2:0.7:0.3 molar ratio of
D:60:C12) with various PEG-lipid conjugates in acetonitrile and then pipet-mixed
them with GFP-encoding plasmid DNA in sodium acetate buffer (pH 5.2). The PEG-
lipid conjugates varied in the structure of the lipid tail (phosphoethanolamine/PE
vs. ceramide; carbon chain length/saturation) as well as the PEG chain lengths (3
kDa or 5 kDa), and we used two molar ratios of the PEG-lipid conjugate to the
polymer content (3% or 10%). The polymer:DNA weight ratio was held fixed at
20:1. Once prepared, the formulations were dialyzed against PBS for 3 h, and their
transfection activities were compared in HeLa cells at a DNA dose of approximately
75 ng per well.
The results of this experiment demonstrate that the identity of the PEG-lipid
conjugate strongly influences the stability of the nanoparticle formulations and their
corresponding transfection efficacies (Figure 4.11). When the terpolymer/DNA
nanoparticles are prepared without PEG-lipid, HeLa transfection efficiency was
-20%. In contrast, transfection efficiency was -75% or higher with some of the
formulation prepared with PEG-lipid conjugates, particularly C18:0 PEG PE (5 kDa
PEG, 3 mol%), C16:0 PEG PE (5 kDa, 10 mol%), and C8 PEG ceramide (5 kDa, 10
mol%). Other formulations containing PEG-lipid conjugates did not improve
transfection efficacy over the simple polyplexes, such as those containing C14:0 PEG
PE (3 or 5 kDa, 3 mol%) and C16 PEG ceramide (5 kDa, 3 mol%).
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Figure 4.11 HeLa transfection efficiencies of D60-C12-122/DNA nanoparticle
formulations containing various PEG-lipid conjugates
D60-C 12-122 nanoparticle formulations containing various PEG-lipid conjugates
were prepared by nanoprecipitation with GFP-encoding plasmid DNA and used to
transfect HeLa cells 3 h after dialysis against PBS. FAGS analysis was used after two
days to quantify the proportion of cells expressing GFP.
In general, for the PEG-lipid conjugates containing phosphoethanolamine
(PE), longer lipid tails, longer PEG, and a higher molar ratio of the PEG-lipid
conjugate improved transfection efficacy. The observed trends make sense given
that these factors should in principle promote nanoparticle stability and aggregation
resistance during the dialysis against PBS. Nonetheless, for the PEG ceramide
conjugates, while higher molar ratio improved performance, the conjugate with the
shorter lipid tails (C8) was superior to that with the longer tails (C 16). With the
exception of one PEG ceramide formulation (C8, 5 kDa, 10 mol%), the PEG ceramide
formulations were generally less efficacious than their PEG PE counterparts. Taken
together, these data highlight the significance of certain structural features of PEG-
lipid conjugates contributing to improved polymer/DNA nanoparticle stability and
transfection activity.
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Figure 4.12 Intraperitoneal and intravenous gene delivery in mice using D60-
C12-122 and D90-C12-122 terpolymers
(a) Whole-animal optical images of luciferase expression in BALB/c mice 6 hours, 1
day, and 3 days after injection of D60-C12-122 and D90-C12-122 formulations and
C32-122 polyplexes. Radiance (photons/sec/cm 2/sr) is indicated in the color scale
bar at left. (b) Quantification of whole-body luciferase expression (total flux/mouse)
at various times after treatment as indicated (mean ± SD, n = 3 mice per group).
Using the results of this experiment, we then prepared D60-C12-122 and
D90-C12-122 nanoparticle formulations with luciferase-encoding plasmid DNA and
C16:0 PEG 5 kDa PE (20:1 w/w polymer:DNA; 10 mol% PEG-lipid). After dialysis
against PBS for 3 h and storage overnight at 4*C, the formulations were
administered to BALB/c mice via intraperitoneal (IP) or intravenous (IV) injections
at approximately a 1 mg/kg DNA dose. We also administered freshly prepared C32-
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122 polyplexes IP as a positive control. Whole-animal bioluminescence was assayed
for each group at three time points (6 h, 1 d, and 3 d) following injection. We
observed that the kinetics of expression varied for each of the treatment groups
(Figure 4.12). At 6 h after injection, we observed moderately strong luciferase
expression in the abdominal cavities of mice injected IP with the D60 and D90
formulations, with no detectable expression in the mice injected IV with these
formulations or in the mice injected IP with the C32-122 polyplexes.
However, one day after injection, significant luciferase expression in the
abdominal cavity was observed in the C32-122 treated mice, while luciferase
expression decreased in the mice treated IP with the terpolymer formulations. At
this time point, we also detected low but significant transgene expression in the tails
of the mice injected IV with the terpolymer formulations, and this signal persisted at
the 3 d time point. Meanwhile, at this 3 d time point, luciferase expression
significantly decreased in all of the IP-injected animals, with the most durable
expression observed in the mice treated with the D90 terpolymer formulations.
These preliminary in vivo data suggest that the terpolymer formulations are capable
of mediating significant transgene expression after IP or IV injection that persists for
at least three days. Further experiments will be necessary to characterize the
pharmacokinetics of expression in greater detail and to optimize the formulations
and dosing for maximal in vivo transfection efficacy.
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4.4 CONCLUSIONS
Through a series of screens, PBAE terpolymers were identified that mediated
superior gene delivery to various difficult-to-transfect cell types relative to a
popular commercially available lipid reagent, Lipofectamine 2000, and to one of the
top-performing PBAE copolymers lacking alkyl side chains, C32-122. PBAE
terpolymers, including DD24-C12-122 and LL24-C12-122, demonstrated excellent
transfection potency in HUVECs, porcine MSCs, and neonatal rat cardiomyocytes.
Synthesis and screening of a small library of terpolymers surrounding the chemical
space of DD24-C12-122 and LL24-C122 identified polymers with high transfection
efficacy in HeLa cells, HUVECs, and rat cortical neurons. While there was some
correlation between polymer DNA encapsulation efficiency and transfection activity,
structural differences appeared to account for most of the variation in polymer
transfection activity. Finally, formulation development with the terpolymer D60-
C12-122 suggested that the identity of the PEG-lipid conjugate strongly affects the
stability of the nanoparticle formulations and their corresponding transfection
efficacies. Following IP or IV administration, terpolymer formulations yielded
observable transgene expression in mice that persisted for at least three days.
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5 EFFECT OF MOLECULAR WEIGHT OF AMINE END-
MODIFIED POLY(BETA-AMINO ESTER)S ON GENE
DELIVERY EFFICIENCY AND TOXICITYt
5.1 INTRODUCTION
Gene therapy is a promising treatment strategy for many inherited disorders
including cystic fibrosis, severe combined immunodeficiency, and hemophilia, in
addition to cancer and infectious diseases such as AIDS. Despite recent clinical
progress[1I, concerns with the use of viral vectors, including immunogenicity, small
DNA cargo capacity, and difficulty of large-scale production, have led to continued
interest in the development of synthetic carriers[21 .A diverse collection of materials
has been studied for potential as synthetic gene delivery agents, including lipids,
polymers, polysaccharides, polypeptides, dendrimers, and inorganic
nanoparticles[ 3l. However, sub-optimal delivery efficiency in vivo relative to viral
vectors has inhibited their widespread clinical use[4 , 51. Though viruses have been
naturally selected to efficiently navigate the multiple intra- and extra-cellular
barriers to successful gene transfer, the flexibility of polymer chemistries offers
great potential to identify and incorporate functionalities that confer not only
t This chapter has been published as Eltoukhy, A. A., Siegwart, D. I., Alabi, C. A.,
Rajan, J. S., Langer, R., Anderson, D. G. Effect of molecular weight of amine end-
modified poly(P-amino ester)s on gene delivery efficiency and toxicity. Biomaterials
33, 3594 (2012).
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effective gene transfection, but also superior biocompatibility, enhanced
formulation stability, and low toxicity[6 ,71.
Toward this end, a more comprehensive understanding of the structure-
property relationship for gene delivery polymers is critical to the elucidation of
design principles for future generations of synthetic gene vectors. The molecular
weight (MW) and molecular weight distribution (MWD) of cationic polymers are
among the factors known to dramatically affect their gene delivery performance. For
example, it was reported that higher MW poly(2-(dimethylamino) ethyl
methacrylate (PDMAEMA), (Mw > 300 kDa) yielded greater in vitro gene transfection
than polymers with lower MW (Mw < 60 kDa)[81. This trend was confirmed more
recently by another group, which found that transfection activity increased with the
Mw of PDMAEMA up to at least 915 kDa[91. Similarly, for various other polymeric
carriers including trehalose-based glycopolymers[101, four-branched star vectors[11],
and quaternized celluloses[121, higher MW was correlated with increasing gene
delivery activity for the range of molecular weights examined. For poly(L-lysine)
(PLL), however, polymers of intermediate length (Mw = 54 kDa) produced optimal
gene transfection relative to longer (Mw = 225 kDa) or shorter (Mw < 22.4 kDa)
variants[1 31, a phenomenon that has been attributed to an optimal rate of vector
unpacking[14].
For polyethylenimine (PEI), there are a variety of studies on the relationship
between polymer MW and DNA transfection activity. Using branched PEls ranging
in MW from 0.6 to 70 kDa, one group found that higher MW variants mediated
significantly greater in vitro DNA transfection, which they speculated might owe to a
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greater capacity for endosomal escape [151. In contrast, another group reported that
in vitro transfection activity decreased with increasing MW for three branched PEls
ranging in Mw from 1.8 to 70 kDa [161. Likewise, in a comparison between a low MW
PEI (Mw = 11.9 kDa) with low degrees of branching and a high MW, highly branched
PEI (Mw = 1,616 kDa), it was observed the low MW variant had much greater
transfection potency and lower toxicity[17]. In another study, 25 kDa branched PEI
was fractionated by size, and a particular fraction with Mw of roughly 4-10 kDa
displayed optimal performance relative to higher or lower MW fractions[181. Finally,
with linear PEIs ranging in Mw from 1.0-9.0 kDa, it was observed that at low N:P
ratios, transfection generally increased with MW, but that at higher N:P ratios,
polymers of intermediate length were superior[191.
Poly(p-amino esters) (PBAEs) are a promising class of polymeric gene
vectors characterized by their ease of synthesis and biodegradability 20-241. With
their capacity to condense plasmid DNA (pDNA) into nanoparticles on the order of
50-200 nm in diameter, PBAEs have yielded high gene delivery efficiency to a
variety of cell types with low toxicity[25 ,261. The use of combinatorial polymer library
synthesis coupled with high-throughput screening and characterization has
revealed structural motifs associated with highly active gene delivery polymers; in
particular, the presence of hydroxyl groups in the side chains and the conjugation of
certain primary amines to the chain ends dramatically modulate the efficiency of
DNA transfection in different cell types[27-30I. Amine end-capped PBAEs, especially
those based on poly(5-amino-1-pentanol-co-1,4-butanediol diacrylate) (C32), have
demonstrated potential for a number of clinically relevant applications, including
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suicide gene therapy for ovarian cancer[311, genetic modification of stem cells for
treatment of ischemia[321, and gene transfer to glioblastoma cells[ 3 3 1. However, the
impact of chain length on nucleic acid delivery has not yet been systematically
examined for this important group of degradable gene delivery polymers.
In this chapter, we applied two strategies to obtain amine end-modified
PBAEs with variation in MW: modulation of monomer stoichiometry and
preparative size exclusion chromatography (SEC). Using the first approach, we
observed that polymers of intermediate MW mediated optimal DNA transfection
activity. For these polymers, we did not observe a significant correlation between
polymer MW and toxicity. Optimal performance was associated with higher DNA
encapsulation efficiency and smaller nanoparticle size, but not with nanoparticle ;-
potential. However, using preparative SEC to obtain more monodisperse polymer
fractions from a polydisperse starting polymer, we found that the transfection
efficiencies of size-fractionated, well-defined PBAEs generally increased with MW.
In addition, this approach allowed us to isolate polymer fractions that were more
potent than the starting material, which indicates the potentially broad applicability
of this separation technique for gene delivery polymers synthesized by step-growth
polymerization.
5.2 MATERIALS AND METHODS
5.2.1 Materials
1,4-butanediol diacrylate ("C") and 5-amino-1-pentanol ("32") were
purchased from Alfa Aesar (Ward Hill, MA, USA). 1,3-diaminopropane ("103"), 1,3-
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pentanediamine ("117"), and 2-methyl-1,5-pentanediamine ("118") were obtained
from Sigma-Aldrich (St. Louis, MO, USA). (PEO)4-bis-amine ("122") was acquired
from Molecular Biosciences (Boulder, CO, USA). All reagents were used without
further purification. Plasmid DNA encoding green fluorescent protein (gWiz-GFP)
was purchased from Aldevron (Fargo, ND, USA). HeLa cells (ATCC, Manassas, VA,
USA) were cultured in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with
10% fetal bovine serum (Invitrogen). Quant-IT PicoGreen dsDNA reagent was
purchased from Invitrogen.
5.2.2 Polymer synthesis
Acrylate-terminated C32 poly(p-amino ester) was synthesized in -5 g
batches by reacting 1,4-butanediol diacrylate ("C") and 5-amino-1-pentanol ("32")
in bulk at 70"C for 48 h with stirring. To obtain MW variants, 15 monomer molar
ratios between 1:1 and 1.3:1 C:32 were chosen for polymerization: 1.0, 1.02 5, 1.04,
1.05, 1.06, 1.075, 1.1, 1.125, 1.15, 1.175, 1.2, 1.225, 1.25, 1.25, 1.275, and 1.3:1
(C:32). After cooling, 1 g of each batch was end-capped with 2 mmol of each of 4
different amines (103, 117, 118, and 122) by reaction in anhydrous tetrahydrofuran
(THF) overnight at RT at a concentration of 100 mg/mL. The following day, the 60
resulting C32 variants were purified by precipitation in anhydrous hexanes (1:3 v/v
THF:hexanes) and dried under vacuum for 24 h. Polymers were then dissolved at
100 mg/mL in dimethyl sulfoxide (DMSO) and stored at -20"C until use.
In a typical example, for the 1.1:1 C:32 molar ratio, 3.394 g C (17.12 mmol)
was added to 1.605 g 32 (15.55 mmol) in a 20 mL glass vial equipped with stir bar
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and sealed with a screw cap. It was heated in a reaction block at 70'C for 48 h with
stirring. For end-modification of this polymer with the 103 amine, the 5 g batch of
C32-Ac was cooled and then dissolved in 10 mL of anhydrous THF; of this solution, 2
mL was transferred to a 20 mL glass vial containing 8 mL of 103 amine at 0.25 M in
THF (2 mmol). After stirring overnight at RT, the polymer was isolated by
precipitation into hexanes and was then analyzed by SEC.
5.2.3 Analytical size exclusion chromatography (SEC)
Analytical SEC was performed using a Waters system (Milford, MA) equipped
with a 2400 differential refractometer, 515 pump, and 717-plus autosampler. The
flow rate was 1 mL/min and the mobile phase was THF. The Styragel columns
(Waters) and detector were thermostated at 352C. Linear polystyrene standards
were used for calibration.
5.2.4 in vitro GFP plasmid DNA transfection
One day before transfection, 15,000 HeLa cells in 100 [tL of medium were
seeded into each well of a 96-well polystyrene tissue culture plate. In a typical
example, for a 600 ng/well DNA dose, pDNA was diluted to 0.06 mg/mL in 25 mM
sodium acetate (NaOAc) buffer at pH 5.2. Polymers were thawed immediately prior
to transfection and diluted in NaOAc buffer to a concentration 20, 30, or 40 times
that of the DNA concentration, depending on the desired polymer:DNA w/w ratio.
To form DNA-polymer nanoparticles, 25 [tL of polymer solution was added to 25 1tL
of DNA in a half-area 96-well plate, mixed by repeated pipetting using a
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multichannel pipette, and allowed to incubate for 5 min at RT. 30 [tL of polymer-
DNA complexes were then gently mixed with 195 [tL of fresh medium warmed to
37'C. Conditioned medium was removed using a 12-channel aspirating wand and
replaced with 150 [tL of the complexes diluted in medium. Following a 4 h
incubation, complexes were removed with the aid of a multi-channel aspiration
wand and replaced with 100 pL of fresh medium. GFP expression was assessed 48 h
after transfection by fluorescence-activated cell sorting (FACS).
5.2.5 FA CS analysis
After aspirating conditioned medium, cells were washed with PBS and
detached using 25 ptL per well of 0.25% trypsin-EDTA (Invitrogen). 50 pL of FACS
running buffer, consisting of 98% PBS, 2% FBS, and 1:200 v/v propidium iodide
solution (Invitrogen), was added to each well. Cells were mixed thoroughly and then
transferred to a 96-well round-bottom plate. GFP expression was measured using
FACS on a BD LSR II (Becton Dickinson, San Jose, CA, USA). Propidium iodide (PI)
staining was used to exclude dead cells from the analysis. PI staining was also used
to determine the viabilities of treated cells relative to non-treated control cells,
where the relative viability was calculated as the ratio of live (unstained) treated
cells per well to the mean number of live non-treated cells per well. 2D gating was
used to separate increased auto-fluorescence signals from increased GFP signals to
more accurately count positively expressing cells. Gating and analysis were
performed using FlowJo v8.8 software (TreeStar, Ashland, OR, USA).
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5.2.6 Dynamic light scattering (DLS) measurements
To form complexes using the same concentrations and conditions that were
optimal for transfection (40 w/w polymer:DNA), 150 [tL of polymer at 2.4 mg/mL in
NaOAc buffer was mixed with 150 ttL of plasmid DNA (gWiz-GFP) at 0.06 mg/mL in
NaOAc buffer. After incubation for 5 min at RT, 1.2 mL of 10% serum-containing
medium was added to the mixture, which was then immediately subjected to DLS
measurements using a ZetaPALS DLS detector (Brookhaven Instruments Corp.,
Holtsville, NY, USA, 15-mW laser, incident beam 676 nm). To ensure that all
measurements represented the same time point of analysis, the size and -potential
data were obtained independently. Correlation functions were collected at a
scattering angle of 900, and particle sizes were calculated using the MAS option of
BICs particle sizing software (v. 2.30) using the viscosity and refractive index of
water at 25*C. Particle sizes are expressed as effective diameters assuming a log-
normal distribution. Electrophoretic mobilities were measured at 25*C using BIC
Phase Analysis Light Scattering (PALS) C-potential software, and -potentials were
calculated using the Smoluchowski model for aqueous suspensions.
5.2.7 Dye exclusion assay
The dye exclusion assay to determine polymer-DNA encapsulation efficiency
was performed as described previously[2 91. Briefly, a working solution of PicoGreen
was prepared by diluting 80 [tL of stock solution in 15.92 mL NaOAc buffer. In each
well of a 96-well plate, 50 RL of polymer at 2.4 mg/mL in NaOAc buffer was added to
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50 [tL of DNA at 0.06 mg/mL in NaOAc buffer. After 5 min, 100 [tL of PicoGreen
working solution was added to the complexes. After an additional 5 min incubation,
30 tLl was transferred to 200 tL of 10% serum-containing medium in a black 96-
well assay plate. The fluorescence was then measured on a Tecan Infinite M1000
plate reader using the FITC filter set (excitation 485 nm, emission 535 nm). The
reduction in relative fluorescence (RF), or the relative encapsulation efficiency, was
calculated using the relationship (FDNA- Fsample)/(FDNA - Fbiank), where Fsample is the
fluorescence of the polymer-DNA-PicoGreen sample, FDNA is the fluorescence of
DNA-PicoGreen (no polymer), and FbIank is the fluorescence of a sample with no
polymer or DNA (only PicoGreen).
5.2.8 Preparative SEC
Polymers were fractionated based on size with a Phenogel 5[im MXL gel
filtration column (300 mm x 7.8 mm, Phenomenex, P/No. OOH-3087-KO) using THF
as the mobile phase at a flow rate of 1 mL/min. The separation was done on a 1200
Series Agilent HPLC system equipped with a UV diode array detector and a 1260
Infinity analytical scale fraction collector. The column compartment was kept at
40'C during fractionation. Polymer fractions were collected at 0.2 min intervals
based on the absorption of the polymer at 254 nm. The fractions were transferred
into tared vials, dried, weighed, and then dissolved to 100 mg/mL in DMSO. They
were stored at -20*C until further use.
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5.3 RESULTS AND DISCUSSION
5.3.1 Synthesis and analytical SEC ofstoichiometric PBAE variants
One straightforward method for molecular weight control of polymers
synthesized by step-growth addition is to vary the stoichiometric ratio of the
starting monomers. According to the Carothers relationship, the weight-average
molecular weight Mw depends on the molar ratio of reactants r, the fractional
monomer conversion p, and the molecular weight of the polymer repeat unit Mo as
follows: Mw = Mo(1+p)(1+r)/(1-2pr+r). In this report, the PBAE C32 was synthesized
using a range of 15 monomer molar feed ratios between 1:1 and 1.3:1 "C" (1,4-
butanediol diacrylate) to "32" (5-amino-1-pentanol); these acrylate-terminated C32
polymers (C32-Ac) were then end-capped with each of four different amine
molecules (Figure 5.1). These end-capping amines, denoted 103, 117, 118, and 122,
were selected because they improved transfection performance relative to
unmodified C32 polymer 281.
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Figure 5.1 Synthesis scheme for end-modified poly(p -amino ester)s.
(A) 5-amino-1-pentanol (32) is added to an excess of 1,4-butanediol diacrylate (C)
to yield acrylate-terminated C32, which is then reacted with excess amine to
produce end-modified PBAE. (B) Structures of diamine molecules used for amine
end-capping.
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Figure 5.2 Relationship between Mw and C:32 monomer molar feed ratio for
amine end-modified PBAEs
As expected, SEC analysis revealed that the molecular weight of these end-
modified PBAEs decreased as the feed ratios deviated from stoichiometric unity
(Figure 5.2). The polymers ranged in Mw from a maximum of 16.4 kDa for C32-118
synthesized at a feed ratio of 1:1 C:32 to a minimum of 2.4 kDa for C32-103
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synthesized at 1.3:1 C:32. Because the end-modified polymers were synthesized
from the same 15 batches of intermediate C32-Ac polymer, the differences in MW
observed between end-modified PBAEs at the same monomer feed ratio may reflect
a limited extent of polymer cross-linking or degradation.
5.3.2 Plasmid DNA transfection and cytotoxicity
To investigate the relationship between the molecular weight of end-
modified PBAEs and in vitro transfection activity, we formed complexes using the
synthesized polymers and GFP-encoding plasmid DNA (pDNA), and then incubated
these nanoparticles with cultured HeLa cells in serum-containing growth medium
for 4 h. Two days after transfection, we used fluorescence activated cell sorting
(FACS) to quantify the proportion of HeLa cells expressing GFP.
When the transfection efficiencies of the various end-modified PBAEs were
correlated with Mw, we observed that for a given weight ratio of polymer:DNA,
polymers of intermediate length (Mw ~ 5-8 kDa) generally outperformed polymers
with higher or lower Mw (Figure 5.3). For example, at a polymer:DNA w/w ratio of
40:1 (equivalent to N:P ratio of -44:1), C32-122 with Mw = 5.5 kDa (synthesized at a
C:32 molar feed ratio of 1.125:1) successfully transfected -80% of HeLa cells, in
contrast to -26% for the highest MW variant (Mw = 11.7 kDa) and -49% for the
lowest MW variant (Mw = 3.0 kDa). At a lower polymer:DNA w/w ratio of 30:1 (N:P
- 33), this trend of optimal transfection activity for polymers of intermediate MW
persisted. However, at a w/w ratio of 20:1 or below (N:P - 22), none of the MW
variants yielded significant transfection.
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Figure 5.3 Correlation between polymer Mw and gene transfection efficiency in
HeLa cells for PBAE stoichiometric variants
Correlation between PBAE Mw and DNA transfection efficiency (mean ± SD, n = 4) in
HeLa cells for the stoichiometric variants of C32-103 (A), C32-117 (B), C32-118 (C),
and C32-122 (D). The DNA dose is fixed at 600 ng per well of a 96-well plate and
transfection was assessed by FACS 48 h.
Because of the frequent reports of a correlation between toxicity and
polymer MW for many polymers, including PEI, we examined this relationship by
staining transfected cells with propidium iodide immediately prior to FACS. When
the viabilities of transfected cells relative to non-treated control cells were plotted
against polymer Mw at the highest polymer:DNA w/w ratio used (40:1), we did not
observe any significant association between the length of end-modified PBAEs and
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their toxicity during transfection (Figure 5.4). Although there was some toxicity
associated with C32-103 and C32-117, for each of these polymers, it did not increase
with increasing MW. Importantly, for the most effective end-modified PBAE, C32-
122, the relative viabilities of transfected cells were not significantly reduced. These
results suggest that PBAEs have low toxicity over a wide range of MW, and therefore
show promise as non-toxic transfection materials.
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Figure 5.4 Correlation between polymer Mw and relative viability of HeLa cells
following DNA transfection with PBAE stoichiometric variants
Correlation between polymer Mw and the relative viability (mean ± SD, n = 4) of
HeLa cells following DNA transfection with the stoichiometric variants of C32-103
(A), C32-117 (B), C32-118 (C), and C32-122 (D) at a polymer:DNA w/w ratio of
40:1. The DNA dose is held constant at 600 ng per well of a 96-well plate.
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5.3.3 Biophysical characterization of polymer/DNA nanoparticles
For various other polymeric gene delivery systems, the relationship between
MW and gene delivery has been associated with variation in nanoparticle size and
charge. To assess the hypothesis that the dependence of transfection efficiency on
the MW of end-modified PBAEs reflects biophysical characteristics of the
polymer/DNA nanoparticles, we used dynamic light scattering (DLS) to measure the
sizes and ;-potentials of complexes formed from our stoichiometric variants.
Polymers and plasmid DNA were mixed at the optimal weight ratio for transfection,
40:1 w/w polymer:DNA (N:P - 44:1). To replicate transfection conditions,
complexes were prepared by repeated pipetting in 25 mM sodium acetate buffer at
pH 5.2, incubated for 5 min at room temperature to allow for self-assembly, and
then subjected to DLS immediately following dilution in 10% serum-containing
medium.
We observed that for three of the four end-modified PBAEs, C32-118, C32-
122, and to a limited extent, C32-103, polymer/DNA nanoparticle diameters were
relatively uniform with respect to Mw up to -6-8 kDa, but above this threshold,
particle size increased with increasing Mw (Figure 5.5). The most effective end-
modified PBAEs generally yielded nanoparticles less than 200 nm in size. In contrast
to all of the other polymers tested, for C32-117, there was no clear association
between polymer length and nanoparticle size, with all polymer variants resulting in
complexes between 150-200 nm in diameter. Although for a given end-modified
PBAE, smaller nanoparticles generally mediated more efficient transfection (Figure
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5.6), the smallest complexes were never the most effective, which suggests the
significance of factors other than particle size.
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Figure 5.5 Correlation between polymer M. and polyplex diameter for PBAE
stoichio metric variants
Correlation between polymer Mw and diameter (mean ± SD, n = 3) of complexes
formed from DNA and stoichiometric variants of C32-103 (A), C32-117 (B), C32-
118 (C), and C32-122 (D) at a polymer:DNA w/w ratio of 40: 1. Polyplexes were
formed in sodium acetate buffer at pH 5.2 and then diluted in serum-containing
medium immediately prior to measurement.
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Figure 5.6 Correlation between gene transfection efficiency and polyplex
diameter for PBAE stoichiometric variants.
Correlation between transfection efficiency (mean ± SD, n = 4) in HeLa cells and the
mean diameters of complexes formed from DNA and stoichiometric variants of C32-
103 (A), C32-117 (B), C32-118 (C), and C32-122 (D) at a polymer:DNA w/w ratio of
40:1. Polyplexes were formed in sodium acetate buffer at pH 5.2 and then diluted in
serum-containing medium immediately prior to measurement.
Because we wanted a direct comparison with our in vitro transfection results,
we chose to perform DLS analysis, including the charge measurements, with
complexes that were diluted in serum-containing medium. Under these conditions,
we observed no significant variation in the nanoparticle -potential, with most
polymers producing complexes that were near-neutral in serum-containing medium
regardless of MW (Figure 5.7).
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Figure 5.7 Correlation between polymer M and -potential for PBAE
stoichiometric variants
Correlation between polymer M and c-potential (mean ± SD, n = 3) of complexes
formed from DNA and stoichiometric variants of C32-103 (A), C32-117 (B), C32-
118 (C), and C32-122 (D) at a polymer:DNA w/w ratio of 40: 1. Polyplexes were
formed in sodium acetate buffer at pH 5.2 and then diluted in serum -containing
medium immediately prior to measurement.
We speculated that either the lack of a buffering agent or the presence of
negative ly- charged serum proteins could generate spurious data or otherwise mask
an underlying trend. However, when we conducted charge measurements of C32-
122/DNA nanoparticles in 25 mM sodium acetate buffer at pH 5.2, all particles were
similarly characterized by near-neutral -potentials within a narrow range of -1 to
+1 mV (Figure 5.8). Therefore, for these end-modified PBAEs, the superior
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transfection activity of polymers of intermediate length depends to a certain degree
on smaller nanoparticle size, but is independent of nanoparticle charge.
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Figure 5.8 Correlation between polymer M, and c-potential for C32-122
stoichiometric variants in sodium acetate buffer
Correlation between polymer Mw and -potential (mean ± SD, n = 3) of complexes
formed from DNA and stoichiometric variants of C32-122 at a polymer:DNA w/w
ratio of 40:1. Polyplexes were formed and measured in sodium acetate buffer at pH
5.2.
5.3.4 Relative DNA binding efficiency
To assess whether the presence of an optimal polymer MW for transfection
reflects enhanced condensation and loading of free plasmid DNA into nanoparticles,
we quantified the DNA encapsulation efficiencies of these end-modified PBAE
variants by measuring the reduction in relative fluorescence due to the protection of
entrapped DNA from intercalation by the PicoGreen dye[34]. Using the same
conditions as those for transfection as well as for the DLS measurements above, we
found that for at least two of the four end-modified PBAEs, C32-103 and C32-117,
polymers of intermediate MW entrapped plasmid DNA with greater efficiency than
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higher or lower MW variants (Figure 5.9). For these polymers, the variants with the
greatest gene delivery activity in HeLa cells also encapsulated DNA the most
efficiently (Figure 5.10). For C32-118 and C32-122, however, encapsulation
efficiency generally decreased with polymer MW, and the variants most effective at
transfection did not coincide with those that entrapped DNA with the highest
efficiency.
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Figure 5.9 Correlation between polymer M. and relative DNA binding for
PBAE stoichiometric variants
Correlation between polymer M, and relative DNA binding efficiency (mean ± SD, n
= 3) of stoichiometric variants of C32-103 (A), C32-117 (B), C32-118 (C), and C32-
122 (D) at a polymer:DNA w/w ratio of 40:1.
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Figure 5.10 Correlation between gene transfection efficiency and relative DNA
binding for PBAE stoichiometric variants
Correlation between transfection efficiency (mean ± SD, n = 4) in HeLa cells and
relative DNA binding efficiency of stoichiometric variants of C32-103 (A), C32-117
(B), C32-118 (C), and C32-122 (D) at a polymer:DNA w/w ratio of 40:1.
From these data, we hypothesize that at least for C32-103 and C32-117, the
relatively high DNA entrapment efficiencies of polymers of intermediate MW
contribute to their enhanced transfection. Though useful in establishing trends
when comparing variants of a particular end-modified polymer, the encapsulation
efficiency values obtained from this dye exclusion assay in general appeared to have
limited predictive power with respect to transfection activity; for instance, C32-122
variants loaded DNA the least efficiently relative to other end-capped C32 polymers,
but actually transfected HeLa cells the most efficiently. These results suggest that
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for a given gene delivery polymer, DNA complexation efficiency is one important
factor among others, including chemical composition and nanoparticle size,
responsible for the variation in transfection activity due to polymer MW.
5.3.5 Preparative SEC
Although they vary in MW, the stoichiometric PBAE variants synthesized
above through step-growth polymerization are characterized by broad MWDs.
Besides their high polydispersity indices (PDIs), variation of the diacrylate:amine
ratio in the polymerization reaction could alter the degree to which polymers are
amine end-capped. To obtain polymers varying in MW, but characterized by a
narrower MWD, we re-synthesized a particular feed ratio variant of C32-122 (C:32 =
1.1:1; Mw = 6.69 kDa, PDI = 1.50) and subjected it to preparative SEC using an HPLC
system with an automated liquid fraction collector (Figure 5.11).
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Figure 5.11 Chromatogram of C32-122 eluting from the HPLC/SEC column
An example chromatogram showing the elution of C32-122 polymer from the SEC
column. Polymer fractions were collected at 0.2 min intervals between 5 and 9 min.
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Analytical SEC of -13 of the 20 fractions collected (representing -75% of the
total polymer mass loaded) revealed that Mw decreased smoothly with elution time
(Figure 5.12A). Furthermore, this method allowed for the isolation of fractions with
lower PDI (<1.2) than the crude polymer (Figure 5.12B).
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Figure 5.12 Preparative HPLC/SEC on C32-122
The Mw (A) and polydispersity indices (B) of various successive C32-122 polymer
fractions collected by preparative SEC. The dashed lines represent the values for the
crude, unfractionated polymer (Mw = 6.66 kDa, PDI = 1.50).
We performed a pDNA transfection experiment using these fractionated C32-
122 polymers and assessed the overall transfection efficiency in HeLa cells after 48
h. When polymer length was correlated with transfection efficiency at high DNA
doses and polymer:DNA w/w ratio, we observed that transfection efficiency
generally increased with polymer Mw (Figure 5.13). At a lower DNA dose, or at a
lower polymer:DNA w/w ratio, we found that some high MW fractions exhibited
dramatically greater potency than fractions with low MW. These high MW fractions
were also more potent than the crude, unfractionated polymer. For example, at a
DNA dose of 150 ng per well with a polymer:DNA w/w ratio of 40:1, C32-122 with a
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Mw of 12.9 kDa transfected -62% of cells, in contrast to <10% for polymers below 5
kDa, and -39% for the crude polymer.
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Figure 5.13 Correlation between gene transfection efficiency and Mw of C32-
122 polymer fractions isolated by SEC
Correlation between DNA transfection efficiency (mean ± SD, n = 4) in HeLa cells
and Mw of C32-122 polymer fractions isolated by SEC. In the left plot (A), the DNA
dose per well of a 96-well plate is varied as indicated as the polymer:DNA w/w ratio
is held at 40:1. In the right plot (B), the polymer:DNA w/w ratio is varied as the DNA
dose is held at 300 ng/well. The filled symbols represent the activity of the crude
polymer sample (mean ± SD, n = 4).
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These transfection data underscore the importance of using freshly
synthesized materials when working with degradable gene-delivery polymers, since
the MW threshold for optimal performance can be rather narrow, and the
consequence of a small degree of degradation accordingly steep. Furthermore, the
isolation of monodisperse polymers improved consistency of physical properties
across the samples, and enhanced delivery at higher MW.
When we conducted DLS measurements of the DNA nanoparticles formed
using these size-fractionated polymers in serum-containing media, we did not
observe significant variation in particle diameter; however, the variation in relative
DNA binding efficiency among the size-fractionated polymers appeared to correlate
to a certain extent with the observed transfection activities (Figure 5.14).
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Figure 5.14 Correlation between nanoparticle biophysical properties and
polymer Mw for C32-122 SEC fractions
Effective diameters (A) and relative DNA binding efficiencies (B) of nanoparticles
formed from size-fractionated C32-122 at a polymer:DNA w/w ratio of 40:1 in
serum-containing medium. The filled symbols represent the values for the crude
polymer.
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In contrast to our data with the polymer feed ratio variants, we did observe
an association between polymer MW and relative cell viability following
transfection, which was most prominent at the highest dose and polymer:DNA
weight ratio tested (Figure 5.15). Given that under these conditions some polymer
fractions transfected nearly 100% of cells, the transfection and viability data taken
together imply that a careful selection of polymer MW, DNA dose, and weight ratio
(in addition to other known variables such as cell density) could permit highly
efficient gene delivery with low cytotoxicity.
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Figure 5.15 Correlation between Mw of C32-122 SEC fractions and relative
viability following gene transfection in HeLa cells
Correlation between Mw of C32-122 polymer fractions isolated by SEC and the
relative viability (mean ± SD, n = 4) of HeLa cells 48 h after transfection. In the left
plot (A), the DNA dose per well of a 96-well plate is varied as indicated as the
polymer:DNA w/w ratio is held at 40:1. In the right plot (B), the polymer:DNA w/w
ratio is varied as the DNA dose is held at 300 ng/well. The filled symbols represent
the activity of the crude polymer sample.
As suggested above, we hypothesize that the observed differences in trends
between the C32-122 feed ratio variants and the size-fractionated C32-122 polymer
likely result from the high polydispersity indices of the feed ratio variants as well as
possible heterogeneity in the extent of amine end-modification. For researchers
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working with gene delivery polymers synthesized by step-growth polymerization,
our data highlight the potentially broad utility of preparative SEC for the isolation of
well-defined, monodisperse fractions with higher transfection potency than the
starting material. We expect that this approach should also help to reduce
variability between batches of polymers.
Because both data sets suggested a role for DNA complexation efficiency in
modulating the relationship between polymer MW and transfection activity, we
hypothesize that the best gene delivery polymers owe their performance at least in
part to an optimal balance of the rates of complex formation during particle
assembly and unpacking within the cell. Additional studies are required to address
this hypothesis in greater detail.
5.4 CONCLUSIONS
Working with amine end-modified PBAEs, a promising class of degradable
gene delivery polymers, we investigated the effect of polymer MW on the
transfection activity, toxicity, and biophysical properties of the resulting polymer-
DNA nanoparticles. Using variation of monomer stoichiometry, we observed that
polymers of intermediate length mediated optimal DNA transfection in HeLa cells.
Characterization of these feed ratio variants suggested that optimal performance
was related to higher polymer-DNA complexation efficiency and smaller
nanoparticle size, but not to nanoparticle charge. In contrast, using preparative SEC
to obtain well-defined, monodisperse polymer fractions, we observed that the
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transfection activities of size-fractionated PBAEs generally increased with MW, a
trend that was weakly associated with more efficient DNA binding. Our ability to
isolate polymer fractions with higher transfection potency than the starting material
indicates the potentially broad utility of this approach. These results further our
understanding of the influence of polymer MWD on nucleic acid delivery, a critical
aspect of the structure-property relationship for gene delivery materials.
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6 THE CHOLESTEROL TRANSPORTER NIEMANN
PICK C1 PLAYS A CRITICAL ROLE IN DNA
INTERNALIZATION AND TRANSFECTION BY
POLY(BETA-AMINO ESTER)S
6.1 INTRODUCTION
The tremendous medical promise of gene therapy remains largely unfulfilled
due to the lack of safe and effective delivery vehicles[1 1. Though regarded as efficient
gene carriers, viral vectors also carry serious safety risks including insertional
mutagenesis and adverse immune responses[21. Non-viral gene vectors offer the
possibility of improved safety, but have generally failed to attain satisfactory
delivery efficacy in clinical testing[3 ,41. Unfortunately, the rational design of synthetic
carriers is at present extremely challenging because of the limited mechanistic
understanding of the numerous hurdles involved in gene delivery 51.
Cellular uptake constitutes an early step for which there is an increasingly
refined picture of the endocytic pathways available for use by nanoparticles[ 61. For
most cells types other than phagocytes, these endocytic mechanisms include
macropinocytosis, clathrin-dependent endocytosis, caveolae-mediated endocytosis,
and a growing number of clathrin- and caveolae-independent pathways such as
RhoA-dependent, Arf6-dependent, Cdc42-dependent, and flotillin-dependent
endocytosis[ 7 . A handful of nanocarriers appear to rely predominantly on a single
pathway. Certain kinds of poly(lactic-co-glycolic acid) (PLGA) nanoparticles, for
instance, were reported to be internalized by vascular smooth muscle cells via
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clathrin-dependent endocytosis 8 -10, whereas DOXIL@ and Abraxane@ nanoparticles
enter tumor cells via caveolae-mediated endocytosis 11 , 121. Macropinocytosis,
meanwhile, appeared to be the major pathway used for entry in HeLa cells by
siRNA-containing cationic lipid-based nanoparticles (LNPs) formulated with PEG[1 31.
Nonetheless, for most of the nanoparticles commonly used for non-viral gene
delivery, including poly-L-lysine (PLL) and polyethylenimine (PEI)-based
polyplexes, as well as various lipoplexes and liposomes, evidence exists for the use
of multiple endocytic mechanisms[ 14 2 1 1.
Poly(beta-amino ester)s (PBAEs) are biodegradable cationic polymers that
have demonstrated effective gene delivery in a variety of in vitro and in vivo
contexts, including suicide gene therapy of several animal models of cancer[22-24 1 as
well as genetic modification of stem cells for treatment of ischemia[25 . These
polymers have consistently shown superior performance and less toxicity in several
difficult-to-transfect cell types[26-281 compared to commercially available
transfection reagents such as Lipofectamine 2000 (LF 2000). The versatility of the
polymerization chemistry[291 has allowed a broad set of structures to be synthesized
and screened in a high-throughput manner[30-341, allowing systematic investigation
of key parameters affecting gene delivery potency such as polymer molecular
weight distribution[35 , hydrophobicity of the side chains[ 361, and amine end-group
structure[37-40 l. However, the endocytic mechanisms used by PBAEs for
internalization have not yet been studied.
In this chapter, we explore the uptake of PBAE/DNA nanoparticles through
complementary approaches including pharmacological inhibition and marker co-
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localization studies. We observe that PBAE/DNA nanoparticles appear to enter
immortalized mouse embryonic fibroblast (MEF) cells through multiple pathways,
with an apparent requirement for normal cholesterol trafficking. We show that
PBAE polyplex transfection efficacy is dramatically reduced in MEFs deficient in a
late endosomal and lysosomal cholesterol transport protein, Niemann-Pick CI
(Npc1), mutations of which are associated with a fatal disease characterized by
abnormal lysosomal accumulation of cholesterol[411.
Highlighting the role of this protein in endocytic uptake and cellular
trafficking, Npcl-deficient cells were recently identified to inhibit endosomal escape
and cellular entry of Ebola virus[4 2 4 4 1; in contrast, retention and efficacy of lipid-
based nanoparticles for siRNA delivery were greatly enhanced in Npcl-/- cells
(Sahay et al., forthcoming). Here, we find that Npcl knockout in MEFs greatly
inhibits PBAE-mediated DNA internalization, with a slight decrease in DNA uptake
mediated by PEI and no apparent effect on DNA uptake mediated by LF 2000. We
show that retention of various endocytic markers is altered in Npci-deficient MEFs,
with over 20-fold reduction in uptake of cholera toxin B, two-fold reduction in
uptake of transferrin, and -50%-increase in uptake of dextran. PBAE/DNA
polyplexes showed the greatest extent of co-localization with cholera toxin B,
suggesting the involvement of shared uptake pathways that are altered in cells
lacking Npc1. These studies provide further evidence that Npcl plays a key role in
regulating endocytic mechanisms affecting internalization and efficacy of
nanoparticles.
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6.2 MATERIALS AND METHODS
6.2.1 Materials
1,4-butanediol diacrylate and 5-amino-1-pentanol were purchased from Alfa
Aesar (Ward Hill, MA, USA). Dodecylamine was purchased from Sigma-Aldrich (St.
Louis, MO, USA). (PEO) 4-bis-amine ("122") was acquired from Molecular Biosciences
(Boulder, CO, USA). All chemical reagents were used without further purification.
Plasmids encoding green fluorescent protein (gWiz-GFP) and firefly luciferase
(gWiz-Luc) were purchased from Aldevron (Fargo, ND, USA). jetPEI (Polyplus
Transfection, Illkirch, France) and Lipofectamine 2000 were purchased from VWR
(Radnor, PA, USA) and Invitrogen (Carlsbad, CA, USA), respectively. Transferrin,
cholera toxin B, and 10,000 MW dextran, each labeled with AlexaFluor 647, were
purchased from Invitrogen. Cytochalasin D, dynasore hydrate, chlorpromazine
hydrochloride, filipin III, genistein, methyl-P-cyclodextrin, 5-(N-ethyl-N-
isopropyl)amiloride (EIPA), and U18666A were obtained from Sigma-Aldrich.
Immortalized mouse embryonic fibroblast (MEF) cell lineswere cultured in DMEM
(Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen).
6.2.2 Polymer synthesis
To synthesize C32-122, acrylate-terminated C32 poly(p-amino ester) was
first prepared in a 5 g batch by reacting 1,4-butanediol diacrylate ("C") and 5-amino-
1-pentanol ("32") (1.2:1.0 diacrylate:amine molar ratio) without solvent at 900C for
24 h with stirring. After cooling to RT and dissolving the polymer in 10 mL of
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anhydrous THF, it was added to a vial containing 10 mmol of (PEO) 4-bis-amine (10
mmol in 40 mL anhydrous THF). Following overnight stirring at RT, the amine end-
modified polymer was purified by precipitation in anhydrous diethyl ether (1:3 v/v
THF:ether) and dried under vacuum for 24 h. C32-122 was then dissolved at 100
mg/mL in dimethyl sulfoxide (DMSO) and stored at -20'C with desiccant until use.
For synthesis of C32-122 terpolymers containing C12 alkyl side chains,
dodecylamine, 5-amino-1-pentanol, and 1,4-butanediol diacrylate were sequentially
added to a vial equipped with stir bar such that the total mass of monomers was 200
mg, the diacrylate:amine monomer molar ratio was 1.2:1.0, and the molar ratios of
the amines C12:32 varied as indicated (0% C12 = 0:1 C12:32, 10% = 0.1:0.9, 20% =
0.2:0.8, etc.). After heating and stirring at 90"C for 48 h, the reactions were allowed
to cool to RT, then dissolved in 1 mL of DMSO, to which a solution of (PEO)4 -bis-
amine (0.8 mmol in 1 mL DMSO) was added. The reactions were stirred at RT
overnight and then stored frozen with desiccant at -20"C.
6.2.3 DNA transfection experiments
One day before transfection, cells (100 pl) were seeded into each well of a
96-well polystyrene tissue culture plate (HeLa: 12,500 per well; MEFs: 9,000 per
well). For studies using the pharmacological inhibitors, conditioned medium was
removed 1 hour prior to transfection and replaced with fresh, pre-warmed medium
containing the indicated concentration of pharmacological inhibitor. For GFP
transfection experiments, gWiz-GFP (5 mg mla) was diluted to 160 [tg ml-' in 25 mm
sodium acetate (NaOAc) buffer at pH 5.2; for DNA uptake experiments, gWiz-Luc
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was labeled with Cy3 or Cy5 using the Labellt kit (Mirus, Madison, WI, USA)
following the manufacturer's instructions, and was diluted in NaOAc buffer as
above. PBAEs (100 mg ml1) were thawed immediately prior to transfection and
diluted in NaOAc buffer to a concentration of 3.2 mg ml[ (20:1 w/w polymer:DNA).
To form DNA-polymer nanoparticles, polymer solution (200 [d) was added to the
diluted DNA (200 [l), mixed by repeated pipetting, and allowed to incubate for 10
min at RT. Depending on the dose, polymer-DNA complexes were diluted in NaOAc
as needed, and then were gently mixed in a deep 96-well plate with pre-warmed
fresh medium (360 [l). For inhibition experiments, this medium was prepared with
the indicated concentration of pharmacological inhibitor, whereas for co-
localization experiments, labeled transferrin, cholera toxin B, or dextran were
present Conditioned medium was removed using a 12-channel aspirating wand and
replaced with the complexes diluted in medium (100 Rl). jetPEI and Lipofectamine
2000 were used according to the manufacturers' protocols.
For GFP transfection experiments, following a 3-h incubation at 37'C,
complexes were removed with the aid of a multi-channel aspiration wand and
replaced with fresh medium (100 [d), and the cells were analyzed for GFP
expression by fluorescence-activated cell sorting (FACS) after 24 h at 37"C. For DNA
uptake experiments, cells were washed three times at the indicated time point and
prepared for analysis by either confocal microscopy or FACS.
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6.2.4 FACS analysis
After aspirating conditioned medium and washing cells three times with PBS,
cells were detached using 25 iil per well of 0.25% trypsin-EDTA (Invitrogen).
Following a 5 min incubation at 37*C, fresh medium (50 il) was added to the cells,
which were mixed thoroughly and then transferred to a 96-well round-bottom
plate. Cells were then pelleted, re-suspended in fixation buffer (4% v/v
formaldehyde in PBS), incubated for 10 min at RT, pelleted again, and finally re-
suspended in ice-cold FACS running buffer (2% v/v FBS in PBS) containing 1:200
v/v propidium iodide (Invitrogen). The cells were kept at 4*C until FACS analysis
using a BD LSR II (Becton Dickinson, San Jose, CA, USA). Except for experiments with
Cy3-labeled DNA, propidium iodide (PI) staining was used to exclude dead cells
from the analysis. PI staining was also used to determine the viabilities of treated
cells relative to non-treated control cells, where the relative viability was calculated
as the ratio of live (unstained) treated cells per well to the mean number of live non-
treated cells per well. For GFP expression analysis, 2D gating was used to separate
increased auto-fluorescence signals from increased GFP signals to more accurately
count positively expressing cells. Gating and analysis were performed using FlowJo
v8.8 software (TreeStar, Ashland, OR, USA). Geometric mean fluorescent intensities
of transfected cells were normalized to those of the corresponding non-transfected
control cells.
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6.3 RESULTS AND DISCUSSION
6.3.1 Pharmacological inhibition studies
One approach toward identification of the endocytic mechanisms utilized by
nanomaterials involves the use of pharmacologic inhibitors known to interfere with
certain uptake pathways. However, this approach has concomitant disadvantages
including a lack of pathway selectivity and the induction of toxicity at excessive
doses. With these caveats in mind, we screened a set of such inhibitors for their
potential to reduce cellular internalization of labeled DNA by C32-122, one of the
top-performing amine end-modified poly(-amino ester) (PBAE) polymers[351. The
inhibitors we initially tested and the pathways these molecules are thought to
inhibit are provided in Table 6.1.
Cytochalasin D Actin-dependent 10, 1, 0.5, 0.05
pathways
Dynasore Clathrin & caveolar 100, 10, 1.0, 0.1
(dynamin-dependent)
Chlorpromazine Clathrin-mediated 100, 10, 1.0, 0.1
Filipin Caveolar 100, 10, 1.0, 0.1
5-(N-ethyl-N- Macropinocytosis 100, 10, 1.0, 0.1
isopropyl)amiloride (EIPA)
U18666A Cholesterol 100, 10, 1.0, 0.1
synthesis/trafficking
Table 6.1 Pharmacologic inhibitors tested in the initial screen
The set of pharmacologic inhibitors included in the initial screen along with the
pathways they target and the concentrations tested.
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Figure 6.1 Screen for small molecule-mediated inhibition of C32-122-
mediated DNA uptake in MEFs
MEFs were transfected with various doses of C32-122 polyplexes containing Cy5-
labeled DNA in the presence of the indicated concentrations of endocytic pathway
inhibitors. MEFs were pre-treated with the inhibitors 1 h prior to transfection. After
3 h, the cells were washed, fixed, stained with propidium iodide, and analyzed by
FACS to determine (a) cell viability of control cells treated with inhibitors (mean
SD, n = 3), and (b) DNA uptake efficiency (mean ± SD, n = 3) at various doses. DNA
uptake efficiencies plotted only for the 5 ng DNA/well dose.
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In the initial screen, immortalized mouse embryonic fibroblasts (MEFs) were
pre-treated with these inhibitors for 1 h, then transfected with various doses of C32-
122 polyplexes containing Cy5-labeled DNA in the presence of these inhibitors. After
3 h, the cells were washed, fixed, stained with propidium iodide to label dead cells,
and analyzed by FACS to quantify relative cell viability and DNA internalization
efficiency (Figure 6.1). To avoid the possibility of confounding effects, we omitted
certain inhibitor treatments that at high concentrations resulted in a major
reduction in cell viability. It is interesting to note that with some of the inhibitors, at
lower concentrations of the drug and higher concentrations of the DNA polyplexes,
uptake appears to be elevated, suggesting that the cells may compensate for
incomplete suppression by promoting alternate endocytic pathways[45 -481. In many
cases, this effect was not actually statistically significant due to the large standard
deviations observed for the cells transfected in the absence of inhibitors.
The clearest trends with respect to the effect of each inhibitor on C32-122
polyplex uptake are observed at the 5 ng DNA dose (Figure 6.1c). Dose-dependent
decreases in uptake efficiency are seen for cells treated with cytochalasin D,
dynasore, chlorpromazine, and U18666A. However, a one-way analysis of variance
(ANOVA) test indicates that the only treatments that caused statistically significant
decreases in uptake are cytochalasin D (10 pM) and U18666A (100 pM).
To follow-up on this screen, we repeated the pharmacologic inhibition
experiment using each inhibitor at a concentration just below the threshold for
toxicity and performed high-throughput (HT) confocal microscopy on the treated
MEFs. We included two other inhibitors of caveolae-mediated endocytosis, genistein
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and methyl- P-cyclodextrin. To test the hypothesis that a component in serum might
interact with the PBAE polyplexes and contribute to internalization, we also
transfected cells in the absence of serum. The microscopy results were analyzed for
DNA uptake and quantified as presented in Figure 6.2.
0
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0
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Figure 6.2 C32-122-mediated DNA uptake in MEFs in the presence of various
endocytic pathway inhibitors
MEFs were transfected with C32-122 polyplexes containing Cy3-labeled DNA (red)
in the presence of various endocytic pathway inhibitors (5 pM U18666A, 50 gM
dynasore, 1 mM methyl-p-cyclodextrin, 10 gM genistein, 5 gM filipin, 5 pM
chlorpromazine, 10 pM EIPA, and 10 pM cytochalasin D). MEFs were pre-treated
with the inhibitors 1 h prior to transfection. After 3 h, the cells were washed, fixed,
treated with the nuclear stain Hoescht (blue), and analyzed by high-throughput
confocal microscopy to quantify (a) DNA uptake (mean ± SD, n = 3). Representative
images showing DNA uptake in MEFs (b) in the absence of an inhibitor and (c) in
the presence of U18666A.
In accordance with the initial screening data, we found that U18666A
significantly inhibited C32-122-mediated DNA uptake, as seen in the representative
microscopy images (Figure 6.2b-c). In contrast, treatment with dynasore yielded a
significant decrease in DNA uptake, and surprisingly, cytochalasin D treatment at
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this dose caused a significant increase in transfection. As suggested previously, it is
possible that the cells may overcome pharmacologic inhibition of one pathway by
upregulating alternate pathways through which the polyplexes enter.
The fact that none of the commonly used inhibitors of clathrin-dependent
endocytosis (chlorpromazine), caveolae -mediated endocytosis (filipin), and
macropinocytosis (EIPA) were effective suggests that PBAE polyplexes may use
multiple pathways to enter MEFs. This hypothesis is supported by the statistically
significant but inconsistent inhibition observed using cytochalasin D and dynasore,
which suppress a broad set of actin- and dynamin-dependent pathways,
respectively. Nonetheless, we observed clear and consistent inhibitory effects with
U18666A, which prompted us to perform further investigations of the dependence
of cholesterol regulation on PBAE-mediated gene delivery.
To determine if U18666A inhibits overall gene transfection by PBAEs, we
transfected MEFs with various doses of C32-122 polyplexes containing GFP-
encoding plasmid DNA in the presence of the inhibitor and assessed GFP expression
efficiency by FACS at 24 h. As was observed with DNA uptake efficiency, U18666A
significantly inhibited gene transfection at nearly all DNA doses tested (Figure 6.3).
U18666A is an amphipathic steroid with multiple actions, inhibiting both the
synthesis of cholesterol[49-s21 and its trafficking from late endosomes and lysosomes
to the plasma membrane and the endoplasmic reticulum[3-55I. As a result of the
latter action, it has also been widely studied as a means of inducing a model of
Niemann-Pick type C1 disease[56-581 and may in fact directly interact with and inhibit
the sterol sensing site of the Npcl protein[5 7,s59 ,60 .
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Figure 6.3 U18666A inhibits C32-122-mediated DNA transfection of MEFs
MEFs were pre-treated for 1 h with 5 iM U18666A prior to transfection with the
indicated doses of C32-122 polyplexes containing GFP-encoding plasmid DNA in the
presence of the inhibitor. After 24 h, GFP expression efficiency was analyzed by
FACS (mean ±SD, n = 4).
6.3.2 Studies with cell lines varying in Npcl expression
To ascertain whether the Npcl protein plays a role in inhibition of C32-122-
mediated DNA transfection, we compared gene transfection efficiencies in Npcl +/+
and Npcl-/- MEF cell lines (Figure 6.4). Fluorescence microscopy one day after
transfection with C32-122 polyplexes containing GFP-encoding plasmid DNA
showed that GFP expression was dramatically lower in Npcl-/- MEFs relative to
wild-type cells for the same DNA dose (Figure 6.4a). When FACS analysis was used
to compare the dose-response profiles of the two cell lines, we observed that the
ED50 concentration was approximately threefold greater for the Npcl KO cells than
that for the wild-type cells (Figure 6.4b). Even more strikingly, GFP expression
levels of positively transfected cells were reduced over tenfold in Npcl KO cells
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(Figure 6.4c). These data indicate that the Npcl protein plays a crucial role in gene
transfection by C32-122.
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Figure 6.4 Npcl knockout inhibits C32-122-mediated DNA transfection of
MEFs
Npcl 1+/+ and Npcl-/- MEFs were incubated for 3 h with various doses of C32-122
polyplexes containing GFP-encoding plasmid DNA, and GFP expression was
assessed by fluorescence microscopy and FACS after 24 h. (a) Representative
images showing decreased GFP expression in Npcl-/- MEFs relative to wild-type
MEFs, and FACS analysis of (b) GFP expression efficiency and (c) normalized
geometric mean fluorescent intensity (MFI) of GFP-expressing cells (mean ± SD, n =
4).
Inhibition of PBAE-mediated gene transfection in Npcl-deficient cells could
be the result of multiple factors, such as reduced cellular internalization or reduced
endosomal escape. To determine whether Npcl knockout reduces DNA uptake by
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C32-122, HT confocal microscopy was used to compare the fluorescent intensity
levels of Npcl+/+ and Npcl-/- MEFs treated with polyplexes incorporating Cy3-
labeled DNA (Figure 6.5). We observed that Npcl deficiency was associated with
significantly decreased uptake across a range of DNA doses tested.
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Figure 6.5 Npcl knockout inhibits C32-122-mediated internalization of DNA in
MEFs
Npcl+/+ and Npcl-/- MEFs were transfected with various doses of C32-122
polyplexes containing Cy3-labeled plasmid DNA (green). After 3 h, the cells were
washed, fixed, treated with the nuclear stain Hoescht (blue), and analyzed by HT
confocal microscopy. (a) Representative images showing inhibition of uptake in
Npcl-/- MEFs, and (b) quantification of DNA uptake (mean ± SD, n = 3).
Characterization of Cy5-labeled DNA internalization by FACS analysis
confirmed that Npcl knockout significantly reduced both the efficiency and the
fluorescent intensity of MEFs transfected using C32-122 (Figure 6.6a). To determine
whether Npcl deficiency also affected DNA internalization mediated by other
transfection reagents, we conducted analogous experiments with polyethylenimine
(PEI) and Lipofectamine 2000 (LF 2000). For LF 2000, Npcl knockout had no
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significant impact on labeled DNA uptake efficiency or on the fluorescent intensity
of transfected cells (Figure 6.6c). In contrast, for PEI, Npcl knockout was associated
with a reduction in fluorescent intensity of positively transfected cells but had little
effect on uptake efficiency (Figure 6.6b). Comparing the uptake efficiency results, we
hypothesize that Npcl deficiency significantly affects certain early endocytic
mechanisms by which PBAE polyplexes are internalized, but not those upon which
PEI and LF 2000 rely. Based on the overall uptake results, we further speculate that
Npcl knockout is associated with a later downstream blockage of uptake - perhaps
a defect in endosomal escape - that prohibits accumulation of DNA delivered by
PBAEs and PEI, but not by LF 2000.
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Figure 6.6 Effects of Npcl knockout on internalization of DNA in MEFs
following transfection with C32-122, PEI, and Lipofectamine 2000
Npcl+/+ and Npcl-/- MEFs were incubated with various doses Cy5-labeled plasmid
DNA (green) complexed with (a) C32-122, (b) polyethylenimine (PEI), or (c)
Lipofectamine 2000 (LF2000). After 3 h, the cells were washed, fixed, and analyzed
by FACS to determine DNA uptake efficiency (top, mean ± SD, n = 4) and normalized
geometric mean fluorescent intensity (MFI) of Cy5-positive cells (bottom, mean
SD, n = 4).
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Figure 6.7 Increasing C32-122 terpolymer hydrophobicity improves genetransfection potency 
in Npcl-/- MEFs but does not rescue inhibition
Npcl+/+ and Npcl-/- MEFs were incubated for 3 h with the indicated doses of the
C32-122 terpolymer variants complexed with GFP-encoding plasmid DNA. GFP
expression efficiency (mean ± SD, n = 4) was assessed by FACS after 24 h.
Due to the differences in behavior observed for the three materials, we
hypothesized that modifying certain chemical properties of the material might
alleviate the impact of Npcl deficiency on gene transfection. We have previously
reported that hydrophobic PBAE terpolymers incorporating alkyl side chains
demonstrate enhanced gene delivery efficacy and nanoparticle stability[61 1.
Therefore, we synthesized C32-122 terpolymers of varying hydrophobicity and
compared transfection efficacy in wild-type and Npcl knockout MEFs (Figure 6.7).
Although increasing C32-122 terpolymer hydrophobicity was associated with
improved gene delivery in both Npcl+/+ and Npcl-/- MEFs, it did not rescue the
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inhibitory effect of Npcl knockout on PBAE gene transfection efficiency. We
speculate that the enhancement in gene delivery observed as a result of increasing
polymer hydrophobicity likely owes more to a biophysical property of the polyplex
such as increased DNA binding efficiency (cf. Figure 3.10, Figure 3.11) than to
alteration of the cellular internalization mechanism.
To further elucidate the effects of Npcl, we examined C32-122/DNA uptake
and transfection in Chinese hamster ovary (CHO) epithelial cell lines varying in
Npcl expression (Figure 6.8). These cell lines included wild-type CHO cells, Npcl-
deficient CHO cells (Null), CHO cells expressing Npcl with a missense mutation in
the sterol-sensing domain (SSD) resulting in defective cholesterol trafficking 6 21
(P692S), and wild-type CHO cells stably overexpressing human Npcl[ 631 (hNpcl). As
was observed with the immortalized MEFs, Npcl deficiency in CHO cells inhibited
both DNA uptake and transfection mediated by C32-122. In the P692S CHO cells,
uptake and transfection were inhibited to a nearly identical extent as the null cells,
confirming the specific dependence on Npcl's cholesterol-trafficking function for
PBAE-mediated gene delivery. Surprisingly, we observed increased C32-122-
mediated DNA uptake and transfection in the CHO cells stably overexpressing
human Npc1 (Figure 6.8). These cells have been reported to have a 1.5-fold increase
in total cellular cholesterol and a 2.9-fold increase in cholesterol at the plasma
membrane[63]. We hypothesize that increased cholesterol localization at the plasma
membrane may enhance the activities of certain endocytic mechanisms used by
PBAE/DNA nanoparticles. These observations raise the possibility of modulating
key cellular factors to improve non-viral gene delivery.
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Figure 6.8 C32-122-mediated DNA uptake and transfection in CHO cell lines
varying in Npcl expression
CHO cells varying in Npcl expression were incubated for 3 h with the indicated
doses of (a) Cy5-labeled plasmid DNA or (b) GFP-encoding plasmid DNA complexed
with C32-122 polymer. FACS analysis was used to assess the (a) Cy5 geometric
mean fluorescent intensities (MFI) of treated cells relative to non-treated cells
immediately after washing, or (b) the GFP geometric MFI of treated cells relative to
non-treated cells after 24 h (mean ± SD, n = 4).
To examine the hypothesis that Npcl deficiency affects endocytic processes
that contribute to PBAE polyplex entry, we assessed the relative uptake of various
known markers of endocytic pathways in Npcl+/+ and Npcl-/- MEFs. These
markers included fluorescently labeled transferrin, cholera toxin B, and 10,000 MW
dextran, which are thought to undergo internalization via clathrin-dependent
endocytosis, caveolin-mediated endocytosis, and macropinocytosis, respectively.
After a 3 h incubation with the cell lines and multiple washes, we observed
dramatically reduced uptake of cholera toxin B in the Npcl-deficient cells (Figure
6.9). Furthermore, transferrin uptake appeared to be slightly decreased and dextran
uptake slightly increased.
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Figure 6.9 Confocal microscopy analysis of relative endocytic pathway
activities in Npcl+/+ and Npcl-/- MEFs
MEFs were incubated for 3 h with media containing various AF647-labeled (red)
markers: 50 pig/ml transferrin (left), 55 ng/ml cholera toxin B (middle), or 100
jig/ml 10,000 MW dextran (right), traditional markers of clathrin-dependent,
endocytosis, caveolae-mediated endocytosis, and macropinocytosis, respectively.
After 3 h, the cells were washed, fixed, treated with the nuclear stain Hoescht (blue),
and analyzed by HT confocal microscopy.
Quantification of these microscopy results by FACS analysis corroborated
these trends (Figure 6.10). Comparing Npc1-deficient cells to wild-type cells,
cholera toxin B internalization was reduced -20-30-fold; transferrin uptake was
reduced about twofold; and dextran uptake was increased by -50%. These results
demonstrate in a quantitative manner that Npcl knockout in MEFs significantly
alters normal activities of various endocytic pathways, implying significantly
decreased caveolae-mediated endocytosis, slightly reduced clathrin-mediated
endocytosis, and slightly upregulated macropinocytosis. However, it should be
noted that cholera toxin B is not necessarily a selective marker of caveolae-mediated
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endocytosis as some studies have reported its entry through alternative pathways
depending on the cell type[6 4 .
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Figure 6.10 FACS analysis of relative endocytic pathway activities in Npc 1+/+
and Npc1-/- M EF s
MEFs were incubated for 3 h with media containing various doses of AF647-labeled
(a) transferrin, (b) cholera toxin B, or (c) dexran. After 3 h, the cells were washed,
fixed, and analyzed for AF647 signal by FACS.
To determine whether PBAE polyplexes share common uptake pathways
with these markers during endocytosis, we incubated the C32-122 polyplexes
containing labeled DNA in the presence of each one of these markers and used
confocal microscopy to characterize the extent of co-localization in wild-type MEFs
at various time points (Figure 6.11). Confirming our hypothesis that PBAEs utilize
multiple endocytic pathways, we observed evidence of DNA co-localization with all
three markers. However, the greatest extent of co-localization occurred with cholera
toxin B. Moreover, the kinetics of PBAE/DNA uptake indicated on an intermediate
time scale corresponding more closely to that of cholera toxin B uptake than to
either the fast or slow kinetics of transferrin or dextran uptake, respectively (data
not shown). These results suggests that PBAE polyplexes and cholera toxin B may
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rely on common uptake pathways for internalization and retention in MEFs that are
dramatically altered in cells lacking Npcl.
(a) Transferrin (b) Cholera Toxin B (C) Dextran
Figure 6.11 Co-localization of internalized DNA delivered by C32-122 with
markers of distinct endocytic pathways in MEFs
Npcl 1+/+ MEFs were transfected with C32-122 polyplexes containing Cy3-labeled
DNA in the presence of AF647-labeled (a) 50 ig/ml transferrin, (b) 55 ng/ml
cholera toxin B, or (c) 100 ug/mi 10,000 MW dextran. After 3 h, the cells were
washed, fixed, treated with the nuclear stain Hoescht (blue), and analyzed by high-
throughput confocal microscopy for intracellular co-localization of DNA (green)
with each marker (red).
Taken together, these data imply that Npcl regulates certain uptake and
trafficking pathways that markedly affect internalization and retention of
PBAE/DNA polyplexes. Because Npcl plays a key role in regulating the trafficking of
cholesterol, and because cholesterol has been shown to be critically involved in both
caveolin- and clathrin-mediated endocytosis[ 65-6 91, it is quite plausible that Npcl
knockout would affect these processes. To our knowledge, although Npcl knockout
has been associated with altered intracellular localization of cholera toxin B and
lactosylceramide (LacCer),[ 59,701 two markers of caveolin-mediated endocytosis, and
with defective recycling of transferrin receptor[711, quantitative analysis of uptake
for multiple endocytic markers has not yet been reported. Despite previous reports
that fluid-phase uptake of horseradish peroxidase is impaired in Npcl knockout
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cells[7 2 , 7 31, possibly due to abnormal localization of annexin II, our results suggest
that macropinocytic internalization of dextran is slightly increased in Npcl-deficient
cells.
At present, the precise molecular mechanisms by which Npcl affects
endocytic processes is unknown. One group has recently reported that perturbation
of cholesterol content by U18666A can induce mislocalization of caveolin-1 from the
plasma membrane to late endosomes and lysosomes 6 5l. However, the authors did
not test whether this mislocalization also occurs in Npcl knockout cells. Another
study suggested that Npcl deficiency is associated with deregulation of lysosomal
calcium that is in turn responsible for sphingolipid accumulation as well as defects
in endosomal trafficking[74 . Further studies are needed to determine whether Npcl
plays a more direct role in regulation of early endocytic pathways. Such studies
would help to elucidate both the biology of endolysosomal trafficking and the
pathology of glycosphingolipid storage diseases.
Finally, the novel investigation of non-viral DNA transfection of Npcl-
deficient cells reported here demonstrates the importance of proper regulation of
cholesterol trafficking for certain delivery reagents such as poly(p-amino ester)s.
Future studies should evaluate whether Npcl plays a similar role in cell types other
than MEF and CHO cells, particularly human fibroblast and epithelial cells. In this
study, one of the most striking observations was that stable overexpression of Npcl
significantly improved DNA internalization and transfection by PBAEs. These
findings raise the tantalizing prospect of enhancing non-viral gene delivery through
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active modulation of cellular factors known to play key roles in internalization, such
as lysobisphosphatidic acid (LBPA), Rab5, and perhaps Npcl.
6.4 CONCLUSIONS
In this chapter, the uptake of PBAE/DNA nanoparticles was investigated
through pharmacological inhibition and marker co-localization studies. Our results
indicated that internalization of PBAE/DNA polyplexes in immortalized mouse
embryonic fibroblast (MEF) cells likely proceeds through multiple pathways, with
an apparent dependence on normal cholesterol trafficking. We showed that MEFs
deficient in a lysosomal cholesterol transport protein, Npcl, exhibit significantly
reduced PBAE gene transfection efficacy. Moreover, Npcl knockout in MEFs greatly
inhibited PBAE-mediated DNA internalization, with a slight decrease in DNA uptake
mediated by PEI and no apparent effect on DNA uptake mediated by LF 2000.
Strikingly, stable overexpression of human Npcl in Chinese hamster ovary (CHO)
cells was associated with enhanced gene uptake and transfection by PBAEs. We
observed that retention of various endocytic markers was altered in Npcl-deficient
MEFs, with significant reduction in uptake of cholera toxin B, a marker traditionally
associated with caveolae-mediated endocytosis. DNA internalized by PBAEs showed
the greatest extent of co-localization with the cholera toxin B marker, suggesting the
involvement of shared uptake pathways that are altered in cells lacking Npcl. These
studies provide additional support for the idea that Npcl plays a critical role in the
regulation of endocytic mechanisms affecting internalization and efficacy of
nanoparticles.
181
6.5 REFERENCES
[1] Kay, M. A. State-of-the-art gene-based therapies: the road ahead. Nat. Rev.
Genet. 12, 316 (2011).
[2] Giacca, M., Zacchigna, S. Virus-mediated gene delivery for human gene
therapy. J Con trol Release 161, 377 (2012).
[3] Mintzer, M. A., Simanek, E. E. Nonviral vectors for gene delivery. Chem. Rev.
109, 259 (2009).
[4] Edelstein, M. in J Gene Med, Vol. 2011 (Wiley, 2011).
[5] Guo, X., Huang, L. Recent advances in nonviral vectors for gene delivery. Acc
Chem Res 45, 971 (2012).
[6] Sahay, G., Alakhova, D. Y., Kabanov, A. V. Endocytosis of nanomedicines.J
Control Release 145, 182 (2010).
[7] Doherty, G. J., McMahon, H. T. Mechanisms of endocytosis. Annu Rev Biochem
78, 857 (2009).
[8] Vasir, J. K., Labhasetwar, V. Quantification of the force of nanoparticle-cell
membrane interactions and its influence on intracellular trafficking of
nanoparticles. Biomaterials 29, 4244 (2008).
[9] Panyam, J., Labhasetwar, V. Dynamics of endocytosis and exocytosis of
poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm
Res 20, 212 (2003).
[10] Qaddoumi, M. G., Ueda, H., Yang, J., Davda, J., Labhasetwar, V., Lee, V. H. The
characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit
conjunctival epithelial cell layers. Pharm Res 21, 641 (2004).
[11] Sahay, G., Kim, J. 0., Kabanov, A. V., Bronich, T. K. The exploitation of
differential endocytic pathways in normal and tumor cells in the selective targeting
of nanoparticulate chemotherapeutic agents. Biomaterials 31, 923 (2010).
[12] Miele, E., Spinelli, G. P., Tomao, F., Tomao, S. Albumin-bound formulation of
paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Intl Nanomedicine
4, 99 (2009).
[13] Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J.
R., Qin, J., Cantley, W., Qin, L. L., Racie, T., Frank-Kamenetsky, M., Yip, K. N., Alvarez,
R., Sah, D. W., de Fougerolles, A., Fitzgerald, K., Koteliansky, V., Akinc, A., Langer, R.,
Anderson, D. G. Lipid-like materials for low-dose, in vivo gene silencing. Proceedings
of the National Academy of Sciences 107, 1864 (2010).
[14] Rejman, J., Bragonzi, A., Conese, M. Role of clathrin- and caveolae-mediated
endocytosis in gene transfer mediated by lipo- and polyplexes. Mol Ther 12,468
(2005).
[15] Luhmann, T., Rimann, M., Bittermann, A. G., Hall, H. Cellular uptake and
intracellular pathways of PLL-g-PEG-DNA nanoparticles. Bioconjug Chem 19, 1907
(2008).
182
[16] van der Aa, M. A., Huth, U. S., Hafele, S. Y., Schubert, R., Oosting, R. S.,
Mastrobattista, E., Hennink, W. E., Peschka-Suss, R., Koning, G. A., Crommelin, D. J.
Cellular uptake of cationic polymer-DNA complexes via caveolae plays a pivotal role
in gene transfection in COS-7 cells. Pharm Res 24, 1590 (2007).
[17] von Gersdorff, K., Sanders, N. N., Vandenbroucke, R., De Smedt, S. C., Wagner,
E., Ogris, M. The internalization route resulting in successful gene expression
depends on both cell line and polyethylenimine polyplex type. Mol Ther 14, 745
(2006).
[18] Wong, A. W., Scales, S. J., Reilly, D. E. DNA internalized via caveolae requires
microtubule-dependent, Rab7-independent transport to the late endocytic pathway
for delivery to the nucleus.J Biol Chem 282, 22953 (2007).
[19] Grosse, S., Aron, Y., Thevenot, G., Frangois, D., Monsigny, M., Fajac, 1.
Potocytosis and cellular exit of complexes as cellular pathways for gene delivery by
polycations. The Journal of Gene Medicine 7, 1275 (2005).
[20] Rejman, J., Conese, M., Hoekstra, D. Gene transfer by means of lipo- and
polyplexes: role of clathrin and caveolae-mediated endocytosis.J Liposome Res 16,
237 (2006).
[21] Khalil, I. A., Kogure, K., Futaki, S., Harashima, H. High density of octaarginine
stimulates macropinocytosis leading to efficient intracellular trafficking for gene
expression.J Biol Chem 281, 3544 (2006).
[22] Anderson, D. G., Peng, W., Akinc, A., Hossain, N., Kohn, A., Padera, R., Langer,
R., Sawicki, J. A. A polymer library approach to suicide gene therapy for cancer. Proc.
Nati. Acad. Sci. USA 101, 16028 (2004).
[23] Peng, W., Anderson, D. G., Bao, Y., Padera, R. F., Jr., Langer, R., Sawicki, J. A.
Nanoparticulate delivery of suicide DNA to murine prostate and prostate tumors.
Prostate 67, 855 (2007).
[24] Huang, Y. H., Zugates, G. T., Peng, W., Holtz, D., Dunton, C., Green, J. J., Hossain,
N., Chernick, M. R., Padera, R. F., Jr., Langer, R., Anderson, D. G., Sawicki, J. A.
Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor
burden in mice. Cancer Res 69, 6184 (2009).
[25] Yang, F., Cho, S. W., Son, S. M., Bogatyrev, S. R., Singh, D., Green, J., Mei, Y.,
Park, S., Bhang, S. H., Kim, B. S., Langer, R., Anderson, D. Genetic engineering of
human stem cells for enhanced angiogenesis using biodegradable polymeric
nanoparticles. Proc. Nati. Acad. Sci. USA 107, 3317 (2010).
[26] Green, J., Shi, J., Chiu, E., Leshchiner, E., Langer, R., Anderson, D.
Biodegradable Polymeric Vectors for Gene Delivery to Human Endothelial Cells.
Bioconjugate Chem. 17, 1162 (2006).
[27] Green, J., Zhou, B., Mitalipova, M., Beard, C., Langer, R., Jaenisch, R., Anderson,
D. Nanoparticles for Gene Transfer to Human Embryonic Stem Cell Colonies. Nano
Lett. 8, 3126 (2008).
[28] Yang, F., Green, J. J., Dinio, T., Keung, L., Cho, S. W., Park, H., Langer, R.,
Anderson, D. G. Gene delivery to human adult and embryonic cell-derived stem cells
using biodegradable nanoparticulate polymeric vectors. Gene Ther 16, 533 (2009).
[29] Lynn, D. M., Langer, R. Degradable Poly ([beta]-amino esters): Synthesis,
Characterization, and Self-Assembly with Plasmid DNA.J. Am. Chem. Soc 122, 10761
(2000).
183
[30] Lynn, D., Anderson, D., Putnam, D., Langer, R. Accelerated Discovery of
Synthetic Transfection Vectors: Parallel Synthesis and Screening of a Degradable
Polymer Library. J. Am. Chem. Soc. 123, 8155 (2001).
[31] Akinc, A., Lynn, D., Anderson, D., Langer, R. Parallel Synthesis and Biophysical
Characterization of a Degradable Polymer Library for Gene Delivery. j. Am. Chem.
Soc. 125, 5316 (2003).
[32] Anderson, D. G., Lynn, D. M., Langer, R. Semi-Automated Synthesis and
Screening of a Large Library of Degradable Cationic Polymers for Gene Delivery.
Angew. Chem. Int. Ed. 42, 3153 (2003).
[33] Akinc, A., Anderson, D. G., Lynn, D. M., Langer, R. Synthesis of Poly(-amino
ester)s Optimized for Highly Effective Gene Delivery. Bioconjugate Chem. 14, 979
(2003).
[34] Anderson, D., Akinc, A., Hossain, N., Langer, R. Structure/property studies of
polymeric gene delivery using a library of poly(beta-amino esters). Mol Ther 11, 426
(2005).
[35] Eltoukhy, A. A., Siegwart, D. J., Alabi, C. A., Rajan, J. S., Langer, R., Anderson, D.
G. Effect of molecular weight of amine end-modified poly(beta-amino ester)s on
gene delivery efficiency and toxicity. Biomaterials 33, 3594 (2012).
[36] Eltoukhy, A. A., Chen, D., Alabi, C. A., Langer, R., Anderson, D. G. Degradable
terpolymers with alkyl side chains demonstrate enhanced gene delivery potency
and nanoparticle stability. Adv Mater 25, 1487 (2013).
[37] Green, J. J., Zugates, G. T., Tedford, N. C., Huang, Y., Griffith, L. G.,
Lauffenburger, D. A., Sawicki, J. A., Langer, R., Anderson, D. G. Combinatorial
modification of degradable polymers enables transfection of human cells
comparable to adenovirus. Adv. Mater. 19, 2836 (2007).
[38] Zugates, G. T., Peng, W., Zumbuehl, A., Jhunjhunwala, S., Huang, Y. H., Langer,
R., Sawicki, J. A., Anderson, D. G. Rapid optimization of gene delivery by parallel end-
modification of poly(beta-amino ester)s. Mo. Ther. 15, 1306 (2007).
[39] Zugates, G., Tedford, N., Zumbuehl, A., Jhunjhunwala, S., Kang, C., Griffith, L.,
Lauffenburger, D., Langer, R., Anderson, D. Gene Delivery Properties of End-Modified
Poly(p-amino ester)s. Bioconjugate Chem. 18, 1887 (2007).
[40] Sunshine, J., Green, J. J., Mahon, K. P., Yang, F., Eltoukhy, A. A., Nguyen, D. N.,
Langer, R., Anderson, D. G. Small-Molecule End-Groups of Linear Polymer Determine
Cell-type Gene-Delivery Efficacy. Adv. Mater. 21, 4947 (2009).
[41] Scott, C., Ioannou, Y. A. The NPC1 protein: structure implies function. Biochim
BiophysActa 1685, 8 (2004).
[42] Cote, M., Misasi, J., Ren, T., Bruchez, A., Lee, K., Filone, C. M., Hensley, L., Li, Q.,
Ory, D., Chandran, K., Cunningham, J. Small molecule inhibitors reveal Niemann-Pick
C1 is essential for Ebola virus infection. Nature 477, 344 (2011).
[43] Carette, J. E., Raaben, M., Wong, A. C., Herbert, A. S., Obernosterer, G.,
Mulherkar, N., Kuehne, A. I., Kranzusch, P. J., Griffin, A. M., Ruthel, G., Dal Cin, P., Dye,
J. M., Whelan, S. P., Chandran, K., Brummelkamp, T. R. Ebola virus entry requires the
cholesterol transporter Niemann-Pick C1. Nature 477, 340 (2011).
[44] Miller, E. H., Obernosterer, G., Raaben, M., Herbert, A. S., Deffieu, M. S.,
Krishnan, A., Ndungo, E., Sandesara, R. G., Carette, J. E., Kuehne, A. I., Ruthel, G.,
Pfeffer, S. R., Dye, J. M., Whelan, S. P., Brummelkamp, T. R., Chandran, K. Ebola virus
184
entry requires the host-programmed recognition of an intracellular receptor. EMBO
j 31, 1947 (2012).
[45] Hussain, K. M., Leong, K. L., Ng, M. M., Chu, J. j. The essential role of clathrin-
mediated endocytosis in the infectious entry of human enterovirus 71.J Biol Chem
286, 309 (2011).
[46] Hufnagel, H., Hakim, P., Lima, A., Hollfelder, F. Fluid phase endocytosis
contributes to transfection of DNA by PEI-25. Mol Ther 17, 1411 (2009).
[47] Duchardt, F., Fotin-Mleczek, M., Schwarz, H., Fischer, R., Brock, R. A
comprehensive model for the cellular uptake of cationic cell-penetrating peptides.
Traffic 8, 848 (2007).
[48] Damke, H., Baba, T., van der Bliek, A. M., Schmid, S. L. Clathrin-independent
pinocytosis is induced in cells overexpressing a temperature-sensitive mutant of
dynamin.J Cell Biol 131,69 (1995).
[49] Phillips, W. A., Avigan, J. Inhibition of cholesterol biosynthesis in the rat by 3
beta-(2-diethylaminoethoxy) androst5-en-17-one hydrochloride. Proc Soc Exp Biol
Med 112, 233 (1963).
[50] Cenedella, R. J. Concentration-dependent effects of AY-9944 and U18666A on
sterol synthesis in brain. Variable sensitivities of metabolic steps. Biochem
Pharmacol 29, 2751 (1980).
[51] Sexton, R. C., Panini, S. R., Azran, F., Rudney, H. Effects of 3 beta- [2-
(diethylamino)ethoxy]androst-5-en-17-one on the synthesis of cholesterol and
ubiquinone in rat intestinal epithelial cell cultures. Biochemistry 22, 5687 (1983).
[52] Panini, S. R., Sexton, R. C., Rudney, H. Regulation of 3-hydroxy-3-
methylglutaryl coenzyme A reductase by oxysterol by-products of cholesterol
biosynthesis. Possible mediators of low density lipoprotein action.J Biol Chem 259,
7767 (1984).
[53] Liscum, L., Faust, J. R. The intracellular transport of low density lipoprotein-
derived cholesterol is inhibited in Chinese hamster ovary cells cultured with 3-beta-
[2-(diethylamino) ethoxy]androst-5-en-17-one. j Biol Chem 264, 11796 (1989).
[54] Liscum, L. Pharmacological inhibition of the intracellular transport of low-
density lipoprotein-derived cholesterol in Chinese hamster ovary cells. Biochim
Biophys Acta 1045, 40 (1990).
[55] Liscum, L., Collins, G. J. Characterization of Chinese hamster ovary cells that
are resistant to 3-beta- [2-(diethylamino) ethoxy]androst-5-en-17-one inhibition of
low density lipoprotein-derived cholesterol metabolism. J Biol Chem 266, 16599
(1991).
[56] Liscum, L., Klansek, J. J. Niemann-Pick disease type C. Curr Opin Lipidol 9, 131
(1998).
[57] Lange, Y., Ye, J., Rigney, M., Steck, T. Cholesterol movement in Niemann-Pick
type C cells and in cells treated with amphiphiles.J Biol Chem 275, 17468 (2000).
[58] Ko, D. C., Gordon, M. D., Jin, J. Y., Scott, M. P. Dynamic movements of
organelles containing Niemann-Pick C1 protein: NPC1 involvement in late endocytic
events. Mol Biol Cell 12, 601 (2001).
[59] Sugimoto, Y., Ninomiya, H., Ohsaki, Y., Higaki, K., Davies, J. P., Ioannou, Y. A.,
Ohno, K. Accumulation of cholera toxin and GM1 ganglioside in the early endosome
of Niemann-Pick Cl-deficient cells. Proc NatlAcad Sci USA 98, 12391 (2001).
185
[60] Liu, R., Lu, P., Chu, J. W., Sharom, F. J. Characterization of fluorescent sterol
binding to purified human NPC1.J Biol Chem 284, 1840 (2009).
[61] Eltoukhy, A. A., Chen, D., Alabi, C. A., Langer, R., Anderson, D. G. Degradable
terpolymers with alkyl side chains demonstrate enhanced gene delivery potency
and nanoparticle stability. Adv. Mater., Forthcoming (2013).
[62] Millard, E. E., Gale, S. E., Dudley, N., Zhang, I., Schaffer, J. E., Ory, D. S. The
sterol-sensing domain of the Niemann-Pick C1 (NPC1) protein regulates trafficking
of low density lipoprotein cholesterol. Journal of Biological Chemistry 280, 28581
(2005).
[63] Millard, E. E., Srivastava, K., Traub, L. M., Schaffer, J. E., Ory, D. S. Niemann-
pick type C1 (NPC1) overexpression alters cellular cholesterol homeostasis. Journal
of Biological Chemistry 275, 38445 (2000).
[64] Wernick, N. L. B., Chinnapen, D. J. F., Cho, J. A., Lencer, W. I. Cholera Toxin: An
Intracellular Journey into the Cytosol by Way of the Endoplasmic Reticulum. Toxins
2, 310 (2010).
[65] Mundy, D. I., Li, W. P., Luby-Phelps, K., Anderson, R. G. Caveolin targeting to
late endosome/lysosomal membranes is induced by perturbations of lysosomal pH
and cholesterol content. Mol Biol Cell 23, 864 (2012).
[66] Subtil, A., Gaidarov, I., Kobylarz, K., Lampson, M. A., Keen, J. H., McGraw, T. E.
Acute cholesterol depletion inhibits clathrin-coated pit budding. Proc NatlAcad Sci U
SA 96,6775 (1999).
[67] Rodal, S. K., Skretting, G., Garred, 0., Vilhardt, F., van Deurs, B., Sandvig, K.
Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation of
clathrin-coated endocytic vesicles. Mol Biol Cell 10, 961 (1999).
[68] Cheng, Z. J., Singh, R. D., Sharma, D. K., Holicky, E. L., Hanada, K., Marks, D. L.,
Pagano, R. E. Distinct mechanisms of clathrin-independent endocytosis have unique
sphingolipid requirements. Mol Biol Cell 17, 3197 (2006).
[69] Hooper, N. M. Detergent-insoluble glycosphingolipid/cholesterol-rich
membrane domains, lipid rafts and caveolae (review). Mol Membr Biol 16, 145
(1999).
[70] Sun, X., Marks, D. L., Park, W. D., Wheatley, C. L., Puri, V., O'Brien, J. F., Kraft, D.
L., Lundquist, P. A., Patterson, M. C., Pagano, R. E., Snow, K. Niemann-Pick C variant
detection by altered sphingolipid trafficking and correlation with mutations within a
specific domain of NPC1. Am J Hum Genet 68, 1361 (2001).
[71] Pipalia, N. H., Hao, M., Mukherjee, S., Maxfield, F. R. Sterol, protein and lipid
trafficking in Chinese hamster ovary cells with Niemann-Pick type C1 defect. Traffic
8, 130 (2007).
[72] Mayran, N., Parton, R. G., Gruenberg, J. Annexin II regulates multivesicular
endosome biogenesis in the degradation pathway of animal cells. EMBOJ 22, 3242
(2003).
[73] te Vruchte, D., Lloyd-Evans, E., Veldman, R. J., Neville, D. C., Dwek, R. A., Platt,
F. M., van Blitterswijk, W. J., Sillence, D. J. Accumulation of glycosphingolipids in
Niemann-Pick C disease disrupts endosomal transport.J Biol Chem 279, 26167
(2004).
[74] Lloyd-Evans, E., Morgan, A. J., He, X., Smith, D. A., Elliot-Smith, E., Sillence, D. J.,
Churchill, G. C., Schuchman, E. H., Galione, A., Platt, F. M. Niemann-Pick disease type
186
C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium.
Nat Med 14, 1247 (2008).
187
7 NUCLEIC ACID CONJUGATION ENABLES EFFICIENT
INTRACELLULAR PROTEIN DELIVERY BY LIPID-
BASED NANOPARTICLES
7.1 INTRODUCTION
Since the approval of recombinant human insulin for diabetes treatment
nearly three decades ago, protein therapeutics now comprise a major class of
pharmaceuticals with a range of functions and applications, including enzyme
replacement, monoclonal antibodies, hormones, and protein-based vaccines[1].
However, most protein therapeutics act extracellularly or at the cell surface, or if
endocytosed, carry out their function within lysosomes. Effective intracellular
protein delivery remains an enormous technical challenge[ 2, 31, yet offers the
potential to broaden the scope of diseases amenable to this class of drugs and
circumvent the inherent risks of gene therapeutics[4].
Cell-penetrating peptides[5l represent one widely studied approach to
achieving intracellular delivery through covalent or non-covalent attachment of
protein transduction domains, which include TAT-derived peptides[ 6-8l, arginine-
rich peptides[9' 101, Antennapedia-derived penetratin peptides[111, and amphiphilic
peptide carriers such as Pep-1[121.A related approach involves fusion of a protein
known or engineered to achieve intracellular localization, such as herpes simplex
virus protein VP22[13, 141 or more recently, a supercharged variant of GFP[151.
Limitations with these methods include the lack of protection from proteases and
the absence of an active mechanism to achieve endosomal escape[16, 171.
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A number of materials have been described for encapsulation and
intracellular delivery of proteins, including lipids and liposomes[18'191, charge-
conversional polyionic micelles[201, cationic amphiphiles[ 211, and various polymers[22.
241. Nonetheless, because protein loading depends on the strength of non-covalent
interactions between the protein cargo and the material, these techniques may be
useful only for a subset of proteins with suitable physicochemical properties. A
more promising approach involves synthesis of a biodegradable polymeric shell
directly from the protein itself, so that the protein core is encapsulated within a
nanocarrier that facilitates intracellular delivery[25 . In general, most of these
materials have not yet achieved clinical or even preclinical demonstration of their
safety and efficacy for systemic delivery.
By comparison, a much wider array of materials has been developed for non-
viral delivery of nucleic acids[261. In particular, a group of lipid-like molecules
termed lipidoids has demonstrated safe, effective, and potent delivery of RNAi
therapeutics in preclinical studies involving mice, rats, and nonhuman primates[27 ,
281. We hypothesized that these lipid-based nanoparticle (LNP) formulations might
also mediate effective protein encapsulation and intracellular delivery if the protein
cargo were conjugated to one or more oligonucleotides (Figure 7.1). To our
knowledge, this simple idea has not yet been tested with other delivery reagents.
189
oligonucleotide cationic lipid
protein~+ ~
Figure 7.1 Scheme for delivery of proteins by lipid-based nanoparticles via
oligonucleotide conjugation
In this chapter, we develop LNP formulations for intracellular delivery of
protein-oligonucleotide conjugates. Working with horseradish peroxidase (HRP) as
a model protein, we show that one particular lipidoid, C14-113, mediates effective
intracellular delivery of HRP-oligonucleotide conjugates to HeLa cells, that the
enzyme retains activity after delivery, and that delivery depends on HRP-
oligonucleotide conjugation. Similarly, with NeutrAvidin, a variant of avidin, we
show that oligonucleotide conjugation significantly improves intracellular protein
delivery by C14-113 in HeLa cells, likely owing to a threefold enhancement in
NeutrAvidin loading. When we formulated C14-113 LNPs with either free
NeutrAvidin or with NeutrAvidin-oligonucleotide conjugates and injected them
intravenously in mice, we observed that oligonucleotide conjugation significantly
enhanced intracellular protein uptake in macrophages and dendritic cells within the
spleen, suggesting delivery of protein-based vaccines as a potential application of
this approach.
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7.2 MATERIALS AND METHODS
7.2.1 Materials
Lipidoids were synthesized as previously described[271. Horseradish
peroxidase (type VI, 250-330 units/mg), copper (11) sulfate, tris(2-
carboxyethyl)phosphine hydrochloride (TCEP), tris[(1-benzyl-1H-1,2,3-triazol-4-
yl)methyl]amine (TBTA), cholesterol, and 0-phenylenediamine were purchased
from Sigma-Aldrich (St. Louis, MO, USA). Unlabeled NeutrAvidin, Oregon Green 488-
labeled NeutrAvidin, and AlexaFluor 488 carboxylic acid, succinimidyl ester, were
purchased from Invitrogen (Carlsbad, CA, USA). Cy5.5 mono-reactive NHS ester was
acquired from GE Healthcare (Pittsburgh, PA, USA). Three oligonucleotide variants
(unmodified, 5'-hexynyl, and 5'-biotin-PEG4-modified) with the following sequence
were custom synthesized and desalted by Integrated DNA Technologies (Coralville,
IA, USA): 5'-CGGGCGCGACTAGTGTGAAATCTGAATAATTTTGTGTTACTC-3'. NHS-
PEG 4-Azide crosslinker, Slide-A-Lyzer G2 dialysis cassettes (20K MWCO), and Zeba
Spin desalting columns (40K MWCO) were acquired from Pierce Biotechnology
(Rockford, IL). mPEG2000-DMG was synthesized by Alnylam (Cambridge, MA, USA)
as described[2 81. 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) were obtained from Avanti
Polar Lipids (Alabaster, AL, USA). HeLa cells (ATCC, Manassas, VA, USA) were
cultured in DMEM (Invitrogen) supplemented with 10% fetal bovine serum
(Invitrogen).
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7.2.2 Protein-oligon ucleotide conjugation
For DNA oligonucleotide conjugation to horseradish peroxidase (HRP), HRP
was first azide-functionalized using NHS-PEG 4-Azide crosslinker according to the
manufacturer's directions. Briefly, NHS-PEG 4-Azide (2.27 mM, MW = 388.37 Da) in
anhydrous DMSO was added to HRP (0.176 mM, MW = 44 kDa) in a total volume of
2.425 mL PBS (20 mM sodium phosphate, 0.15 M sodium chloride, pH 7.2) and then
incubated for 30 min at RT. To quench the reaction, 1 M Tris-HCl (pH 8.0) was
added to achieve a final Tris-HCl concentration of 0.1 M. The reaction was incubated
for an additional 5 min at RT and then dialyzed against 3 L PBS overnight at 4C
using a Slide-A-Lyzer G2 cassette (20 K MWCO) with two buffer exchanges. Azide-
functionalized HRP (72.5 iM) was then incubated with 5'-alkyne-modified
oligonucleotide (109 ptM, MW = 13.14 kDa), CuSO4 (1 mM), TCEP (4 mM), and TBTA
(100 [M) in a final volume of 3.9 mL for 5 h at RT, with minor modification from a
previous report[29 . The reaction was then purified by dialysis against 3 L PBS
overnight at 4"C using a Slide-A-Lyzer G2 cassette (20 K MWCO) with two buffer
exchanges. The HRP-oligo conjugate concentration was determined in two ways
with roughly equivalent results: absorbance measurement at 403 nm (EHRP, 403 nm
102 mM-1 cm-1) using a NanoDrop 1000 spectrophotometer (Thermo Scientific,
Waltham, MA, USA), and a BCA Protein assay (Thermo Scientific).
For oligo conjugation to NeutrAvidin (nAv), 5'-biotin-PEG4-functionalized
oligo (37.2 pM, MW = 13.46 kDa) was incubated with fluorescently labeled nAv
(18.6 pM, MW = 60 kDa) in a final volume of 0.75 ml PBS for 1 h at RT and used
without purification. nAv was pre-labeled with either Cy5.5 mono-reactive NHS
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ester (GE Healthcare) or AF 488 carboxylic acid, succinimidyl ester, (Invitrogen)
using the manufacturers' instructions and was purified prior to conjugation using a
Zeba Spin desalting column (40 K MWCO) equilibrated with PBS. For both labeling
reactions, the final fluorophore:protein labeling molar ratio was approximately 1:1
as determined with a spectrophotometer. The conjugate concentration was
determined by using the absorbance measurement at 280 nm (EnAv, 280 nm= 99.6 mM
1 cm-1).
7.23 Microfluidic device formulation of lipid nanoparticles (LNPs)
Stock solutions of lipidoid, cholesterol (MW = 387 Da), DSPC (MW = 790 Da),
and mPEG2000-DMG (MW = 2660 Da) were prepared in ethanol at concentrations
of 100, 20, 20, and 20 mg/mL, respectively. In most experiments, the components
were combined to yield molar fractions of 50:38.5:10:1.5; however, in one
experiment, DSPC was substituted with DOPE (MW =744 Da) at the same molar
fraction.
The HRP-DNA conjugate, or the free HRP control, was diluted in 10 mM
citrate buffer (pH 3.0) at a concentration of 0.5 mg/mL DNA, corresponding to an
HRP concentration of 1.13 mg/mL. Due to differences in stabilities between the free
nAv protein and the nAv-DNA conjugate, the nAv-DNA conjugate was diluted in 25
mM citrate buffer (pH 5.2) at a concentration of 0.375 mg/mL DNA (equivalent
protein concentration of 0.845 mg/mL), while the free nAv was diluted to 0.845
mg/mL in 10 mM citrate buffer (pH 3.0). The lipid solution was diluted as necessary
to yield a lipidoid:DNA weight ratio of 10:1.
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Microfluidic devices were synthesized as described previously[13 0 . To prepare
LNPs, the protein solution and the lipid solution were injected into the microfluidic
device at a relative volumetric flow rate of 3:1 (0.9 mL/min: 0.3 mL/min) using two
syringes (Gastight syringes, Hamilton Company, NV, USA) that were controlled by
two syringe pumps (PHD 2000, Harvard Apparatus, MA, USA). To remove ethanol,
the freshly prepared LNPs were dialyzed for 2 h against 3 L PBS using Slide-A-Lyzer
G2 cassettes (20K MWCO).
72.4 In vitro protein transfection
One day before transfection, HeLa cells (100 pL) were seeded in a clear 96-
well tissue culture plate at 15,000 cells per well. LNPs and naked protein/conjugate
control treatments were diluted in freshly warmed growth medium as necessary to
achieve the desired protein dose (generally 100 ng - 1 pg per 150 pL per well). The
conditioned medium was aspirated just before transfection and replaced with the
LNPs/proteins diluted in fresh medium. The nanoparticles were incubated with the
cells for 3 h at 37*C.
7.2.5 HRP activity assay
After incubation with the nanoparticles, the cells were washed 3 times with
PBS (200 pL) and treated with 0.25% w/v trypsin-EDTA (25 pL) for 5 min at 37*C to
detach cells as well as to digest any remaining membrane-bound HRP. Upon
addition of growth medium (50 pL), the cells were pipet-mixed, transferred to a
clear 96-well assay plate, pelleted using a centrifuge, re-suspended in 100 pL of
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substrate solution, and repeatedly pipet-mixed. Substrate solution was prepared by
dissolving a 15 mg tablet of o-phenylenediamine in 12.5 mL 100 mM sodium citrate,
pH 4.5, and adding 3.5 ptL of hydrogen peroxide solution (30% w/v) immediately
before use. The assay plate was incubated for 10 min at RT with orbital shaking
prior to addition of 50 jiL 2.5 M H2SO4 . The absorbance at 490 nm was then
immediately measured using a SpectraMax 190 microplate reader (Molecular
Devices, Sunnyvale, CA, USA). The activity assay was performed in an analogous
manner on a series of dilutions of the free HRP protein and the conjugate to
generate a standard curve for each.
7.2.6 FACS analysis
After aspirating conditioned medium and washing cells three times with PBS,
cells were detached using 2 5 l per well of 0.25% trypsin-EDTA (Invitrogen).
Following a 5 min incubation at 37"C, fresh medium (50 pil) was added to the cells,
which were mixed thoroughly and then transferred to a 96-well round-bottom
plate. Cells were then pelleted, re-suspended in fixation buffer (4% v/v
formaldehyde in PBS), incubated for 10 min at RT, pelleted again, and finally re-
suspended in ice-cold FACS running buffer (2% v/v FBS in PBS) containing 1:200
v/v propidium iodide (Invitrogen). The cells were kept at 4*C until FACS analysis
using a BD LSR II (Becton Dickinson, San Jose, CA, USA). Gating and analysis were
performed using FlowJo v8.8 software (TreeStar, Ashland, OR, USA).
7.2.7 Gel electrophoresis
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Oligos and protein-oligo conjugates were run on a pre-cast 4-20%
polyacrylamide-TBE gel (Bio-Rad, Hercules, CA, USA) for 1 h at 100 V. The gel was
then stained for 30 min with SYBR Gold (Invitrogen) and visualized with a Bio-Rad
GelDoc XR+ imager.
LNPs formulated with nAv or nAv-oligo conjugates were run on a pre-cast
Any kD mini-Protean TGX gel (Bio-Rad) for 30 min at 100 V. The gel was stained for
1 h with Bio-Safe Coomassie Stain (Bio-Rad), destained overnight, and visualized
using a Bio-Rad GelDoc XR+ imager. The entrapment efficiency was determined as:
(Sfree - SLNP)/Sfree, where Sfree is the total signal per lane for the free protein or
conjugate and SLNP that for the LNP-encapsulated protein or conjugate.
7.2.8 Animal experiments
Animal experiments were performed using 6-8 wk old, female C57BL/6 mice
(Charles River, Wilmington, MA) in accordance with protocols approved by MIT's
Committee on Animal Care (CAC). Mice were injected intravenously via the tail-vein
with 0.2 mL of LNP formulations, unformulated controls, or PBS at a nAv protein
dose of 2.5 mg/kg. After 2 h, the animals were euthanized, and the livers, spleens,
kidneys, lungs and heart were dissected and analyzed for fluorescence (ex = 675 nm,
em = 720 nm) using an IVIS imaging system (Xenogen, Alameda, CA). Xenogen
Living Image v. 4.2 acquisition and analysis software was used to quantify
fluorescent radiant efficiency of each organ from the optical images. The livers and
spleens were then frozen on dry ice using Tissue-Tek OCT (Sakura, Torrance, CA,
USA) and sectioned with a cryotome. Some frozen sections were scanned for Cy5.5
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fluorescence using a Li-COR Odyssey imager (Lincoln, NE, USA). The other frozen
sections were fixed and stained for analysis of Cy5.5-nAv uptake by confocal
microscopy.
For analysis of splenocyte uptake, spleens were harvested 2 h post-injection,
and the spleen cell suspension was analyzed for different immune cell populations
and for AF488-labeled nAv uptake by flow cytometry (CD11b+: cells of the
macrophage/monocyte lineage; CD11b+GR1+: neutrophils; CD11c+: dendritic cells;
GR1+: granulocytes; CD19+: B-cells; TCRb+: T cells).
7.3 RESULTS AND DISCUSSION
7.3.1 Intracellular delivery of horseradish peroxidase
Horseradish peroxidase (HRP), a 44 kDa enzyme with an isoelectric point of
approximately 8.0-9.0, was initially selected as a model protein for intracellular
delivery, since the enzymatic activity of the delivered protein could be readily
assayed. We prepared HRP-oligonucleotide conjugates via an azide-alkyne click
reaction. Briefly, HRP was azide-functionalized using an NHS-ester crosslinker with
a short PEG spacer. The azide-modified HRP was then conjugated to a 42 base 5'-
hexynyl-functionalized DNA oligonucleotide (oligo) with reaction conditions as
reported previously[2 91 using a molar ratio of 1.5:1.0 oligo:HRP.
A gel shift assay confirmed the presence of HRP-DNA conjugates bearing one
or more oligonucleotides (Figure 7.2a). To determine whether these HRP-DNA
conjugates still retained their activity, we compared the enzymatic activity of the
HRP-oligonucleotide conjugates to that of the free HRP protein (Figure 7.2b) using
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o-phenylenediamine (OPD). Surprisingly, the HRP-oligo conjugates displayed
greater apparent activity than unmodified HRP, a result that we initially attributed
to an underestimation of the conjugate protein concentration as determined by the
absorbance at 403 nm. However, an independent measurement of the conjugate
protein concentration using a bicinchoninic acid (BCA) assay yielded essentially the
same result to within 10% as that of UV/vis spectroscopy, so we relied on these
concentrations as measured for the ensuing transfection experiments.
(a) (b)
' 10
-< H RP
E -0- HRP-DNA
C o1'
c 0.1
< 0.011
1 10 100 1000 10000
HRP Concentration (pM)
Figure 7.2 Characterization of HRP-DNA oligonucleotide conjugates.
(a) Polyacrylamide gel electrophoresis of free DNA oligonucleotide (42 nt) and HRP-
DNA oligo conjugates. (b) OPD-based assay of peroxidase activity for free HRP and
HRP-oligo conjugates.
We first screened a panel of lipidoid formulations for in vitro delivery of the
HRP-oligo conjugates. Sixteen lipidoids varying in their amine cores and alkyl tails
as described 271 were mixed with DSPC, PEG-DMG, and cholesterol and then
formulated with HRP-oligonucleotide conjugates. The resulting nanoparticle
formulations were incubated with HeLa cells for 4 h, after which the cells were
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washed 3 times with PBS and treated with trypsin to digest any remaining
membrane-bound HRP. Subsequently, the cells were transferred to an assay plate,
pelleted, and re-suspended in OPD substrate buffer for an HRP activity assay. As
shown in Figure 7.3, lipidoids bearing longer alkyl tails (C14) generally displayed
more effective delivery of active HRP-oligo conjugates. Using the top four lipidoids
from this screen, further optimization of formulation conditions indicated that
formulations including DSPC and cholesterol delivered HRP conjugates more
effectively than those containing DOPE (Figure 7.4). In particular, the lipidoid C14-
113 appeared to outperform the other lipidoids with respect to delivery activity.
0.4
0.3
- 0.2
U
0.1
0.0
Figure 7.3 Screen of various lipidoids for delivery of active HRP-oligo
conjugates
The indicated lipidoids were formulated with HRP-oligo conjugates (250 ng
HRP/well; 96-well plate) and incubated for 4 h with HeLa cells, which were then
washed, trypsinized, and subjected to an HRP activity assay.
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Figure 7.4 Optimization of LNP formulations for delivery of HRP-oligo
conjugates
Four lipidoids were formulated with HRP-oligo conjugates as indicated and
incubated for 4 h with HeLa cells, which were then washed, trypsinized, and
subjected to an HRP activity assay.
Having identified an LNP formulation mediating delivery of HRP-DNA
conjugates, we then tested whether effective delivery depends on oligonucleotide
conjugation. C14-113 LNPs were formulated in one of four ways: with HRP protein
alone; with a mixture of HRP protein and unconjugated, unmodified oligonucleotide;
with a mixture of free HRP protein and unconjugated, 5'-hexynyl-modified
oligonucleotide; or with the HRP-oligonucleotide conjugates prepared by click
chemistry. In addition to naked HRP protein and naked HRP-oligo conjugates as
control treatments, the formulations were incubated for 4 h with HeLa cells. As
shown in Figure 7.5, only the C14-113 LNPs formulated with HRP-oligo conjugates
yielded significant HRP activity after washing and trypsinizing the cells. This result
suggests that HRP-oligonucleotide conjugation is required to achieve significant
intracellular HRP delivery with these LNPs.
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Figure 7.5 Oligonucleotide conjugation is required for effective delivery of
HRP by LNPs
HeLa cells were incubated for 4 h with C14-113 LNPs formulated with HRP; with
HRP and free unmodified DNA oligo; with HRP and free hexynl-modified DNA oligo;
or with HRP-DNA oligo conjugates (500 ng HRP/well; 96-well plate). Controls
included naked HRP protein and naked HRP-DNA conjugates. The cells were then
washed, trypsinized, and subjected to an HRP activity assay.
To confirm that the HRP-oligonucleotide conjugates localized within the cells,
we performed immunocytochemistry (ICC) and confocal microscopy. The imaging
data revealed significant intracellular HRP staining within cells treated with LNPs
containing HRP-oligo conjugates, but no such staining in cells treated with naked
HRP-oligo conjugates (Figure 7.6). These results substantiate the conclusions from
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the enzymatic activity assay that the C14-113 LNP mediates intracellular
transfection of horseradish peroxidase-oligonucleotide conjugates.
(a)
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Figure 7.6 Intracellular localization of HRP-oligo conjugates
HeLa cells were treated in 6-well plates with (a) naked HRP-oligo conjugates or (b)
C14-113 LNPs formulated with HRP-oligo conjugates (10 ug HRP per well). The cells
were then washed, fixed, stained for various markers including HRP, and analyzed
by confocal microscopy. Blue: nuclei (DAPI), green: membrane (AF488-labeled
wheat germ agglutinin), purple: HRP (AF647-labeled anti-HRP).
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7.3.2 Intracellular delivery of NeutrAvidin
The same principle was illustrated for intracellular delivery of another model
protein, NeutrAvidin, a deglycosylated variant of avidin with a molecular weight of
60 kDa and an isoelectric point of 6.3. Fluorescently labeled NeutrAvidin-
oligonucleotide conjugates were prepared by incubating Oregon Green 488-labeled
NeutrAvidin (nAv), which has four biotin binding sites, with various stoichiometric
ratios of 5'-biotinylated oligonucleotides. The resulting conjugates were analyzed
with a gel shift assay, which showed efficient conjugation at the 1:1 and 2:1 molar
ratios of oligo:nAv (Figure 7.7a). Excess free oligo was detected in the mixture
prepared at a 4:1 oligo:nAv ratio, most likely due to interference of the fluorescent
label with one or more of NeutrAvidin's four potential biotin-binding sites. For
ensuing experiments, the oligo:nAv ratio was maintained at 2:1.
To determine whether oligonucleotide conjugation affected the
encapsulation efficiency of nAv within LNPs, C14-113 LNPs were formulated either
with free nAv or with nAv-oligo conjugates and characterized by SDS-PAGE
alongside naked nAv and naked nAv-oligo conjugates (Figure 7.7b). Quantification
of the gel results indicated that the encapsulation efficiency of nAv alone within
C14-113 LNPs was -11.0%, in comparison with -30.8% for nAv-oligo conjugates.
These data suggest that oligonucleotide conjugation enhances the encapsulation
efficiency of nAv within C14-113 LNPs by approximately threefold.
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Figure 7.7 Characterization of NeutrAvidin-oligonucleotide conjugates and
LNPs by gel electrophoresis
(a) Polyacrylamide gel electrophoresis (PAGE) of free (F) biotinylated DNA
oligonucleotide (42 nt) and NeutrAvidin-DNA oligo conjugates prepared at various
molar ratios of oligo:DNA (1:1, 2:1, and 4:1). (b) SDS-PAGE of naked nAv protein (P),
naked nAv-oligo conjugate (C), C14-113 LNPs encapsulating nAv protein (LP), and
C14-113 LNPs encapsulating nAv-oligo conjugates (LC).
To characterize the effect of oligo conjugation on intracellular nAv delivery in
vitro, HeLa cells were incubated with one of three C14-113 LNP formulations: those
encapsulating nAv protein alone, those encapsulating a mixture of nAv protein and
unconjugated, unmodified oligo; and those encapsulating the nAv-oligo conjugates.
HeLa cells were treated for 4 h with these formulations, along with the naked
protein and the naked conjugate treatments. The cells were then washed several
times, trypsinized, and analyzed by fluorescence-activating cell sorting (FACS) for
Oregon Green 488 signal. As displayed in Figure 7.8, neither the naked nAv nor the
naked nAv-oligo conjugates yielded significant cellular internalization. At the same
nAv dose, the C 14-113 LNPs encapsulating nAv-oligo conjugates transfected -65%
of HeLa cells, in comparison with -19% transfection efficiency for LNPs
encapsulating the nAv protein alone, and -5% transfection efficiency for LNPs
encapsulating a mixture of nAv and unconjugated oligo. These results demonstrate
that oligo conjugation significantly improves intracellular delivery of nAv mediated
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by C14-113 LNPs. Meanwhile, the reduction in transfection observed for LNPs
formulated with a mixture of nAv and unconjugated oligo compared with those
formulated with nAv alone suggests that the unconjugated oligo may compete with
nAv for loading into the C14-113 LNPs. The extent of protein uptake for these
treatments was also evaluated by microscopy, which confirmed that only the HeLa
cells treated with C14-113 LNPs encapsulating nAv-oligo conjugates showed
significant uptake (Figure 7.9).
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Figure 7.8 Oligonucleotide conjugation is required for efficient delivery of nAv
by LNPs
He La cells were incubated for 4 h with C14-113 LNPs formulated with nAv; with
nAv and free unmodified DNA oligo; or with nAv-DNA oligo conjugates (100 ng
nAv/well; 96-well plate). Controls included naked nAv protein and naked nAv-DNA
conjugates. For all treatments, nAv was labeled with OregonGreen 488. The cells
were then washed, trypsinized, and analyzed by FACS for uptake of nAv.
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Figure 7.9 Uptake of nAv-oligo conjugates in HeLa cells
HeLa cells were treated with naked nAv, with naked nAv-DNA oligo conjugates, with
C14-113 LNPs formulated with free nAv, or with C14-113 LNPs formulated with
nAv-DNA conjugates (100 ng nAv/well; 96-well plate). The cells were then washed,
trypsinized, and fixed. Red: Cy5.5-nAv.
To examine whether oligo conjugation also affects LNP-mediated protein
uptake in vivo, we investigated the biodistribution of these LNPs 2 h after
intravenous (IV) administration to mice. As displayed by fluorescence imaging of
the dissected organs, both the LNPs encapsulating the nAv-oligo conjugates (C14-
113/nAv-DNA LNPs) and the LNPs encapsulating the free nAv protein (C14-
113/nAv) were associated with greatly increased nAv-associated Cy5.5 signal in the
liver as compared with naked nAv-oligo conjugates (Figure 7.10). However, the C14-
113/nAv-DNA LNP-treated mice showed higher Cy5.5 signal within the spleens and
lower signal within the kidneys than those that were treated with C14-113 / nAv
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LNPs, suggesting altered biodistribution of the LNPs as a result of protein-oligo
conjugation.
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Figure 7.10 Biodistrlbution of nAv-oligo conjugates in mice
Optical images of Cy5.5 fluorescence in dissected mouse organs 2 h after
intravenous injection of the indicated Cy5.5-labeled nAy treatments (2.5 mg/kg nAy
dose). Radiant efficiency (photons/s/sr/ iiW) is indicated in the color scale bar at
left. L to R: liver, heart, lungs, spleen, kidneys.
To quantify the difference in protein localization observed in the spleens, we
imaged the organ sections using a Li-COR Odyssey near-infrared fluorescence
scanner (Figure 7.11). The results indicated approximately 2.5-fold higher uptake of
nAv in the spleens of mice treated with LNPs encapsulating the nAv-oligo conjugates
compared with those treated with LNPs containing the nAv protein alone.
Furthermore, comparing treatment with C14-113/nAv-DNA LNPs and treatment
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with naked nAv-DNA conjugates, encapsulation within LNPs increased spleen
protein uptake approximately 3.5-fold.
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Figure 7.11 Quantification of nAv-oligo localization in mouse spleens
Left: Near-infrared fluorescence scans of Cy5.5 signal in spleen sections harvested
from mice 2 h after IV injection of the indicated Cy5.5-labeled nAv treatments (2.5
mg/kg nAv dose). Right: Quantification of mean gray values of spleens for each
group (n = 3).
Immunohisto chemical staining and confocal microscopy confirmed increased
accumulation of CyS.5-labeled nAv in those mice treated with C14-113/nAv-DNA
LNPs (Figure 7.12). By comparison, much less accumulation was observed for those
mice treated with either naked nAv-DNA conjugates or with C14-113/nAv LNPs.
Moreover, in the spleens of mice treated with C14-113 / nAv-DNA LNPs, the nAv
signal was quite diffuse within the tissue, contrasting sharply with the punctate nAv
signal observed in the spleens of mice treated with the naked conjugates. This
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observation suggests the possibility of enhanced endosomal escape and cytosolic
localization of nAv-DNA conjugates mediated by the C14-113 LNPs.
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Figure 7.12 Immunohistochemical analysis of mouse spleen sections following
nAv-oligo delivery
Immunohistochemical staining revealed increased accumulation of Cy5.5-labeled
nAv in spleen sections harvested from mice 2 h after IV injection of C14-113 / nAv-
DNA LNPs.
To determine more quantitatively which immune cell populations within the
spleen were transfected, mice were injected IV with LNPs encapsulating AF488-
labeled nAv protein or nAv-oligo conjugates, along with their naked counterparts.
Two hours after injection, the spleens were harvested and the spleen cell
suspension was analyzed by FACS for various immune cell markers as well as for
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AF488-labeled NAv uptake (Figure 7.13). Both LNP treatments showed increased
nAv transfection efficiency in splenic dendritic cells and cells of the
macrophage/monocyte lineage relative to naked nAv or nAv-DNA conjugates
(Figure 7.13a). Interestingly, comparing the two LNP treatments, the FACS data
showed only slightly higher or equivalent nAv uptake efficiency within
macrophages/monocytes (CD11b+) and dendritic cells (CD11c+) for the LNPs
encapsulating nAv-oligo conjugates. For example, the C14-113/nAv-DNA LNPs
transfected -37% of splenic dendritic cells, compared with -29% uptake efficiency
for C14-113/nAv LNPs, a statistically significant but relatively narrow difference.
However, analysis of the AF488 geometric mean fluorescent intensity (GMFI) of
transfected macrophages/monocytes and dendritic cells indicated 2-to-3-fold
enhancement in nAv uptake for the LNPs encapsulating the nAv-oligo conjugates
(Figure 7.13b). This enhancement is especially noteworthy considering that there
were no major differences in the uptake levels of transfected macrophages or
dendritic cells among the naked control treatment groups and the group treated
with LNPs encapsulating free nAv. These results suggest that protein-oligo
conjugation significantly increases the level of protein uptake in those immune cells
within the spleen susceptible to transfection by LNPs.
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Mice were injected IV with the indicated AF488-labeled nAy treatments, and the
spleens were harvested 2 h post-injection. The spleen cell suspension was analyzed
by FACS for different immune cell populations as well as for (a) nAy uptake
efficiency (% AF488+) and (b) geometric mean fluorescent intensity (GMFI) of
AF488+ cells. CD1 1b+: macrophages/monocytes; CD1 1b+GR1 +: neutrophils; CD1 1c+:
dendritic cells; GR1 +: granulocytes; CD1 9+: B-cells; TCRb+: T cells.
Recombinant protein-based vaccines are considered less toxic and easier to
produce than traditional vaccines based on whole organisms; however, the
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comparatively lower immunogenicity of protein-based vaccines requires the
development of methods for improved delivery to and activation of antigen-
presenting cells including dendritic cells and macrophages[ 31 , 321. In this regard, our
observation that oligonucleotide conjugation results in enhanced LNP-mediated
protein uptake within splenic dendritic cells and macrophages/monocytes
represents a promising preliminary finding. Further experiments are necessary to
determine whether this enhanced protein uptake is also associated with the
induction of a more robust immune response characterized by increases in relevant
cytokine levels and stimulation of specific T-cell and B-cell responses. Because
immunostimulatory oligos such as those enriched in unmethylated CpG motifs are
known to be potent vaccine adjuvants[ 33-35 , the approach outlined here could be
well suited for the delivery of a vaccine comprising a protein antigen conjugated to a
functional, immunostimulatory oligo adjuvant[361. Moreover, since many vaccines
are delivered intramuscularly or subcutaneously, future studies should evaluate
whether these administration routes similarly yield enhanced uptake of conjugates
in antigen-presenting cells not only within the spleen, but also within the lymph
nodes and the peritoneal cavity.
More broadly, the delivery studies with HRP and nAv offer potential for the
use of this oligonucleotide conjugation approach for LNP-mediated delivery of other
protein cargo. In many cases, the protein-oligonucleotide conjugation will likely
require optimization in terms of the number of attached oligos, their length, and
their cleavability in order to conserve protein function and achieve delivery. Further
study is needed to determine whether the properties of these nanoparticles can be
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tailored in terms of size and charge to achieve intracellular protein delivery to
specific organs and tissues other than the spleen. Successfully tuning both the
conjugation strategy and the properties of the lipid nanoparticles may permit
realization of a range of applications, such as the introduction of reprogramming
factors to generate induced pluripotent stem cells, enzyme replacement for
inherited liver diseases, and the transfection of engineered nucleases for genome
editing.
7.4 CONCLUSIONS'
In this chapter, using two distinct model proteins, we demonstrated that
intracellular protein delivery with LNPs is significantly enhanced through
conjugation of oligonucleotides to the protein cargo. Using click chemistry, we
synthesized conjugates of horseradish peroxidase (HRP) and a DNA oligonucleotide,
and we show that one particular lipidoid, C 14-113, mediates effective intracellular
delivery to HeLa cells of HRP-oligo conjugates but not free HRP protein. Similarly,
with NeutrAvidin (nAv), a variant of avidin, we show that binding to a biotinylated
oligo significantly enhances intracellular nAv delivery by C14-113 in HeLa cells.
When mice were injected intravenously with C 14-113 LNPs encapsulating either
free nAv or nAv-oligo conjugates, we observed that oligonucleotide conjugation
significantly improved intracellular nAv uptake in macrophage/monocytes and
dendritic cells within the spleen. These preliminary in vivo results suggest that this
approach may be suitable for improved delivery of protein-based vaccines by LNPs.
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8 CONCLUSIONS
8.1 MAIN CONTRIBUTIONS
The overarching aim of this thesis was to develop polymer and lipid-based
materials for safe, effective intracellular delivery of gene and protein therapeutics.
This objective was specifically motivated by a set of unaddressed challenges and
questions relating to two groups of materials, poly(p-amino ester)s (PBAEs) and
lipidoids. For the promising PBAE gene delivery polymers, these issues included the
poor stability of polymer/DNA polyplexes under physiological conditions, polymer
batch-to-batch variability, and a lack of knowledge regarding polyplex cellular
uptake and trafficking mechanisms. For lipidoids, the question was whether these
materials, which have demonstrated exceptional potency for delivery of
oligonucleotides, could also be applied toward effective intracellular delivery of
proteins.
To address the issue of PBAE polyplex stability, we developed novel,
degradable PBAE polymers displaying enhanced gene delivery potency and
nanoparticle aggregation resistance. We hypothesized that the inclusion of alkyl
side chains within PBAE polymers would render them sufficiently hydrophobic to
interact with PEG-lipid conjugates, and upon association with DNA, result in the
formation of ternary complexes with improved stability. Using a combinatorial
library approach to synthesize and screen over 120 structurally distinct
hydrophobic PBAE terpolymers, we identified several polymers that displayed
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transfection activities in HeLa cells significantly greater than that of the popular
commercially available transfection reagent Lipofectamine 2000. The most effective
PBAE terpolymers were characterized by transfection potencies in HeLa cells
approximately 10 to 20-fold that of C32-122, one of the top-performing amine end-
modified polymers from the previous generation of PBAEs. We observed that
increasing polymer hydrophobicity, as defined by either increasing the feed ratio of
alkylamine monomer or increasing its chain length, was associated with increasing
transfection activity, an observation which we attribute to tighter binding and
encapsulation of DNA. Furthermore, increasing polymer hydrophobicity was
correlated with greater polyplex stability at low DNA concentration. In a
confirmation of our hypothesis, at high DNA concentrations under conditions of
physiological pH and ionic strength, these hydrophobic PBAE terpolymers
facilitated interaction with PEG-lipid and DNA to yield stable, well-defined
nanoparticles capable of transfecting cultured cells in vitro.
Through a series of additional experiments, hydrophobic PBAE terpolymers,
including DD24-C12-122 and LL24-C12-122, were found to mediate superior
transfection of HUVECs, porcine MSCs, and neonatal rat cardiomyocytes relative to
C32-122 and to Lipofectamine 2000. Formulation development with the terpolymer
D60-C12-122 suggested that the identity of the PEG-lipid conjugate strongly affects
the stability of the nanoparticle formulations and their corresponding transfection
efficacies. Following IP or IV administration, D60-C12-122 and D90-C12-122
terpolymer formulations yielded transgene expression in mice persisting for at least
three days. Taken together, these findings suggest that modulation of
219
hydrophobicity is a simple yet powerful approach to improving the gene
transfection potency and formulation stability of degradable cationic polymers.
Regarding PBAE batch-to-batch variability, we hypothesized that this issue
was related to subtle differences in the molecular weight distribution (MWD) of the
polymers. Therefore, we investigated the effect of PBAE MW on the transfection
activity, toxicity, and biophysical properties of the resulting polymer-DNA
nanoparticles. In spite of the tendency of these polymers to lose transfection activity
upon work-up, we developed a method based on size-exclusion chromatography
(SEC) that allowed isolation of well-defined, monodisperse PBAE fractions still
retaining transfection efficacy. We found that the transfection activities of size-
fractionated PBAEs generally increased with MW, a trend that was weakly
associated with more efficient DNA binding. We also observed a relatively steep
drop-off in transfection performance below a threshold polymer length, lending
support to our hypothesis that minor variation in the MW and MWD could in fact
account for the inconsistency in batch-to-batch performance. However, because this
method enabled the preparative isolation of monodisperse polymer fractions with
higher transfection potency than the starting material, it potentially represents a
robust solution to this issue.
To address the issue of limited mechanistic knowledge regarding PBAE
internalization, uptake of PBAE/DNA nanoparticles was investigated through
pharmacological inhibition and marker co-localization studies. Our results indicated
that internalization of PBAE/DNA polyplexes in immortalized mouse embryonic
fibroblast (MEF) cells likely proceeds through multiple pathways, with a potential
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dependence on cholesterol trafficking. Treatment with the cholesterol synthesis and
transport inhibitor U18666A resulted in reduced uptake and transfection efficacy.
Moreover, significantly decreased uptake and transfection efficacy were observed in
MEFs deficient in an endosomal/lysosomal cholesterol transport protein, Niemann-
Pick C1 (Npcl). In contrast, Npcl knockout was only associated with a marginal
decrease in DNA uptake mediated by polyethylenimine (PEI) and no apparent effect
on DNA uptake mediated by Lipofectamine 2000, suggesting that this cholesterol
trafficking dependence is relatively specific to PBAE polyplex uptake. To identify a
potential mechanism, we quantified internalization of various endocytic markers in
Npcl-deficient MEFs and observed significant reduction in uptake of cholera toxin B
(CTB), a marker traditionally associated with caveolae-mediated endocytosis. DNA
internalized by PBAEs showed the greatest extent of co-localization with the CTB
marker, indicating the possibility of shared uptake pathways that are reduced in
cells lacking Npcl. Combined with data indicating improved silencing potency for
lipidoid/siRNA nanoparticles in MEF deficient cells, these studies bolster the
hypothesis that Npcl plays a key role in the regulation of endocytic mechanisms
affecting uptake and efficacy of nanoparticles.
Finally, to develop lipidoids for protein delivery, we applied a simple strategy
showing that effective intracellular protein delivery could be achieved through
conjugation of nucleic acids to the protein cargo. For the model enzyme horseradish
peroxidase (HRP), we demonstrated that one particular lipidoid, C 14-113, mediates
effective intracellular delivery to HeLa cells of active HRP-DNA oligonucleotide
conjugates but not free HRP protein. Analogously, with NeutrAvidin (nAv), a variant
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of avidin, we showed that binding to a biotinylated oligo significantly enhanced
intracellular nAv delivery by C 14-113 in HeLa cells, most likely due to improved
protein entrapment. When mice were injected intravenously with C14-113 lipid-
based nanoparticles (LNPs) encapsulating either free nAv or nAv-oligo conjugates,
we found that oligonucleotide conjugation improved intracellular nAv uptake in
macrophages and dendritic cells within the spleen 2-3-fold. These preliminary in
vivo results indicate the potential utility of this nucleic acid conjugation approach
toward improved LNP-mediated delivery of protein-based vaccines.
8.2 FUTURE OUTLOOK
With a number of promising gene therapeutics currently under advanced
clinical development, the gene therapy field finally appears to be coming of age after
a notoriously turbulent history. Viral vectors remain the preferred delivery vehicle
in most active clinical studies, with considerations of efficacy outweighing concerns
regarding their safety risks. However, non-viral vectors are being employed in a
growing proportion of clinical trials, a trend that will likely persist with the
continued development of improved synthetic gene carriers.
A large focus of this thesis represents an attempt to advance that
development for one class of promising degradable gene vectors, PBAEs. The
development of novel hydrophobic PBAE terpolymers with dramatic enhancements
in gene delivery potency and nanoparticle stability should heighten their prospects
for clinical translation. Poor nanoparticle stability is an issue not only for the PBAEs,
but also for many gene delivery materials. The solution presented in this thesis,
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which involved the incorporation of alkyl side chains into the terpolymers and
formulation with PEG-lipid conjugates to produce stable nanoparticles, may
therefore be applicable to other polymers as well. Although preliminary
experiments suggested that these terpolymers are capable of mediating effective
gene delivery in vivo following intraperitoneal administration without obvious
toxicity, future studies are required to determine their potential for gene delivery
through other injection routes, their dose-response and toxicity profiles, and the
biodistribution and duration of gene expression. These experiments would lay the
groundwork for preclinical studies evaluating their suitability as gene delivery
reagents for therapeutic applications in animal models of disease. Furthermore, the
development of a robust, preparative technique based on size-exclusion
chromatography to isolate homogeneous, well-defined PBAE fractions should
reduce issues of molecular weight (MW) heterogeneity and batch-to-batch
variability that have been frequently encountered.
On a more fundamental level, while the data presented here elucidate some
important structure-activity relationships for these PBAEs, particularly with respect
to polymer hydrophobicity and molecular weight, future studies should investigate
in more detail potential explanations for the trends that were observed. For
example, for the PBAE terpolymers, optimal gene delivery activity was associated
with an intermediate degree of polymer hydrophobicity. One hypothesis is that this
optimum represents a balance between the rates or extents of DNA binding and
unpacking. This hypothesis could be tested experimentally by measuring the DNA
binding affinities of terpolymers of varying hydrophobicities by surface plasmon
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resonance (SPR). Similarly, as it was observed that the surface charge of the
polyplexes became more positive as the terpolymer hydrophobicity increased, a
variety of techniques including cryo-transmission electron micrscopy (TEM), atomic
force microscopy (AFM), sum frequency generation (SFG) spectroscopy, and
molecular dynamics simulations could shed light on the surface characteristics and
morphology of the nanoparticles.
The discovery of a critical role for cholesterol trafficking and regulation for
gene transfection by PBAEs should enable the identification of potential targets,
including Npcl, which might be selectively leveraged to further improve delivery
efficacy. As was observed, stable overexpression of Npcl was associated with
increased gene uptake and transfection by PBAEs. High-throughput screening of
small molecules or bioactive lipids may reveal compounds that enhance polymeric
gene delivery through modulation of critical cellular factors including Npcl. Given
the contradictory role of Npcl in PBAE/DNA and lipid/siRNA transfection,
respectively, future studies should elucidate the mechanisms responsible for this
discrepancy. One possibility is that in the case of lipid/siRNA transfection of Npcl-
deficient cells, the nanoparticles enter through a pathway that is uninhibited by
impaired cholesterol trafficking (such as macropinocytosis) and accumulate within
late endosomes due to a block in exosomal recycling. In contrast, internalization of
PBAE/DNA nanoparticles proceeds through alternate pathways (perhaps caveolae
and clathrin-mediated endocytosis) that are blocked due to a critical lack of
cholesterol at the plasma membrane, which may impair the formation of caveolae
and clathrin-coated vesicles.
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In some ways, intracellular delivery of protein-based therapeutics represents
a hedge against the risks inherent in gene therapy and therefore also merits suitable
research effort. Unfortunately, in contrast to nucleic acids, the wide range of
physicochemical properties that proteins possess impedes the development of a
generalized protein delivery platform. We have shown the utility of a simple
approach in which nucleic acids serve as a handle for encapsulation of proteins by
lipidoids, and the resulting LNPs are able to mediate effective intracellular delivery
of model proteins in vitro and in vivo. Future studies should determine the
generality of this approach for the delivery of protein-based vaccines as well as
other protein cargo of interest, such as enzymes for inherited liver diseases and
engineered nucleases for genome editing.
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